US5254463A
(en)
*
|
1981-09-18 |
1993-10-19 |
Genentech, Inc. |
Method for expression of bovine growth hormone
|
GB8308235D0
(en)
*
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
*
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4923805A
(en)
*
|
1983-11-02 |
1990-05-08 |
Integrated Genetics, Inc. |
Fsh
|
DE3486469T2
(en)
*
|
1983-11-02 |
1999-04-15 |
Applied Research Systems |
Production of heterodimic human fertility hormones
|
US4840896A
(en)
*
|
1983-11-02 |
1989-06-20 |
Integrated Genetics, Inc. |
Heteropolymeric protein
|
US5639639A
(en)
*
|
1983-11-02 |
1997-06-17 |
Genzyme Corporation |
Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
|
US6455282B1
(en)
|
1983-11-02 |
2002-09-24 |
Genzyme Corporation |
Cells, vectors and methods for producing biologically active TSH
|
US7138505B1
(en)
|
1984-01-12 |
2006-11-21 |
Novartis Vaccines And Diagnostics, Inc. |
Factor VIII:C nucleic acid molecules
|
DE3520404C2
(en)
*
|
1984-06-08 |
1994-06-16 |
Genzyme Corp |
Pigs ß-FSH
|
US5489529A
(en)
*
|
1984-07-19 |
1996-02-06 |
De Boer; Herman A. |
DNA for expression of bovine growth hormone
|
EP0173494A3
(en)
*
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
US5807715A
(en)
*
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
GB8422238D0
(en)
*
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
US6808901B1
(en)
*
|
1984-09-03 |
2004-10-26 |
Celltech R&D Limited |
Production of chimeric antibodies
|
US5498600A
(en)
*
|
1984-10-12 |
1996-03-12 |
Zymogenetics, Inc. |
Biologically active mosaic proteins
|
EP0487116B1
(en)
*
|
1984-10-12 |
1999-12-29 |
ZymoGenetics, Inc. |
Biologically active PDGF analogs in eucaryotic cells
|
US5187263A
(en)
*
|
1984-10-12 |
1993-02-16 |
Zymogenetics, Inc. |
Expression of biologically active PDGE analogs in eucaryotic cells
|
DE3439843A1
(en)
*
|
1984-10-31 |
1986-04-30 |
Boehringer Mannheim Gmbh, 6800 Mannheim |
PLASMIDE FOR INCREASED PRODUCTION OF PENICILLIN G-AMIDASE
|
US5045633A
(en)
*
|
1985-02-25 |
1991-09-03 |
Zymogenetics, Inc. |
Expression of biologically active PDGF analogs in eucaryotic cells
|
US5169939A
(en)
*
|
1985-05-21 |
1992-12-08 |
Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College |
Chimeric antibodies
|
AU606320B2
(en)
*
|
1985-11-01 |
1991-02-07 |
International Genetic Engineering, Inc. |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US5576195A
(en)
*
|
1985-11-01 |
1996-11-19 |
Xoma Corporation |
Vectors with pectate lyase signal sequence
|
US5618920A
(en)
*
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
FI98829C
(en)
*
|
1986-01-27 |
1997-08-25 |
Chiron Corp |
Process for Preparation of Recombinant Protein Complex with Human Factor VIII: C Activity
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US5260203A
(en)
*
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US5869620A
(en)
*
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
WO1988001649A1
(en)
*
|
1986-09-02 |
1988-03-10 |
Genex Corporation |
Single polypeptide chain binding molecules
|
US4946778A
(en)
*
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
IL84285A
(en)
*
|
1986-10-27 |
1993-03-15 |
Int Genetic Engineering |
Chimeric antibody with specificity to human tumor antigen
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL85035A0
(en)
*
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3856559T2
(en)
*
|
1987-05-21 |
2004-04-29 |
Micromet Ag |
Multifunctional proteins with predetermined objectives
|
US5132405A
(en)
*
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5091513A
(en)
*
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5258498A
(en)
*
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
US5981278A
(en)
*
|
1987-05-29 |
1999-11-09 |
Tanox, Inc. |
Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
|
US5834599A
(en)
*
|
1987-05-29 |
1998-11-10 |
Tanox Biosystems, Inc. |
Immunoconjugates which neutralize HIV-1 infection
|
US6657050B1
(en)
|
1987-05-29 |
2003-12-02 |
Tanox, Inc. |
Chimeric viral-neutralizing immunoglobulins
|
CA1341235C
(en)
*
|
1987-07-24 |
2001-05-22 |
Randy R. Robinson |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US5336603A
(en)
*
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
US6710169B2
(en)
|
1987-10-02 |
2004-03-23 |
Genentech, Inc. |
Adheson variants
|
DE3744595A1
(en)
*
|
1987-12-31 |
1989-07-13 |
Andreas Dr Plueckthun |
METHOD FOR THE GENETIC ENGINEERING OF ANTIBODY
|
EP0327797B1
(en)
*
|
1988-01-05 |
2003-09-03 |
Roche Diagnostics GmbH |
Method for the preparation of proteins or protein-containing gene products
|
US5843708A
(en)
*
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
GB8800077D0
(en)
*
|
1988-01-05 |
1988-02-10 |
Ciba Geigy Ag |
Novel chimeric antibodies
|
US6004781A
(en)
*
|
1988-01-22 |
1999-12-21 |
The General Hospital Corporation |
Nucleic acid encoding Ig-CD4 fusion proteins
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
ATE140963T1
(en)
*
|
1988-01-22 |
1996-08-15 |
Zymogenetics Inc |
METHOD FOR PRODUCING SECRETED RECEPTOR ANALOGUES
|
US5567584A
(en)
*
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
US5750375A
(en)
*
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
US5846534A
(en)
|
1988-02-12 |
1998-12-08 |
British Technology Group Limited |
Antibodies to the antigen campath-1
|
WO1989009393A1
(en)
*
|
1988-03-24 |
1989-10-05 |
Igen, Inc. |
Luminescent chimeric proteins
|
US5582862A
(en)
|
1988-04-04 |
1996-12-10 |
General Hospital Corporation |
Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
|
US5372812A
(en)
*
|
1988-04-04 |
1994-12-13 |
The General Hospital Corporation |
Composition and method for acceleration of clot lysis
|
US4975369A
(en)
*
|
1988-04-21 |
1990-12-04 |
Eli Lilly And Company |
Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
|
US5609869A
(en)
*
|
1988-08-19 |
1997-03-11 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
US5811265A
(en)
*
|
1988-08-19 |
1998-09-22 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
WO1990002762A1
(en)
|
1988-09-02 |
1990-03-22 |
The Rockefeller University |
Macrophage-derived inflammatory mediator (mip-2)
|
AU643189B2
(en)
|
1988-09-06 |
1993-11-11 |
Xoma Corporation |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
JP2919890B2
(en)
|
1988-11-11 |
1999-07-19 |
メディカル リサーチ カウンスル |
Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US20030229208A1
(en)
*
|
1988-12-28 |
2003-12-11 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
CA2057923A1
(en)
*
|
1989-05-16 |
1990-11-17 |
William D. Huse |
Co-expression of heteromeric receptors
|
US6291161B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291159B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
ES2053196T3
(en)
*
|
1989-06-19 |
1994-07-16 |
Akzo Nv |
METHOD FOR THE PRODUCTION OF A RADIO IMMUNOCONJUGATE.
|
US7247475B2
(en)
*
|
1989-07-28 |
2007-07-24 |
Wyeth |
Method for producing monoclonal antibodies
|
US6475787B1
(en)
|
1989-07-28 |
2002-11-05 |
Wyeth |
Method for producing monoclonal antibodies
|
US5580774A
(en)
*
|
1989-07-31 |
1996-12-03 |
Eli Lilly And Company |
Chimeric antibodies directed against a human glycoprotein antigen
|
JPH05500611A
(en)
*
|
1989-08-23 |
1993-02-12 |
ザ・ジェネラル・ホスピタル・コーポレーション |
Non-human primate CD4 polypeptides, glycosylatable human CD4 molecules, fragments thereof, fusion proteins thereof, gene sequences and uses thereof
|
DE10399023I2
(en)
|
1989-09-12 |
2006-11-23 |
Ahp Mfg B V |
TFN-binding proteins
|
US5202422A
(en)
*
|
1989-10-27 |
1993-04-13 |
The Scripps Research Institute |
Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
|
US5959177A
(en)
*
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US7037722B1
(en)
|
1989-10-27 |
2006-05-02 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6995014B1
(en)
|
1989-10-27 |
2006-02-07 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US7005560B1
(en)
*
|
1989-10-27 |
2006-02-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
FR2655660B1
(en)
*
|
1989-12-11 |
1992-03-20 |
Rhone Poulenc Sante |
NOVEL POLYPEPTIDES, DNA SEQUENCES FOR THEIR EXPRESSION, PROCESS FOR THEIR PREPARATION AND THEIR USE.
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
US6657103B1
(en)
*
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
EP0528881A4
(en)
*
|
1990-04-24 |
1993-05-26 |
Stratagene |
Methods for phenotype creation from multiple gene populations
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
*
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
US5595887A
(en)
*
|
1990-07-16 |
1997-01-21 |
Bionebraska, Inc. |
Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
|
CA2073031C
(en)
*
|
1990-11-27 |
2002-10-01 |
Linda C. Burkly |
Anti-cd4 antibody homologs useful in prophylaxis and treatment of aids, arc and hiv infection
|
US6403771B1
(en)
|
1991-02-19 |
2002-06-11 |
Actinium Pharmaceuticals, Limited |
Method and means for site directed therapy
|
DE69230142T2
(en)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Tech |
METHOD FOR PRODUCING SPECIFIC BINDING PAIRS
|
US6492160B1
(en)
|
1991-05-15 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US5962255A
(en)
*
|
1992-03-24 |
1999-10-05 |
Cambridge Antibody Technology Limited |
Methods for producing recombinant vectors
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US5858657A
(en)
*
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
DE69233254T2
(en)
|
1991-06-14 |
2004-09-16 |
Genentech, Inc., South San Francisco |
Humanized Heregulin antibody
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
MX9204374A
(en)
*
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
|
US6136310A
(en)
*
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
ES2129454T3
(en)
|
1991-08-22 |
1999-06-16 |
Becton Dickinson Co |
PROCEDURES AND COMPOSITIONS OF CANCER TREATMENTS AND FORECAST OF REACTIONS TO THE INDICATED TREATMENTS.
|
US20070031409A1
(en)
*
|
1991-09-26 |
2007-02-08 |
Stichting Rega Vzw |
Recombinant DNA-molecule complex for the expression of anti-human-interferon-gamma chimeric antibodies or antibody fragments
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US6025165A
(en)
*
|
1991-11-25 |
2000-02-15 |
Enzon, Inc. |
Methods for producing multivalent antigen-binding proteins
|
PT1696031E
(en)
*
|
1991-12-02 |
2010-06-25 |
Medical Res Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
WO1993011778A1
(en)
*
|
1991-12-12 |
1993-06-24 |
The Scripps Research Institute |
Bifunctional antithrombotic molecules and antithrombotic polypeptides
|
DE69233204T2
(en)
*
|
1991-12-13 |
2004-07-15 |
Xoma Corp., Berkeley |
METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
US5871734A
(en)
*
|
1992-01-13 |
1999-02-16 |
Biogen, Inc. |
Treatment for asthma with VLA-4 blocking agents
|
US5635177A
(en)
|
1992-01-22 |
1997-06-03 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
US5583031A
(en)
*
|
1992-02-06 |
1996-12-10 |
President And Fellows Of Harvard College |
Empty major histocompatibility class II heterodimers
|
US5932214A
(en)
|
1994-08-11 |
1999-08-03 |
Biogen, Inc. |
Treatment for inflammatory bowel disease with VLA-4 blockers
|
US5733743A
(en)
*
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
GB9215541D0
(en)
|
1992-07-22 |
1992-09-02 |
Celltech Ltd |
Protein expression system
|
CA2100709C
(en)
*
|
1992-07-27 |
2004-03-16 |
Maurits W. Geerlings |
Method and means for site directed therapy
|
US5437951A
(en)
*
|
1992-09-03 |
1995-08-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Self-assembling recombinant papillomavirus capsid proteins
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
GB9223377D0
(en)
|
1992-11-04 |
1992-12-23 |
Medarex Inc |
Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
|
WO1994012520A1
(en)
*
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
SG44845A1
(en)
|
1993-01-12 |
1997-12-19 |
Biogen Inc |
Recombitant anti-vla4 antibody molecules
|
JPH08510240A
(en)
|
1993-05-12 |
1996-10-29 |
カイロン コーポレイション |
Conserved motif of hepatitis C virus E2 / NS1 region
|
DE69405102T2
(en)
|
1993-06-03 |
1998-01-15 |
Therapeutic Antibodies Inc |
ANTIBODY FRAGMENTS IN THERAPY
|
US5827690A
(en)
*
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
EP0746613B1
(en)
*
|
1994-03-08 |
2006-05-24 |
Memorial Sloan-Kettering Cancer Center |
Recombinant humanized anti-fb5 antibodies
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
USRE39548E1
(en)
*
|
1994-06-17 |
2007-04-03 |
Celltech R&D Limited |
Interleukin-5 specific recombinant antibodies
|
GB9412230D0
(en)
|
1994-06-17 |
1994-08-10 |
Celltech Ltd |
Interleukin-5 specific recombiant antibodies
|
US6140075A
(en)
*
|
1994-07-25 |
2000-10-31 |
Monsanto Company |
Method for producing antibodies and protein toxins in plant cells
|
US6080560A
(en)
*
|
1994-07-25 |
2000-06-27 |
Monsanto Company |
Method for producing antibodies in plant cells
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
WO1996004925A1
(en)
*
|
1994-08-12 |
1996-02-22 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US6017697A
(en)
|
1994-11-14 |
2000-01-25 |
Eli Lilly And Company |
Excitatory amino acid receptor protein and related nucleic acid compounds
|
US6258529B1
(en)
|
1994-12-01 |
2001-07-10 |
Oravax, Inc. |
PCR amplification of rearranged genomic variable regions of immunoglobulin genes
|
US20030086922A1
(en)
*
|
1994-12-02 |
2003-05-08 |
David B. Ring |
Method of promoting an immune response with a bispecific antibody
|
WO1996017941A2
(en)
*
|
1994-12-07 |
1996-06-13 |
Bionebraska, Inc. |
Production of c-terminal amidated peptides from recombinant protein constructs
|
US20030144483A1
(en)
*
|
1995-05-04 |
2003-07-31 |
Medarex, Inc. |
Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
JPH11507535A
(en)
|
1995-06-07 |
1999-07-06 |
イムクローン システムズ インコーポレイテッド |
Antibodies and antibody fragments that suppress tumor growth
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
JPH09124509A
(en)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
Therapeutic agent for hepatitis
|
US6001358A
(en)
*
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7964190B2
(en)
*
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
GB9610967D0
(en)
|
1996-05-24 |
1996-07-31 |
Cambridge Antibody Tech |
Specific binding members,materials and methods
|
US5961976A
(en)
*
|
1996-06-03 |
1999-10-05 |
United Biomedical, Inc. |
Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
|
EP1378525A3
(en)
|
1996-06-07 |
2004-01-14 |
Neorx Corporation |
Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
|
GB9712818D0
(en)
|
1996-07-08 |
1997-08-20 |
Cambridge Antibody Tech |
Labelling and selection of specific binding molecules
|
US7147851B1
(en)
*
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
WO1998012329A2
(en)
*
|
1996-09-20 |
1998-03-26 |
The General Hospital Corporation |
Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
|
US5916771A
(en)
*
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US6420140B1
(en)
*
|
1996-10-11 |
2002-07-16 |
Abgenix, Inc. |
Production of multimeric protein by cell fusion method
|
US5977319A
(en)
*
|
1996-10-21 |
1999-11-02 |
Cambridge Antibody Technology Limited |
Specific binding members for estradiol; materials and methods
|
US6417337B1
(en)
|
1996-10-31 |
2002-07-09 |
The Dow Chemical Company |
High affinity humanized anti-CEA monoclonal antibodies
|
US6348581B1
(en)
|
1996-10-31 |
2002-02-19 |
The Dow Chemical Company |
High affinity humanized anti-TAG-72 monoclonalantibodies
|
JPH10150984A
(en)
*
|
1996-11-19 |
1998-06-09 |
Hagiwara Yoshihide |
Production of antibody molecule
|
WO1998041641A1
(en)
*
|
1997-03-20 |
1998-09-24 |
The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
|
US5866412A
(en)
*
|
1997-03-27 |
1999-02-02 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US5939316A
(en)
*
|
1997-03-27 |
1999-08-17 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US5955355A
(en)
*
|
1997-03-27 |
1999-09-21 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US5914394A
(en)
*
|
1997-03-27 |
1999-06-22 |
Millenium Pharmaceuticals, Inc. |
Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
|
EP0977862B8
(en)
*
|
1997-04-30 |
2009-09-16 |
Twinstrand Therapeutics Inc. |
Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
|
US6156546A
(en)
*
|
1997-05-16 |
2000-12-05 |
Washington State University Research Foundation |
Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
|
US6528271B1
(en)
|
1997-06-05 |
2003-03-04 |
Duke University |
Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
|
US5891646A
(en)
*
|
1997-06-05 |
1999-04-06 |
Duke University |
Methods of assaying receptor activity and constructs useful in such methods
|
US7541151B2
(en)
|
1997-06-05 |
2009-06-02 |
Duke University |
Single-cell biosensor for the measurement of GPCR ligands in a test sample
|
US7147854B2
(en)
*
|
1997-06-23 |
2006-12-12 |
Yes Biotech Laboratories Ltd. |
Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
|
DE69841139D1
(en)
*
|
1997-07-14 |
2009-10-22 |
Univ Liege |
MUTATIONS IN MYOSTATINGEN INCREASE MUSCLE MASS IN MAMMALS
|
US6103466A
(en)
*
|
1997-07-14 |
2000-08-15 |
University Of Liege |
Double-muscling in mammals
|
US20070067859A1
(en)
*
|
1997-07-14 |
2007-03-22 |
Michel Georges |
Double-muscling in mammals
|
WO1999009153A1
(en)
|
1997-08-21 |
1999-02-25 |
Fred Hutchinson Cancer Research Center |
ISOLATION AND EXPRESSION OF A DISABLED PROTEIN GENE mDabl AND METHODS
|
US20030166106A1
(en)
*
|
1997-09-18 |
2003-09-04 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6756361B1
(en)
|
1997-10-14 |
2004-06-29 |
Nabi |
Enterococcus antigens and vaccines
|
JP2001520038A
(en)
|
1997-10-21 |
2001-10-30 |
ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー |
JMY, a coactivator of P300 / CBP, nucleic acid encoding JMY, and uses thereof
|
WO1999027105A2
(en)
|
1997-11-21 |
1999-06-03 |
Genset |
Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
|
KR100760221B1
(en)
|
1997-11-28 |
2007-10-30 |
세로노 제네틱스 인스티튜트 에스.에이. |
Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US6051228A
(en)
*
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
JP2002506875A
(en)
|
1998-03-16 |
2002-03-05 |
ミレニアム ファーマシューティカルズ インク. |
Methods and compositions for diagnosis and treatment of chromosome 18p-related disorders
|
US20040176572A1
(en)
*
|
1998-03-16 |
2004-09-09 |
Freimer Nelson B. |
Methods of compositions for diagnosing and treating chromosome-18p related disorders
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
US6197947B1
(en)
|
1998-06-01 |
2001-03-06 |
The Rockefeller University |
Translation initiation factor 4AIII and methods of use thereof
|
JP2000000097A
(en)
|
1998-06-15 |
2000-01-07 |
Nippon Zoki Pharmaceut Co Ltd |
Nef-binding protein, dna encoding the protein and monoclonal antibody against the same protein
|
US8609614B2
(en)
*
|
1998-07-22 |
2013-12-17 |
Vanderbilt University |
GBS toxin receptor compositions and methods of use
|
US6803448B1
(en)
*
|
1998-07-22 |
2004-10-12 |
Vanderbilt University |
GBS toxin receptor
|
US6312689B1
(en)
*
|
1998-07-23 |
2001-11-06 |
Millennium Pharmaceuticals, Inc. |
Anti-CCR2 antibodies and methods of use therefor
|
US6696550B2
(en)
|
1998-07-23 |
2004-02-24 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-CCR2 antibodies and methods of use therefor
|
US6727349B1
(en)
|
1998-07-23 |
2004-04-27 |
Millennium Pharmaceuticals, Inc. |
Recombinant anti-CCR2 antibodies and methods of use therefor
|
NZ528199A
(en)
|
1998-08-11 |
2005-06-24 |
Idec Pharma Corp |
Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
|
HUP0103563A3
(en)
*
|
1998-08-31 |
2004-04-28 |
Biogen Idec Ma Inc Cambridge |
Method of modulating memory effector t-cells and compositions
|
CA2343320A1
(en)
*
|
1998-09-18 |
2000-03-30 |
The Rockefeller University |
Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
|
WO2000023579A1
(en)
*
|
1998-10-22 |
2000-04-27 |
The Regents Of The University Of California |
Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
|
ES2338287T3
(en)
*
|
1998-11-09 |
2010-05-05 |
Biogen Idec Inc. |
TREATMENT OF ANTI-CD20 PATIENTS ANTIBODIES RECEIVING TRANSPLANTS OF OSEA MEDULA GRAFT OR MOTHER PERIPHERAL BLOOD CELLS.
|
AU761844C
(en)
*
|
1998-11-09 |
2004-09-23 |
F. Hoffmann-La Roche Ag |
Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
US6358703B1
(en)
|
1998-12-10 |
2002-03-19 |
Bayer Corporation |
Expression system for factor VIII
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
SI1141028T1
(en)
|
1998-12-23 |
2010-05-31 |
Pfizer |
Human monoclonal antibodies to ctla-4
|
JP2002540764A
(en)
*
|
1999-02-12 |
2002-12-03 |
ジェネティックス・インスチチュート・インコーポレーテッド |
Humanized immunoglobulin reacting with B7 molecule and therapeutic method using the same
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
US6531125B1
(en)
|
1999-03-02 |
2003-03-11 |
Twinstrand Therapeutics Inc. |
Antiviral ricin-like proteins
|
US6914128B1
(en)
*
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
CA2669512A1
(en)
|
1999-03-25 |
2000-09-28 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human il-12 and methods for producing
|
US7883704B2
(en)
*
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
ATE403154T1
(en)
|
1999-04-13 |
2008-08-15 |
Wilex Ag |
DIAGNOSTIC AND THERAPEUTIC USE OF ANTIBODIES AGAINST THE UROKINASE RECEPTOR
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
RU2294761C2
(en)
*
|
1999-05-14 |
2007-03-10 |
Имклон Систимс Инкопэритид |
Method for treating resistant human tumors with epidermis growth factor receptors antagonists
|
CA2305716A1
(en)
|
1999-05-28 |
2000-11-28 |
University Of Guelph |
Method for assay of wbpm
|
US20040001826A1
(en)
*
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7291714B1
(en)
*
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
FR2797402B1
(en)
|
1999-07-15 |
2004-03-12 |
Biomerieux Stelhys |
USE OF A POLYPEPTIDE FOR DETECTING, PREVENTING OR TREATING A CONDITION ASSOCIATED WITH A DEGENERATIVE, NEUROLOGICAL OR AUTOIMMUNE DISEASE
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
CA2589418A1
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
JP2004504003A
(en)
|
1999-09-24 |
2004-02-12 |
モルフォゲン ファーマスーティカルズ インコーポレイテッド |
Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
|
US6346249B1
(en)
|
1999-10-22 |
2002-02-12 |
Ludwig Institute For Cancer Research |
Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
|
US6342587B1
(en)
|
1999-10-22 |
2002-01-29 |
Ludwig Institute For Cancer Research |
A33 antigen specific immunoglobulin products and uses thereof
|
EP2067862A1
(en)
|
1999-11-05 |
2009-06-10 |
The General Hospital Corporation |
Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
|
ATE465751T1
(en)
|
2000-02-02 |
2010-05-15 |
Univ Vanderbilt |
METHOD FOR PREVENTING AND RELIEVING ANGIOGENIC DISEASES BY VACCINATION WITH THE GBS TOXIN RECEPTOR (CM101)
|
CA2897626C
(en)
|
2000-02-11 |
2020-03-24 |
Biogen Idec Ma Inc. |
Heterologous polypeptide of the tnf family
|
PT1257297E
(en)
*
|
2000-02-24 |
2006-12-29 |
Philogen Spa |
Compositions and methods for treatemnt of angiogenesis in pathological lesions
|
JP2003524018A
(en)
|
2000-02-24 |
2003-08-12 |
アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ |
Antibodies specific for the ED-B domain of fibronectin, complexes containing said antibodies, and uses thereof for detecting and treating angiogenesis
|
US20030212022A1
(en)
*
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
DE60130743T2
(en)
*
|
2000-03-24 |
2008-07-17 |
Biosphere Medical, Inc., Rockland |
MICROBALLS FOR ACTIVE EMBOLIZATION
|
US20030144236A1
(en)
*
|
2000-03-29 |
2003-07-31 |
Weiss Robert H |
Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1)
|
US20050043262A1
(en)
*
|
2000-03-29 |
2005-02-24 |
Weiss Robert H. |
Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor
|
EP1274720A4
(en)
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
Albumin fusion proteins
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
US6696620B2
(en)
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
MX347175B
(en)
|
2000-05-10 |
2017-04-17 |
Mayo Foundation |
Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system.
|
US6358733B1
(en)
|
2000-05-19 |
2002-03-19 |
Apolife, Inc. |
Expression of heterologous multi-domain proteins in yeast
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
WO2001094586A2
(en)
*
|
2000-06-06 |
2001-12-13 |
Idec Pharmaceuticals Corporation |
Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
Human tumor necrosis factor delta and epsilon
|
ATE494304T1
(en)
|
2000-06-16 |
2011-01-15 |
Human Genome Sciences Inc |
IMMUNE-SPECIFIC BINDING ANTIBODIES AGAINST BLYS
|
EP1176200A3
(en)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances
|
SK1152003A3
(en)
|
2000-06-29 |
2003-07-01 |
Abbott Lab |
Dual specificity antibodies and methods of making and using
|
EP1810978B1
(en)
|
2000-08-08 |
2013-02-13 |
St. Jude Children's Research Hospital |
Group B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof
|
AU9500201A
(en)
*
|
2000-08-09 |
2002-02-18 |
Imclone Systems Inc |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
AU2001283304B2
(en)
*
|
2000-08-11 |
2005-05-05 |
Favrille, Inc. |
Method and composition for altering a T cell mediated pathology
|
US20040082506A1
(en)
|
2000-08-11 |
2004-04-29 |
Takeyoshi Yamashita |
Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
|
US6911204B2
(en)
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
EP1191036A3
(en)
|
2000-08-25 |
2002-07-03 |
Pfizer Products Inc. |
Methods and compositions for diagnosing and treating disorders involving angiogenesis
|
EP1197550A3
(en)
*
|
2000-08-25 |
2002-11-20 |
Pfizer Products Inc. |
Methods and compositions for diagnosing and treating disorders involving angiogenesis
|
IL154596A0
(en)
|
2000-08-25 |
2003-09-17 |
Basf Plant Science Gmbh |
Plant polynucleotides encoding novel prenyl proteases
|
ATE373717T1
(en)
*
|
2000-09-12 |
2007-10-15 |
Univ Washington |
PDE8A AND ITS USE
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
US6610472B1
(en)
*
|
2000-10-31 |
2003-08-26 |
Genetastix Corporation |
Assembly and screening of highly complex and fully human antibody repertoire in yeast
|
EP1339427A4
(en)
*
|
2000-11-01 |
2004-09-15 |
Elusys Therapeutics Inc |
Method of producing biospecific molecules by protein trans-splicing
|
US20050136431A1
(en)
*
|
2000-11-03 |
2005-06-23 |
Oakley Robert H. |
Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
|
US7018812B2
(en)
|
2000-11-03 |
2006-03-28 |
Duke University |
Modified G-protein coupled receptors
|
US7163800B2
(en)
*
|
2000-11-03 |
2007-01-16 |
Molecular Devices Corporation |
Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
|
CA2429544C
(en)
|
2000-11-17 |
2010-10-19 |
University Of Rochester |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
TWI327599B
(en)
|
2000-11-28 |
2010-07-21 |
Medimmune Llc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
US7482435B2
(en)
|
2000-12-05 |
2009-01-27 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
PT1355919E
(en)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Molecules with extended half-lives, compositions and uses thereof
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
US7279324B2
(en)
*
|
2001-01-23 |
2007-10-09 |
Duke University |
Nucleic acid encoding G-protein coupled receptor with modified DRY motif
|
US20030104402A1
(en)
*
|
2001-01-23 |
2003-06-05 |
University Of Rochester |
Methods of producing or identifying intrabodies in eukaryotic cells
|
WO2002062822A2
(en)
*
|
2001-02-02 |
2002-08-15 |
University Of Rochester |
Methods of identifying regulator molecules
|
WO2002064612A2
(en)
|
2001-02-09 |
2002-08-22 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
AU2002254132A1
(en)
*
|
2001-03-06 |
2002-09-19 |
Sierra Sciences, Inc. |
Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
|
AU2002258525A1
(en)
*
|
2001-03-13 |
2002-09-24 |
Sierra Sciences, Inc. |
Telomerase expression repressor proteins and methods of using the same
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US8231878B2
(en)
*
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
*
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
ATE510557T1
(en)
|
2001-04-24 |
2011-06-15 |
Merck Patent Gmbh |
COMBINATION THERAPY WITH ANTIANGIOGENIC AGENTS AND TNFALPHA
|
DE10121255A1
(en)
*
|
2001-04-30 |
2002-11-07 |
Switch Biotech Ag |
Use of alpha 1-antichymotrypsin polypeptide or nucleic acids encoding the polypeptide, or of a cell expressing the polypeptide, or of antibody against the polypeptide, for diagnosing, treating or preventing poorly-healing wounds
|
US7256257B2
(en)
*
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
GB0111628D0
(en)
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
DE60234094D1
(en)
|
2001-05-11 |
2009-12-03 |
Ludwig Inst For Cancer Res Ltd |
SPECIFIC TIE PROTEINS AND ITS USE
|
US6972324B2
(en)
*
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
WO2002094194A2
(en)
*
|
2001-05-22 |
2002-11-28 |
Duke University |
Compositions and methods for inhibiting metastasis
|
WO2002094376A2
(en)
*
|
2001-05-22 |
2002-11-28 |
Duke University |
Compositions and methods for promoting or inhibiting ndpk
|
JP4309758B2
(en)
|
2001-05-25 |
2009-08-05 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
Antibodies that immunospecifically bind to TRAIL receptors
|
GB0112844D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Psimei Pharmaceuticals Plc |
Neutron capture therapy
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7745398B2
(en)
*
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
WO2003000916A2
(en)
*
|
2001-06-21 |
2003-01-03 |
Sierra Sciences, Inc. |
Telomerase expression repressor proteins and methods of using the same
|
WO2003007800A2
(en)
|
2001-07-17 |
2003-01-30 |
The General Hospital Corporation |
Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
|
US6706523B2
(en)
|
2001-07-20 |
2004-03-16 |
University Of Georgia Research Foundation, Inc. |
Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
|
WO2003009740A2
(en)
*
|
2001-07-24 |
2003-02-06 |
Biogen Idec Ma Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
EP1423432A4
(en)
*
|
2001-07-26 |
2006-01-11 |
Lilly Co Eli |
Interleukin-1 beta antibodies
|
JP4266825B2
(en)
|
2001-09-20 |
2009-05-20 |
イミユネツクス・コーポレイシヨン |
Selection of cells expressing heteromeric polypeptides
|
EP1438389A4
(en)
|
2001-10-01 |
2004-12-29 |
Gen Hospital Corp |
Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
|
WO2003029456A1
(en)
*
|
2001-10-01 |
2003-04-10 |
Dyax Corp. |
Multi-chain eukaryotic display vectors and uses thereof
|
US20040151721A1
(en)
*
|
2001-10-19 |
2004-08-05 |
O'keefe Theresa |
Humanized anti-CCR2 antibodies and methods of use therefor
|
WO2003040341A2
(en)
|
2001-11-07 |
2003-05-15 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-hepatitis a virus antibodies
|
AU2002334746B2
(en)
*
|
2001-11-15 |
2007-10-11 |
Becton, Dickinson And Company |
Methods and devices for the integrated discovery of cell culture environments
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
WO2003049673A2
(en)
|
2001-12-05 |
2003-06-19 |
Baylor College Of Medicine |
Methods and compositions for control of bone formation via modulation of sympathetic tone
|
JP2005516917A
(en)
|
2001-12-12 |
2005-06-09 |
アメリカ合衆国 |
Methods for enhancing immune response and inflammation using extracellular adenosine inhibitors and adenosine receptor inhibitors
|
GB0130543D0
(en)
|
2001-12-20 |
2002-02-06 |
Univ Cambridge Tech |
Human antibodies and their use
|
EP2277888A3
(en)
|
2001-12-21 |
2011-04-27 |
Human Genome Sciences, Inc. |
Fusion proteins of albumin and erythropoietin
|
ES2331414T3
(en)
|
2001-12-28 |
2010-01-04 |
Kyowa Hakko Kirin Co Ltd |
ANTIBODIES AGAINST FIBROBLAST GROWTH FACTOR 23.
|
US6578724B1
(en)
*
|
2001-12-29 |
2003-06-17 |
United States Can Company |
Connector for use in packaging aerosol containers
|
US7135174B2
(en)
*
|
2002-01-07 |
2006-11-14 |
Amgen Fremont, Inc. |
Antibodies directed to PDGFD and uses thereof
|
US20040009498A1
(en)
*
|
2002-01-14 |
2004-01-15 |
Diversa Corporation |
Chimeric antigen binding molecules and methods for making and using them
|
US20070166704A1
(en)
*
|
2002-01-18 |
2007-07-19 |
Fei Huang |
Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
WO2003076469A2
(en)
|
2002-03-11 |
2003-09-18 |
Philogen S.P.A. |
Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20030233197A1
(en)
*
|
2002-03-19 |
2003-12-18 |
Padilla Carlos E. |
Discrete bayesian analysis of data
|
US20030182669A1
(en)
*
|
2002-03-19 |
2003-09-25 |
Rockman Howard A. |
Phosphoinositide 3-kinase mediated inhibition of GPCRs
|
EP1497445A2
(en)
*
|
2002-04-01 |
2005-01-19 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
NZ536420A
(en)
*
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
EP2270049A3
(en)
|
2002-04-12 |
2011-03-09 |
Medimmune, Inc. |
Recombinant anti-interleukin-9-antibody
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
AU2003221575B2
(en)
|
2002-05-02 |
2010-06-10 |
Dalia Barsyte |
Teneurin C-terminal associated peptides (TCAP) and uses thereof
|
JP4563171B2
(en)
*
|
2002-05-24 |
2010-10-13 |
シェーリング コーポレイション |
Neutralizing human anti-IGFR antibody
|
US7290215B2
(en)
*
|
2002-06-03 |
2007-10-30 |
Microsoft Corporation |
Dynamic wizard interface system and method
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
PT2314629E
(en)
|
2002-07-18 |
2014-01-22 |
Merus B V |
Recombinant production of mixtures of antibodies
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
CA2493007A1
(en)
*
|
2002-07-19 |
2004-01-29 |
Cellzome Ag |
Protein complexes of the tip60 transcriptional activator protein
|
KR20140058649A
(en)
|
2002-07-19 |
2014-05-14 |
애브비 바이오테크놀로지 리미티드 |
TREATMENT OF TNFα RELATED DISORDERS
|
PT1545613E
(en)
|
2002-07-31 |
2011-09-27 |
Seattle Genetics Inc |
Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
WO2004016750A2
(en)
|
2002-08-14 |
2004-02-26 |
Macrogenics, Inc. |
FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
EP1539947A4
(en)
*
|
2002-08-15 |
2006-09-06 |
Epitomics Inc |
Humanized rabbit antibodies
|
KR20050058407A
(en)
|
2002-08-20 |
2005-06-16 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
|
EP1539234A4
(en)
*
|
2002-09-05 |
2006-02-15 |
Medimmune Inc |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
JP2005538738A
(en)
*
|
2002-09-16 |
2005-12-22 |
エリューシス セラピューティクス,インコーポレーテッド |
Bispecific molecule comprising an anti-CR1 antibody cross-linked to an antigen-binding antibody fragment
|
US20040053363A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
US20040053359A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
US7741437B2
(en)
|
2002-09-19 |
2010-06-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
|
WO2004029246A2
(en)
|
2002-09-26 |
2004-04-08 |
K.U.Leuven Research And Development |
Integrase cofactor
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
CN1684977A
(en)
*
|
2002-09-27 |
2005-10-19 |
奥里迪斯生物医学研究及开发有限责任公司 |
Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
|
US7541440B2
(en)
*
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
HUE034378T2
(en)
|
2002-10-16 |
2018-02-28 |
Purdue Pharma Lp |
Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
|
AU2003287267A1
(en)
|
2002-10-29 |
2004-05-25 |
Centro De Pesquisas Goncalo Moniz |
Lutzomyia longipalpis polypeptides and methods of use
|
ES2387985T3
(en)
|
2002-11-26 |
2012-10-05 |
Abbott Biotherapeutics Corp. |
Chimeric and humanized alpha 5 beta 1 integrin antibodies that modulate angiogenesis
|
MXPA05005921A
(en)
|
2002-12-02 |
2005-10-19 |
Abgenix Inc |
Antibodies directed to tumor necrosis factor and uses thereof.
|
WO2004051268A1
(en)
*
|
2002-12-03 |
2004-06-17 |
Celltech R & D Limited |
Assay for identifying antibody producing cells
|
CA2508348C
(en)
|
2002-12-06 |
2016-07-12 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
|
AU2002953431A0
(en)
*
|
2002-12-19 |
2003-01-09 |
Murdoch University |
BmpB Novel Nucleotide and Amino Acid Sequences and Diagnostic and Therapeutic Uses Thereof
|
JP4898120B2
(en)
|
2002-12-20 |
2012-03-14 |
アボット バイオセラピューティクス コーポレイション |
Antibodies against GPR64 and methods of use thereof
|
CA2511012C
(en)
|
2002-12-20 |
2018-02-27 |
Applera Corporation |
Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
AU2004206250B8
(en)
*
|
2003-01-21 |
2009-09-17 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
|
DE10303974A1
(en)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid β (1-42) oligomers, process for their preparation and their use
|
US20060188512A1
(en)
*
|
2003-02-01 |
2006-08-24 |
Ted Yednock |
Active immunization to generate antibodies to solble a-beta
|
US20040248798A1
(en)
|
2003-02-14 |
2004-12-09 |
Peter Sutovsky |
Contraceptive methods and compositions related to proteasomal interference
|
EP2289559B1
(en)
|
2003-02-20 |
2014-02-12 |
Seattle Genetics, Inc. |
Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
DE10311248A1
(en)
*
|
2003-03-14 |
2004-09-30 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Human monoclonal antibody
|
AU2004224390A1
(en)
|
2003-03-19 |
2004-10-07 |
Abgenix, Inc. |
Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
|
GEP20094629B
(en)
|
2003-03-19 |
2009-03-10 |
Biogen Idec Inc |
Nogo receptor binding protein
|
WO2004083865A2
(en)
|
2003-03-20 |
2004-09-30 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Materials and methods for modulating cell motility
|
KR20110094361A
(en)
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
Recombinant il-9 antibodies and uses thereof
|
SE0301087D0
(en)
|
2003-04-14 |
2003-04-14 |
Cartela Ab |
New monoclonal antibody
|
CA2523142A1
(en)
|
2003-04-23 |
2004-11-04 |
Medarex, Inc. |
Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
|
EP2829283B1
(en)
|
2003-04-30 |
2017-06-07 |
Universität Zürich |
Methods for treating cancer using an immunotoxin
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US9096676B2
(en)
|
2003-05-12 |
2015-08-04 |
Helion Biotech Aps |
Antibodies to MASP-2
|
EP1648427B1
(en)
*
|
2003-05-16 |
2013-12-18 |
Mayo Foundation For Medical Education And Research |
Low dose IgM antibody treatment of demyelinating disorders
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
ES2408582T3
(en)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
US7405274B2
(en)
|
2003-06-04 |
2008-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor antibodies
|
GB0313259D0
(en)
|
2003-06-09 |
2003-07-16 |
Consejo Superior Investigacion |
Magnetic nanoparticles
|
KR101531400B1
(en)
|
2003-06-27 |
2015-06-26 |
암젠 프레몬트 인코포레이티드 |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
GB0315457D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
GB0315450D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
US20050058658A1
(en)
*
|
2003-07-15 |
2005-03-17 |
Barros Research Institute |
Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
|
US7393534B2
(en)
*
|
2003-07-15 |
2008-07-01 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases
|
EP1498133A1
(en)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Use of a pak inhibitor for the treatment of a joint disease
|
US7619059B2
(en)
*
|
2003-07-29 |
2009-11-17 |
Life Technologies Corporation |
Bimolecular optical probes
|
US7727752B2
(en)
*
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
CA2445420A1
(en)
*
|
2003-07-29 |
2005-01-29 |
Invitrogen Corporation |
Kinase and phosphatase assays
|
CA2534382C
(en)
|
2003-08-04 |
2018-12-11 |
The Hospital For Sick Children |
Epm2b gene mutations associated with lafora's disease
|
WO2005014795A2
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
WO2005014051A1
(en)
*
|
2003-08-08 |
2005-02-17 |
Barnes-Jewish Hospital |
Emulsion particles for imaging and therapy and methods of use thereof
|
US20060216292A1
(en)
*
|
2003-09-05 |
2006-09-28 |
Cellzome Ag |
Treatment of neurodegenerative diseases
|
EP1514561A1
(en)
|
2003-09-10 |
2005-03-16 |
Philogen S.p.A. |
Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
|
AU2004272747A1
(en)
|
2003-09-18 |
2005-03-24 |
Genmab A/S |
Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
|
WO2006101474A1
(en)
*
|
2005-03-15 |
2006-09-28 |
University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin k-dependent proteins
|
DE602004025157D1
(en)
*
|
2003-09-23 |
2010-03-04 |
Univ North Carolina |
Cells that co-express vitamin K reductase and vitamin K-dependent protein and their application to improve the productivity of this vitamin K-dependent protein
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US7799518B2
(en)
|
2003-10-07 |
2010-09-21 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
|
ATE540107T1
(en)
*
|
2003-10-14 |
2012-01-15 |
Baxter Int |
VKORC1 (VITAMIN K EPOXIDE RECYCLING POLYPEPTIDE), A THERAPEUTIC TARGET FOR COUMARIN AND THEIR DERIVATIVES
|
JP5037134B2
(en)
|
2003-10-17 |
2012-09-26 |
レハブ アル−ジャマル |
Tissue repair
|
BR122018071808B8
(en)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugate
|
US20060199194A1
(en)
*
|
2003-11-10 |
2006-09-07 |
Q-Rna, Inc. |
Methods of detection using immuno-Q-Amp technology
|
AR046833A1
(en)
|
2003-11-10 |
2005-12-28 |
Schering Corp |
ANTI-INTERLEUQUINA ANTIBODIES-10
|
US20050214805A1
(en)
*
|
2003-11-10 |
2005-09-29 |
Q-Rna, Inc. |
Methods of detection employing immuno-Q-Amp technology
|
DK1687066T3
(en)
|
2003-11-14 |
2012-11-26 |
Brigham & Womens Hospital |
Methods of Immunomodulation
|
CA3050151C
(en)
|
2003-11-26 |
2023-03-07 |
Celera Corporation |
Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
|
JP2007521248A
(en)
|
2003-12-10 |
2007-08-02 |
ミレニアム ファーマシューティカルズ, インコーポレイテッド |
Humanized anti-CCR2 antibody and methods of using the antibody
|
US7427670B2
(en)
*
|
2003-12-19 |
2008-09-23 |
Cytochroma Inc. |
Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
|
US20050249723A1
(en)
*
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
KR20130041373A
(en)
|
2003-12-23 |
2013-04-24 |
제넨테크, 인크. |
Novel anti-il 13 antibodies and uses thereof
|
EP2311873B1
(en)
|
2004-01-07 |
2018-08-29 |
Novartis Vaccines and Diagnostics, Inc. |
M-csf-specific monoclonal antibody and uses thereof
|
EP1737971B1
(en)
|
2004-01-20 |
2017-08-16 |
Merus N.V. |
Mixtures of binding proteins
|
EP1713501B1
(en)
*
|
2004-01-29 |
2008-01-16 |
Cellzome Ag |
Treatment of neurodegenerative diseases by the use of gpr49
|
WO2005075632A2
(en)
*
|
2004-01-29 |
2005-08-18 |
Cellzome Ag |
Treatment of neurodegenerative diseases by the use of atp7a-modulators
|
CN1953766A
(en)
*
|
2004-02-06 |
2007-04-25 |
安斯泰来美国有限公司 |
Methods of treating skin disorders
|
KR101184391B1
(en)
|
2004-02-09 |
2013-03-14 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
Albumin fusion proteins
|
US7767792B2
(en)
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
CN101072797B
(en)
|
2004-03-12 |
2012-05-09 |
瓦斯基因治疗公司 |
Antibody binding EPHB4, inhibiting angiogenesis and tumor growth
|
AU2005224267B2
(en)
*
|
2004-03-19 |
2011-07-21 |
Imclone Llc |
Human anti-epidermal growth factor receptor antibody
|
EP2053062A1
(en)
*
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
ATE455577T1
(en)
*
|
2004-03-26 |
2010-02-15 |
Cellzome Ag |
TREATMENT OF NEURODEGENERATIVE DISEASES BY USING LAPTM4B
|
EP1786463A4
(en)
*
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
Antibodies against nogo receptor
|
US7527791B2
(en)
|
2004-03-31 |
2009-05-05 |
Genentech, Inc. |
Humanized anti-TGF-beta antibodies
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US20080038265A1
(en)
*
|
2004-04-09 |
2008-02-14 |
Reilly Edward B |
Antibodies to Erythropoietin Receptor and Uses Thereof
|
US20060018902A1
(en)
*
|
2004-04-09 |
2006-01-26 |
Reilly Edward B |
Antibodies to erythropoietin receptor and uses thereof
|
TWI439284B
(en)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
Multiple-variable dose regimen for treating tnfα-related disorders
|
US20050227289A1
(en)
|
2004-04-09 |
2005-10-13 |
Reilly Edward B |
Antibodies to erythropoietin receptor and uses thereof
|
ES2442386T3
(en)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Method for the treatment of conditions mediated by T cells by the decrease of positive ICOS cells in vivo.
|
EP1753449A4
(en)
|
2004-04-30 |
2009-09-23 |
Corthera Inc |
Methods and compositions for control of fetal growth via modulation of relaxin
|
BRPI0510691A
(en)
*
|
2004-05-04 |
2007-12-26 |
Genaissance Pharmaceuticals |
haplotype markers and methods of using them to determine response to treatment
|
EP1745154B1
(en)
|
2004-05-07 |
2012-08-01 |
Celera Corporation |
Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
|
US7662921B2
(en)
*
|
2004-05-07 |
2010-02-16 |
Astellas Us Llc |
Methods of treating viral disorders
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
GB0412973D0
(en)
*
|
2004-06-10 |
2004-07-14 |
Celltech R&D Ltd |
Identification of antibody producing cells
|
DK1794313T3
(en)
|
2004-06-21 |
2013-07-22 |
Proteome Sciences Plc |
Method for screenings using C-ABL, FYN and SYK in combination with tau protein
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
WO2006002437A2
(en)
*
|
2004-06-24 |
2006-01-05 |
Biogen Idec Ma Inc. |
Treatment of conditions involving demyelination
|
DK2287195T3
(en)
|
2004-07-01 |
2019-08-19 |
Innate Pharma |
PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND USE IN DIAGNOSTICS AND THERAPY
|
US7973134B2
(en)
*
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US6986264B1
(en)
*
|
2004-07-15 |
2006-01-17 |
Carrier Corporation |
Economized dehumidification system
|
ME00226B
(en)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
CA2573821A1
(en)
|
2004-07-16 |
2006-01-26 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
EP2329714A1
(en)
|
2004-08-03 |
2011-06-08 |
Biogen Idec MA Inc. |
Influence of TAJ in the neuronal functions
|
DE602004010314T2
(en)
*
|
2004-08-09 |
2009-03-05 |
Cellzome Ag |
TREATMENT OF NEURODEEGENERATIVE DISORDERS BY USING DEGS INHIBITORS
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
TWI384069B
(en)
|
2004-08-27 |
2013-02-01 |
Pfizer Ireland Pharmaceuticals |
Production of polypeptides
|
TWI364458B
(en)
*
|
2004-08-27 |
2012-05-21 |
Wyeth Res Ireland Ltd |
Production of tnfr-lg
|
TWI374935B
(en)
|
2004-08-27 |
2012-10-21 |
Pfizer Ireland Pharmaceuticals |
Production of α-abeta
|
US7432359B2
(en)
|
2004-09-06 |
2008-10-07 |
Kirin Pharma Kabushiki Kaisha |
Anti-A33 antibody
|
AU2005280975B2
(en)
|
2004-09-06 |
2009-06-18 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-A33 antibody
|
WO2006029398A2
(en)
*
|
2004-09-09 |
2006-03-16 |
University Of Washington |
All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
MX2007004437A
(en)
|
2004-10-22 |
2007-06-20 |
Amgen Inc |
Methods for refolding of recombinant antibodies.
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
CA2585849A1
(en)
*
|
2004-10-29 |
2006-05-11 |
Elusys Therapeutics, Inc. |
Use of cr1-binding molecules in clearance and induction of immune responses
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
US7709208B2
(en)
*
|
2004-11-08 |
2010-05-04 |
New York University |
Methods for diagnosis of major depressive disorder
|
EP2157102A1
(en)
|
2004-11-09 |
2010-02-24 |
Philogen S.p.A. |
Antibodies against tenascin-C
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP2314618A3
(en)
|
2004-11-12 |
2011-10-19 |
Xencor Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP1817336B1
(en)
|
2004-11-12 |
2019-01-09 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
AU2005307831A1
(en)
|
2004-11-17 |
2006-05-26 |
Amgen, Inc. |
Fully human monoclonal antibodies to IL-13
|
WO2006083355A2
(en)
|
2004-11-19 |
2006-08-10 |
Cornell Research Foundation, Inc. |
Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
|
US20090202527A1
(en)
*
|
2004-11-19 |
2009-08-13 |
Biogen Idec Ma Inc. |
Treatment for multiple sclerosis
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
DE602005025685D1
(en)
|
2004-12-03 |
2011-02-10 |
Schering Corp |
BIOLOGICAL MARKERS FOR THE PRESELECTION OF PATIENTS FOR ANTI-IGF1R THERAPY
|
KR20070085439A
(en)
|
2004-12-06 |
2007-08-27 |
기린 비루 가부시키가이샤 |
Human monoclonal antibodies to influenza m2 protein and methods of making and using same
|
WO2006066171A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Amyloid βετα antibodies for use in improving cognition
|
ES2396555T3
(en)
*
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Antibodies that recognize beta amyloid peptide
|
PE20061329A1
(en)
*
|
2004-12-15 |
2006-12-08 |
Neuralab Ltd |
HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
|
ATE504602T1
(en)
|
2004-12-20 |
2011-04-15 |
Amgen Fremont Inc |
BINDING PROTEINS SPECIFIC TO HUMAN MATRIPTASE
|
US7807789B2
(en)
*
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
EP1836225B1
(en)
|
2005-01-06 |
2011-11-02 |
Novo Nordisk A/S |
Kir-binding agents and methods of use thereof
|
EP1835929B8
(en)
|
2005-01-06 |
2016-07-27 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
CA2595169A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
CN103497993A
(en)
|
2005-02-07 |
2014-01-08 |
基因信息公司 |
Mild osteoarthritis biomarkers and uses thereof
|
US7723486B2
(en)
|
2005-02-08 |
2010-05-25 |
Optein, Inc. |
Antibodies to TGF-β
|
JP2008531730A
(en)
*
|
2005-03-04 |
2008-08-14 |
キュアーディーエム、インク. |
Methods and pharmaceutical compositions for treating type I diabetes mellitus and other conditions
|
US20090142338A1
(en)
*
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
EP1856296A2
(en)
|
2005-03-11 |
2007-11-21 |
Applera Corporation |
Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
|
BRPI0609209A2
(en)
*
|
2005-03-11 |
2010-03-02 |
Sanofi Aventis |
use of mgc4504
|
EP1868647A4
(en)
|
2005-03-24 |
2009-04-01 |
Millennium Pharm Inc |
Antibodies that bind ov064 and methods of use therefor
|
DK1866339T3
(en)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-binding molecules and their applications
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
AU2006236225C1
(en)
|
2005-04-19 |
2013-05-02 |
Seagen Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
CA2604357C
(en)
|
2005-04-26 |
2012-01-17 |
Pfizer Inc. |
P-cadherin antibodies
|
CN104815331A
(en)
|
2005-05-09 |
2015-08-05 |
生物领域医疗公司 |
Compositions and methods using microspheres and non-ionic contrast agents
|
WO2006119905A1
(en)
|
2005-05-11 |
2006-11-16 |
Sanofi-Aventis |
Use of a gip promoter polymorphism
|
EP1882035A2
(en)
|
2005-05-12 |
2008-01-30 |
Novartis AG |
Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
|
CA2903138A1
(en)
|
2005-05-16 |
2006-11-23 |
Abbvie Biotechnology Ltd. |
Use of tnfa inhibitor for treatment of erosive polyarthritis
|
WO2006128083A2
(en)
*
|
2005-05-25 |
2006-11-30 |
Curedm, Inc. |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
EP1899376A2
(en)
|
2005-06-16 |
2008-03-19 |
The Feinstein Institute for Medical Research |
Antibodies against hmgb1 and fragments thereof
|
EP1907001B1
(en)
|
2005-06-17 |
2015-07-15 |
Merck Sharp & Dohme Corp. |
Ilt3 binding molecules and uses therefor
|
KR20080025174A
(en)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
Antibody formulations having optimized aggregation and fragmentation profiles
|
EP1907421A4
(en)
*
|
2005-06-30 |
2012-03-28 |
Abbott Lab |
Il-12/p40 binding proteins
|
EP3498289A1
(en)
|
2005-07-07 |
2019-06-19 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
US8871720B2
(en)
*
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
EP2238986A3
(en)
|
2005-07-08 |
2010-11-03 |
Biogen Idec MA Inc. |
Sp35 antibodies and uses thereof
|
US7482124B2
(en)
*
|
2005-07-08 |
2009-01-27 |
Bristol-Myers Squibb Company |
Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
|
LT1912671T
(en)
|
2005-07-18 |
2017-12-11 |
Seattle Genetics, Inc. |
Beta-glucuronide-linker drug conjugates
|
WO2007011941A2
(en)
|
2005-07-18 |
2007-01-25 |
Amgen Inc. |
Human anti-b7rp1 neutralizing antibodies
|
EP1913027B1
(en)
|
2005-07-28 |
2015-03-04 |
Novartis AG |
M-csf specific monoclonal antibody and uses thereof
|
SI1919503T1
(en)
|
2005-08-10 |
2015-02-27 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
SG165322A1
(en)
|
2005-08-31 |
2010-10-28 |
Schering Corp |
Engineered anti-il-23 antibodies
|
EP1934867A2
(en)
|
2005-08-31 |
2008-06-25 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
WO2007030820A2
(en)
|
2005-09-09 |
2007-03-15 |
The Johns Hopkins University |
Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
|
WO2007037910A2
(en)
|
2005-09-14 |
2007-04-05 |
Fred Hutchinson Cancer Research Center |
Specific removal of activated immune cells
|
US7799530B2
(en)
|
2005-09-23 |
2010-09-21 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
|
US8906864B2
(en)
*
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
CA2624189A1
(en)
*
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
UA92504C2
(en)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
DE102005048898A1
(en)
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2 variants and their use in the prevention or treatment of thromboembolic disorders and coronary heart disease
|
EP1945816B1
(en)
|
2005-10-21 |
2011-07-27 |
GeneNews Inc. |
Method and apparatus for correlating levels of biomarker products with disease
|
EP1945666B1
(en)
*
|
2005-10-21 |
2013-03-27 |
GTC Biotherapeutics, Inc. |
Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
|
PE20070796A1
(en)
*
|
2005-10-24 |
2007-08-15 |
Wyeth Corp |
PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS
|
CA2627309A1
(en)
|
2005-10-28 |
2007-05-03 |
Meiji Seika Kaisha, Ltd. |
Pseudomonas aeruginosa outer membrane protein pa5158
|
US20090074720A1
(en)
*
|
2005-10-28 |
2009-03-19 |
Sabbadini Roger A |
Methods for decreasing immune response and treating immune conditions
|
US20080213274A1
(en)
*
|
2005-10-28 |
2008-09-04 |
Sabbadini Roger A |
Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
|
AU2006337105B2
(en)
|
2005-11-01 |
2013-05-02 |
Abbvie Biotechnology Ltd |
Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
|
CA2628451A1
(en)
|
2005-11-04 |
2007-05-18 |
Biogen Idec Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
CN101355956A
(en)
|
2005-11-04 |
2009-01-28 |
健泰科生物技术公司 |
Use of complement pathway inhibitors to treat ocular diseases
|
US7939069B2
(en)
|
2005-11-09 |
2011-05-10 |
Abbott Laboratories |
Human BNP immunospecific antibodies
|
US20070207152A1
(en)
*
|
2005-11-09 |
2007-09-06 |
Brophy Susan E |
Human BNP immunospecific antibodies
|
EP1957115B8
(en)
|
2005-11-10 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
AU2006316629A1
(en)
*
|
2005-11-17 |
2007-05-31 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
|
TWI461436B
(en)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
Human monoclonal antibody human cd134 (ox40) and methods of making and using same
|
AU2006319358B2
(en)
*
|
2005-11-30 |
2012-01-19 |
AbbVie Deutschland GmbH & Co. KG |
Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
|
RS53270B2
(en)
|
2005-11-30 |
2018-05-31 |
Abbvie Deutschland |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
CA2631181A1
(en)
|
2005-12-02 |
2007-06-07 |
Biogen Idec Ma Inc. |
Treatment of conditions involving demyelination
|
JP2009518446A
(en)
|
2005-12-07 |
2009-05-07 |
メダレックス インコーポレーティッド |
CTLA-4 antibody dose escalation regimen
|
US20070134249A1
(en)
*
|
2005-12-08 |
2007-06-14 |
Genitope Corporation |
Combination therapy and antibody panels
|
EP1963368B3
(en)
|
2005-12-13 |
2020-06-10 |
Eli Lilly And Company |
Anti-il-17 antibodies
|
AR056857A1
(en)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
|
EP2335733B1
(en)
|
2006-01-18 |
2014-08-06 |
Merck Patent GmbH |
Specific therapy using integrin ligands for treating cancer
|
JP5829373B2
(en)
|
2006-01-27 |
2015-12-09 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Nogo receptor antagonist
|
WO2007090126A2
(en)
*
|
2006-01-30 |
2007-08-09 |
Invitrogen Corporation |
Compositions and methods for detecting and quantifying toxic substances in disease states
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
TWI417301B
(en)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
Antibodies against human il-22 and uses therefor
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
EP2253957B1
(en)
|
2006-03-14 |
2013-05-15 |
Oregon Health and Science University |
Methods for producing an immune response to tuberculosis.
|
MX340784B
(en)
|
2006-03-15 |
2016-07-26 |
Alexion Pharma Inc |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement.
|
PL1999152T3
(en)
|
2006-03-27 |
2013-05-31 |
Medimmune Ltd |
Binding member for gm-csf receptor
|
AU2007232894B2
(en)
|
2006-03-30 |
2013-01-31 |
Meiji Seika Kaisha, Ltd. |
Pseudomonas aeruginosa outer membrane protein PA0427
|
AU2007241130A1
(en)
|
2006-03-31 |
2007-11-01 |
EMD Serono Research Centre, Inc. |
Treatment of tumors expressing mutant EGF receptors
|
KR20150006085A
(en)
|
2006-04-05 |
2015-01-15 |
애브비 바이오테크놀로지 리미티드 |
Antibody purification
|
JP5524610B2
(en)
|
2006-04-07 |
2014-06-18 |
ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク |
Transcobalamin receptor polypeptides, nucleic acids and modulators thereof, and related methods used to regulate cell growth and to treat cancer and cobalamin deficiency
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
EP2703010A3
(en)
|
2006-04-10 |
2014-08-06 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of rheumatoid arthritis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
MX2008013363A
(en)
|
2006-04-20 |
2009-03-26 |
Jackson H M Found Military Med |
Methods and compositions based on shiga toxin type 1 protein.
|
EP2881468B1
(en)
|
2006-04-21 |
2017-04-12 |
Intervet International B.V. |
Pestivirus species
|
US8022188B2
(en)
*
|
2006-04-24 |
2011-09-20 |
Abbott Laboratories |
Immunosuppressant binding antibodies and methods of obtaining and using same
|
US20070254338A1
(en)
*
|
2006-04-24 |
2007-11-01 |
Amgen Inc. |
Method for making recombinant protein using complementation dependent DHFR mutants
|
AU2007244705A1
(en)
*
|
2006-04-27 |
2007-11-08 |
Barnes-Jewish Hospital |
Detection and imaging of target tissue
|
WO2007127335A2
(en)
*
|
2006-04-27 |
2007-11-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
|
WO2007133800A2
(en)
|
2006-05-15 |
2007-11-22 |
University Of Kentucky |
Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
|
EP2027284A2
(en)
*
|
2006-05-18 |
2009-02-25 |
Sanofi-Aventis |
Use of adamts4 gene and protein polymorphisms
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
US8796429B2
(en)
*
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
US7862812B2
(en)
*
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US20080138334A1
(en)
|
2006-05-31 |
2008-06-12 |
Sabbadini Roger A |
Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
AT503690A1
(en)
|
2006-06-09 |
2007-12-15 |
Biomay Ag |
HYPOALLERGENIC MOLECULES
|
BRPI0713426A2
(en)
|
2006-06-14 |
2012-10-09 |
Macrogenics Inc |
methods of treating, slowing the progression, or ameliorating one or more symptoms of a disorder, and preventing or delaying the onset of a disorder
|
AU2007345745C1
(en)
*
|
2006-06-19 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
ILT3 binding molecules and uses therefor
|
WO2008019199A2
(en)
|
2006-06-26 |
2008-02-14 |
Macrogenics, Inc. |
FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
ES2427924T3
(en)
|
2006-06-30 |
2013-11-04 |
Merck Sharp & Dohme Corp. |
IGFBP2 biomarker
|
CA2651992A1
(en)
*
|
2006-06-30 |
2008-01-10 |
Abbott Biotechnology Ltd. |
Automatic injection device
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
CA2657248C
(en)
|
2006-07-13 |
2018-10-30 |
Wyeth |
Production of glycoproteins
|
BRPI0714871A2
(en)
|
2006-07-18 |
2013-05-07 |
Sanofi Aventis |
antagonist antibody for cancer treatment
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
CL2007002225A1
(en)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
|
RU2009107707A
(en)
|
2006-08-04 |
2010-09-10 |
Новартис АГ (CH) |
SPECIFIC TO EphB3 ANTIBODY AND ITS APPLICATION
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
DK2383297T5
(en)
|
2006-08-14 |
2022-07-04 |
Xencor Inc |
Optimized antibodies directed against CD19
|
EP3415532A1
(en)
|
2006-08-18 |
2018-12-19 |
XOMA Technology Ltd. |
Prlr-specific antibody and uses thereof
|
KR101314362B1
(en)
|
2006-08-28 |
2013-10-10 |
라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 |
Antagonistic human light-specific human monoclonal antibodies
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
GB0617429D0
(en)
|
2006-09-05 |
2006-10-18 |
Electrophoretics Ltd |
Markers of renal transplant rejection and renal damage
|
NZ575018A
(en)
|
2006-09-05 |
2012-04-27 |
Alexion Pharma Inc |
Compositions for the treatment of antibody mediated neuropathies
|
US20080064045A1
(en)
*
|
2006-09-07 |
2008-03-13 |
Huaiqin Wu |
Biomarker fragments for the detection of human BNP
|
MY188368A
(en)
|
2006-09-08 |
2021-12-06 |
Abbott Lab |
Interleukin-13 binding proteins
|
EP2500416A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
CA2910619A1
(en)
|
2006-09-13 |
2008-03-20 |
Abbvie Inc. |
Cell culture improvements
|
CA2660795C
(en)
*
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
JP2010506839A
(en)
*
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
Methods and compositions with reduced opalescence
|
US20100143254A1
(en)
|
2006-10-16 |
2010-06-10 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
ES2501947T3
(en)
|
2006-10-19 |
2014-10-02 |
Csl Limited |
Interleukin alpha 1 receptor high affinity antibody antagonists
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
CA2666346C
(en)
|
2006-10-20 |
2016-02-23 |
Celera Corporation |
Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
|
PT2087002E
(en)
*
|
2006-10-27 |
2014-11-26 |
Lpath Inc |
Compositions and methods for binding sphingosine-1-phosphate
|
WO2008055072A2
(en)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
EP2433635A1
(en)
|
2006-11-10 |
2012-03-28 |
Massachusetts Institute Of Technology |
PAK Modulators
|
AU2007323799B2
(en)
|
2006-11-15 |
2013-07-18 |
Eli Lilly And Company |
Anti-TSG101 antibodies and their uses for treatment of viral infections
|
US8785400B2
(en)
*
|
2006-11-22 |
2014-07-22 |
Curedm Group Holdings, Llc |
Methods and compositions relating to islet cell neogenesis
|
AU2007355108B2
(en)
|
2006-11-27 |
2013-07-11 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2609932B1
(en)
|
2006-12-01 |
2022-02-02 |
Seagen Inc. |
Variant target binding agents and uses thereof
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
BRPI0720437A2
(en)
|
2006-12-07 |
2014-01-07 |
Novartis Ag |
ANHPHONE ANTIBODIES AGAINST EPHB3
|
US8232372B2
(en)
|
2006-12-14 |
2012-07-31 |
Schering Corp. |
Engineered anti-TSLP antibody
|
CL2007003661A1
(en)
|
2006-12-18 |
2008-07-18 |
Genentech Inc |
VARIABLE AND LIGHT VARIABLE HEAVY CHAIN REGIONS; NUCLEIC ACIDS THAT CODE THEM; METHOD OF PRODUCTION; ANTI-NOTCH3 ANTIBODIES THAT UNDERSTAND THEM; AND USE OF ANTIBODIES TO TREAT DISEASES RELATED TO THE RECEIVER NOTCH3.
|
TR201807425T4
(en)
|
2007-01-09 |
2018-06-21 |
Biogen Ma Inc |
Sp35 antibodies and their use.
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
KR20150038227A
(en)
|
2007-01-16 |
2015-04-08 |
애브비 인코포레이티드 |
Methods for treating psoriasis
|
EP2441464B1
(en)
|
2007-01-18 |
2014-04-09 |
Merck Patent GmbH |
Integrin ligands for use in treating colon cancer
|
EP2121754B1
(en)
|
2007-01-18 |
2015-02-11 |
Eli Lilly and Company |
Pegylated amyloid beta fab
|
WO2008091740A2
(en)
|
2007-01-22 |
2008-07-31 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
CN104013956B
(en)
|
2007-01-25 |
2018-12-18 |
达娜-法勃肿瘤研究所公司 |
Purposes of the anti-egfr antibodies in the mutant mediated disease for the treatment of EGFR
|
EP1958645A1
(en)
|
2007-02-13 |
2008-08-20 |
Biomay AG |
Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
|
US7883705B2
(en)
|
2007-02-14 |
2011-02-08 |
Kyowa Hakko Kirin Co., Ltd. |
Anti FGF23 antibody and a pharmaceutical composition comprising the same
|
AR065368A1
(en)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
ANTIBODIES FOR IGE MOLECULES
|
US8114606B2
(en)
*
|
2007-02-16 |
2012-02-14 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies
|
DK2130044T3
(en)
|
2007-02-16 |
2017-02-06 |
Genzyme Corp |
PROCEDURE FOR IDENTIFYING THE RISK OF A THYRODOIDE DISORDER
|
US8685666B2
(en)
*
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
AU2008218925A1
(en)
|
2007-02-20 |
2008-08-28 |
Anaptysbio, Inc. |
Somatic hypermutation systems
|
DK2426144T3
(en)
|
2007-02-23 |
2019-01-07 |
Merck Sharp & Dohme |
Manipulated Anti-IL-23P19 Antibodies
|
SG178804A1
(en)
|
2007-02-23 |
2012-03-29 |
Schering Corp |
Engineered anti-il-23p19 antibodies
|
EP3118221B1
(en)
|
2007-02-26 |
2019-08-21 |
Oxford BioTherapeutics Ltd |
Proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP2486928A1
(en)
*
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
BRPI0807991A2
(en)
|
2007-02-28 |
2014-06-17 |
Schering Corp |
PREPARED ANTI-IL-23R ANTIBODIES.
|
CA2678404C
(en)
|
2007-02-28 |
2019-03-19 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyury polypeptides and methods for use
|
ES2541454T3
(en)
|
2007-03-02 |
2015-07-20 |
Wyeth Llc |
Use of copper and glutamate in cell cultures for polypeptide production
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
WO2008115404A1
(en)
|
2007-03-15 |
2008-09-25 |
Ludwing Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
CN103214577B
(en)
|
2007-03-22 |
2015-09-02 |
生物基因Ma公司 |
Specific binding CD154 comprises associated proteins of antibody, antibody derivatives and antibody fragment and uses thereof
|
US20090068684A1
(en)
*
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
GB0706070D0
(en)
|
2007-03-28 |
2007-05-09 |
Scancell Ltd |
Nucleic acids
|
CN101679507A
(en)
*
|
2007-03-29 |
2010-03-24 |
艾博特公司 |
crystalline anti-human il-12 antibodies
|
KR101540823B1
(en)
|
2007-03-30 |
2015-07-30 |
메디뮨 엘엘씨 |
Antibody formulation
|
BRPI0809989B8
(en)
|
2007-04-02 |
2021-05-25 |
Philogen Spa |
uses of an antibody or antigen-binding fragment thereof that binds to the extradomain isoform-a (ed-a) of fibronectin and/or to the ed-a of fibronectin
|
EP1985295A1
(en)
|
2007-04-04 |
2008-10-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
JP2011526240A
(en)
*
|
2007-04-18 |
2011-10-06 |
ヤンセン アルツハイマー イミュノセラピー |
Prevention and treatment of cerebral amyloid angiopathy
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
EP2145902A3
(en)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
WO2008132516A1
(en)
|
2007-04-26 |
2008-11-06 |
Opsona Therapeutics Limited |
Toll-like receptor binding epitope and compositions for binding thereto
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP2164868B1
(en)
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Engineered rabbit antibody variable domains and uses thereof
|
US8962273B2
(en)
|
2007-05-11 |
2015-02-24 |
Genzyme Corporation |
Methods of producing a secreted protein
|
PL2068927T3
(en)
|
2007-05-14 |
2016-06-30 |
Medimmune Llc |
Methods of reducing eosinophil levels
|
US20110064744A1
(en)
*
|
2007-05-30 |
2011-03-17 |
Sabbadini Roger A |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
PE20090329A1
(en)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
US8158124B2
(en)
*
|
2007-05-30 |
2012-04-17 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
PL2170956T3
(en)
|
2007-06-15 |
2015-04-30 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Treatment of tumors using specific anti-l1 antibody
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
US20080317768A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Boeing Company |
Bioconjugated nanoparticles
|
KR20100028558A
(en)
*
|
2007-06-29 |
2010-03-12 |
메이지 세이카 가부시키가이샤 |
Pseudomonas aeruginosa outer membrane protein pa4710
|
EP2175884B8
(en)
|
2007-07-12 |
2017-02-22 |
GITR, Inc. |
Combination therapies employing gitr binding molecules
|
CN101754978B
(en)
|
2007-07-25 |
2013-06-05 |
菲洛根股份公司 |
Antigen associated with lung cancer and lymphoma
|
JP2010534719A
(en)
*
|
2007-07-27 |
2010-11-11 |
ファイザー・リミテッド |
Antibody purification by precipitation
|
ES2498040T3
(en)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases with humanized anti-beta antibodies
|
EP2023144A1
(en)
*
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
|
EP2537529B1
(en)
|
2007-08-02 |
2018-10-17 |
Gilead Biologics, Inc. |
Loxl2 inhibitory antibodies and uses thereof
|
CN101821284B
(en)
|
2007-08-03 |
2014-11-19 |
贝林格尔·英格海姆维特梅迪卡有限公司 |
Novel genes and proteins of brachyspira hyodysenteriac and uses thereof
|
CA2693237C
(en)
|
2007-08-03 |
2016-11-01 |
Opsona Therapeutics Limited |
Anti-toll-like receptor 2 antibodies for use in the treatment of cardiac inflammatory conditions
|
BRPI0815399A2
(en)
|
2007-08-13 |
2019-09-24 |
Vasgene Therapeutics Inc |
cancer treatment using humanized antibodies that bind ephb4
|
MX2010001757A
(en)
|
2007-08-14 |
2010-09-14 |
Ludwig Inst Cancer Res |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof.
|
RS57273B1
(en)
|
2007-08-29 |
2018-08-31 |
Sanofi Sa |
Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
|
PT2193142E
(en)
*
|
2007-08-30 |
2015-04-22 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
EP2033971A1
(en)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
JP5963341B2
(en)
|
2007-09-14 |
2016-08-10 |
アムジエン・インコーポレーテツド |
Homogeneous antibody population
|
AU2008304615A1
(en)
|
2007-09-24 |
2009-04-02 |
Cornell University |
Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon
|
GB0718843D0
(en)
|
2007-09-26 |
2007-11-07 |
Cancer Rec Tech Ltd |
Materials and methods relating to modifying the binding of antibodies
|
ES2622460T3
(en)
|
2007-09-26 |
2017-07-06 |
Ucb Biopharma Sprl |
Fusions of antibodies with double specificity
|
WO2009046388A1
(en)
|
2007-10-03 |
2009-04-09 |
United States Medical Research & Material Command |
Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines
|
AU2008311251B9
(en)
*
|
2007-10-11 |
2014-04-17 |
Biogen Ma Inc. |
Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and TrkB agonists
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
JO3076B1
(en)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
Immunotherapy regimes dependent on apoe status
|
GB0720250D0
(en)
|
2007-10-17 |
2007-11-28 |
Univ Edinburgh |
Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
|
AU2008316811B2
(en)
|
2007-10-23 |
2015-01-22 |
The Cleveland Clinic Foundation |
Oxidant resistant apolipoprotein A-1 and mimetic peptides
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
PT3281952T
(en)
|
2007-10-30 |
2020-07-23 |
Philogen Spa |
An antigen associated with rheumatoid arthritis
|
US8039212B2
(en)
|
2007-11-05 |
2011-10-18 |
Celera Corporation |
Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
|
CA2703705A1
(en)
|
2007-11-05 |
2009-05-14 |
Medimmune, Llc |
Methods of treating scleroderma
|
US20110123553A1
(en)
*
|
2007-11-08 |
2011-05-26 |
Biogen Idec Ma Inc. |
Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
|
WO2009067546A2
(en)
|
2007-11-19 |
2009-05-28 |
Celera Corpration |
Lung cancer markers and uses thereof
|
EP2062920A3
(en)
|
2007-11-21 |
2009-06-17 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
|
WO2015164330A1
(en)
|
2014-04-21 |
2015-10-29 |
Millennium Pharmaceuticals, Inc. |
Anti-psyk antibody molecules and use of same for syk-targeted therapy
|
EP2808345A3
(en)
|
2007-12-05 |
2015-03-11 |
Massachusetts Institute of Technology |
Aglycosylated immunoglobulin mutants
|
DK2222706T4
(en)
|
2007-12-14 |
2016-11-21 |
Novo Nordisk As |
Antibodies that bind to NKG2D and its use
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
WO2009081201A2
(en)
|
2007-12-21 |
2009-07-02 |
Medimmune Limited |
BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Rα) - 173
|
EP2236515A4
(en)
|
2007-12-25 |
2012-10-31 |
Meiji Seika Kaisha |
Component protein pa1698 for type-iii secretion system of pseudomonas aeruginosa
|
ES2742268T3
(en)
|
2007-12-26 |
2020-02-13 |
Xencor Inc |
Fc variants with altered FcRn binding
|
US20090203038A1
(en)
*
|
2007-12-27 |
2009-08-13 |
Abbott Laboratories |
Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays
|
EP2225276B1
(en)
|
2007-12-31 |
2014-04-23 |
Bayer Intellectual Property GmbH |
Antibodies to tnf alpha
|
BRPI0906492A2
(en)
|
2008-01-11 |
2015-12-01 |
Synovex Corp |
cadherin-11 antagonists and methods for the treatment of inflammatory joint diseases
|
CA2711771C
(en)
|
2008-01-11 |
2017-01-24 |
Gene Techno Science Co., Ltd. |
Humanized anti-.alpha.9 integrin antibodies and the uses thereof
|
CA3221018A1
(en)
|
2008-01-15 |
2009-07-23 |
Ravindra Majeti |
Markers of acute myeloid leukemia stem cells
|
ES2613963T3
(en)
|
2008-01-18 |
2017-05-29 |
Medimmune, Llc |
Cysteine manipulated antibodies for site specific conjugation
|
US8653020B2
(en)
|
2008-01-25 |
2014-02-18 |
Aarhus Universitet |
Selective exosite inhibition of PAPP-A activity against IGFBP-4
|
PT2250279E
(en)
|
2008-02-08 |
2016-06-03 |
Medimmune Llc |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
US20090221620A1
(en)
|
2008-02-20 |
2009-09-03 |
Celera Corporation |
Gentic polymorphisms associated with stroke, methods of detection and uses thereof
|
EP2363407A1
(en)
|
2008-02-28 |
2011-09-07 |
Murdoch University |
Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
BRPI0908715A2
(en)
|
2008-03-18 |
2016-05-03 |
Abbott Lab |
Methods for psoriasis treatment
|
CA2718942A1
(en)
|
2008-03-18 |
2009-09-24 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
US20110020368A1
(en)
|
2008-03-25 |
2011-01-27 |
Nancy Hynes |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
EP2105742A1
(en)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Use of cathepsin C
|
EP2604280A3
(en)
|
2008-03-27 |
2013-10-16 |
ZymoGenetics, Inc. |
Compositions and methods for inhibiting PDGFRBETA and VEGF-A
|
WO2009117773A1
(en)
|
2008-03-27 |
2009-10-01 |
Murdoch University |
Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
|
EP2274437B1
(en)
|
2008-04-10 |
2015-12-23 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
AU2008201871A1
(en)
*
|
2008-04-16 |
2009-11-26 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Inhibition of angiogenesis and tumor metastasis
|
WO2009131256A1
(en)
|
2008-04-24 |
2009-10-29 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
|
US20090269786A1
(en)
*
|
2008-04-25 |
2009-10-29 |
The Board Of Trustees Of The University Of Illinois |
RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
|
EP2279003A4
(en)
*
|
2008-05-01 |
2013-04-03 |
Gtc Biotherapeutics Inc |
An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
|
EP2282773B1
(en)
|
2008-05-02 |
2014-01-15 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
ES2579554T3
(en)
|
2008-05-09 |
2016-08-12 |
Abbvie Deutschland Gmbh & Co Kg |
Antibodies for the recipient of advanced glycation terminal products (RAGE) and uses thereof
|
CA2726131C
(en)
|
2008-05-29 |
2018-03-13 |
Baoming Jiang |
Expression and assembly of human group c rotavirus-like particles and uses thereof
|
EP2304439A4
(en)
|
2008-05-29 |
2012-07-04 |
Nuclea Biotechnologies Llc |
Anti-phospho-akt antibodies
|
US20100322936A1
(en)
|
2008-06-16 |
2010-12-23 |
Patrys Limited |
Lm-1 antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
|
EP2294183B1
(en)
|
2008-06-18 |
2015-12-16 |
The Texas A&M University System |
Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
|
DK2307042T3
(en)
|
2008-06-25 |
2014-05-12 |
Lundbeck & Co As H |
MODULE TRPV: VPS10P DOMAIN RECEPTOR SYSTEM FOR THE TREATMENT OF PAIN
|
CN104829718A
(en)
|
2008-07-08 |
2015-08-12 |
艾伯维公司 |
Prostaglandin E2 binding proteins and uses thereof
|
FR2933702A1
(en)
*
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR
|
EP2878680B1
(en)
|
2008-07-09 |
2016-06-08 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
US8067339B2
(en)
|
2008-07-09 |
2011-11-29 |
Merck Sharp & Dohme Corp. |
Surface display of whole antibodies in eukaryotes
|
US8148088B2
(en)
*
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
WO2010010469A2
(en)
*
|
2008-07-25 |
2010-01-28 |
Abbott Gmbh & Co. Kg |
Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
|
CN102282172B
(en)
|
2008-09-07 |
2014-02-19 |
台湾醣联生技医药股份有限公司 |
Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
|
US20110236376A1
(en)
*
|
2008-09-08 |
2011-09-29 |
Smiley Stephen T |
Non-neutralizing immunity to influenza to prevent secondary bacterial pneumonia
|
US20100061995A1
(en)
*
|
2008-09-08 |
2010-03-11 |
Damian Michael Carragher |
Immunotherapy To Treat Or Prevent Viral Infection
|
AU2009294415B2
(en)
|
2008-09-19 |
2015-09-24 |
Medimmune Llc |
Antibodies directed to DLL4 and uses thereof
|
EP2385371B1
(en)
|
2008-09-22 |
2014-10-22 |
Oregon Health and Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
EP2344180A2
(en)
|
2008-09-23 |
2011-07-20 |
Wyeth LLC |
Methods for predicting production of activating signals by cross-linked binding proteins
|
WO2010034779A2
(en)
*
|
2008-09-24 |
2010-04-01 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Composition and method for treatment of preterm labor
|
GB0817891D0
(en)
|
2008-09-30 |
2008-11-05 |
Medical Res Council |
Antibodies against il-25
|
US8715654B2
(en)
|
2008-10-02 |
2014-05-06 |
Celtaxsys, Inc. |
Methods of modulating the negative chemotaxis of immune cells
|
TW201024318A
(en)
|
2008-10-20 |
2010-07-01 |
Abbott Lab |
Isolation and purification of antibodies using protein A affinity chromatography
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
WO2010048615A2
(en)
|
2008-10-24 |
2010-04-29 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention |
Human ebola virus species and compositions and methods thereof
|
AR073997A1
(en)
|
2008-10-29 |
2010-12-15 |
Wyeth Corp |
FORMULATIONS OF MOLECULES OF UNION TO ANTIGENO OF UNIQUE DOMAIN. METHOD. KIT
|
CA2739352C
(en)
|
2008-10-29 |
2021-07-13 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
DK3199553T3
(en)
|
2008-10-29 |
2019-07-22 |
Circular Commitment Company |
METHODS AND AGENTS FOR DIAGNOSTICATION AND TREATMENT OF HEPATOCELLULAR CARCINOM
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
WO2010052288A1
(en)
|
2008-11-07 |
2010-05-14 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
PA8849001A1
(en)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
C-MET ANTIBODIES
|
NZ592644A
(en)
*
|
2008-11-28 |
2013-09-27 |
Abbott Lab |
Stable antibody compositions and methods for stabilizing same
|
CA2745436A1
(en)
*
|
2008-12-05 |
2010-06-10 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
US20100159485A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Centre For Dna Fingerprinting And Diagnostics |
Detection of mycobacterium tuberculosis
|
GB0823309D0
(en)
|
2008-12-19 |
2009-01-28 |
Univ Bath |
Functionalising reagents and their uses
|
EP2373343B1
(en)
|
2008-12-19 |
2015-02-11 |
Philogen S.p.A. |
Immunocytokines for tumour therapy with chemotherapeutic agents
|
CN105641694B
(en)
|
2008-12-19 |
2020-08-14 |
H.隆德贝克有限公司 |
Modulation of the Vps10 p-domain receptor family for the treatment of mental and behavioural disorders
|
KR101940059B1
(en)
|
2008-12-19 |
2019-01-18 |
마크로제닉스, 인크. |
Covalent diabodies and uses thereof
|
JP2012513194A
(en)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
Targeted binding agents directed to α5β1 and uses thereof
|
EP2201982A1
(en)
|
2008-12-24 |
2010-06-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Histamine H4 receptor antagonists for the treatment of vestibular disorders
|
CA2748757A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
US20110275791A1
(en)
|
2009-01-06 |
2011-11-10 |
Ziad Mallat |
A B Cell Depleting Agent for the Treatment of Atherosclerosis
|
WO2010078945A2
(en)
|
2009-01-07 |
2010-07-15 |
Philogen S.P.A. |
Cancer treatment
|
EP2379116B1
(en)
|
2009-01-07 |
2015-08-26 |
Philogen S.p.A. |
Antigens associated with endometriosis
|
BRPI1007345A2
(en)
|
2009-01-20 |
2019-04-16 |
H. ZADEH Homayoun |
mediated antibody bone regeneration
|
AU2010207552A1
(en)
|
2009-01-21 |
2011-09-01 |
Oxford Biotherapeutics Ltd. |
PTA089 protein
|
US20100260752A1
(en)
|
2009-01-23 |
2010-10-14 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
EP2389587B1
(en)
|
2009-01-26 |
2013-12-25 |
Electrophoretics Limited |
Diagnostic and prognostic methods relating to alzheimer's disease
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
UA102722C2
(en)
*
|
2009-01-29 |
2013-08-12 |
Эббви Инк. |
Il-1 binding proteins
|
EP2219029A1
(en)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Test systems, methods and uses involving AS160 protein
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US9085795B2
(en)
*
|
2009-02-04 |
2015-07-21 |
Molecular Innovations, Inc. |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
|
US9079942B2
(en)
*
|
2009-02-09 |
2015-07-14 |
Epitomics, Inc. |
CDR-anchored amplification method
|
WO2010093450A2
(en)
|
2009-02-11 |
2010-08-19 |
Ludwing Institute For Cancer Research Ltd. |
Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
HUE033661T2
(en)
|
2009-02-16 |
2017-12-28 |
Cerenis Therapeutics Holding Sa |
Apolipoprotein A-I Mimics
|
WO2010096658A1
(en)
|
2009-02-19 |
2010-08-26 |
The Cleveland Clinic Foundation |
Corin as a marker for heart failure
|
US8030026B2
(en)
*
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
WO2010099536A2
(en)
|
2009-02-27 |
2010-09-02 |
Massachusetts Institute Of Technology |
Engineered proteins with high affinity for dota chelates
|
US8664183B2
(en)
|
2009-02-27 |
2014-03-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
SPANX-B polypeptides and their use
|
US8835610B2
(en)
|
2009-03-05 |
2014-09-16 |
Abbvie Inc. |
IL-17 binding proteins
|
EP2405920A1
(en)
|
2009-03-06 |
2012-01-18 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
EP2406285B1
(en)
|
2009-03-10 |
2016-03-09 |
Gene Techno Science Co., Ltd. |
Generation, expression and characterization of the humanized k33n monoclonal antibody
|
ES2486673T3
(en)
|
2009-03-19 |
2014-08-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Use of NKp46 to prevent type I diabetes
|
WO2010106187A2
(en)
|
2009-03-20 |
2010-09-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders
|
RU2542394C2
(en)
|
2009-03-24 |
2015-02-20 |
ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. |
Humanised anti-light antibodies and using them
|
WO2010112033A2
(en)
|
2009-03-31 |
2010-10-07 |
Østjysk Innovation A/S |
Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
GB0905972D0
(en)
|
2009-04-06 |
2009-05-20 |
Medical Res Council |
Antibodies against IL-17BR
|
AR075989A1
(en)
|
2009-04-10 |
2011-05-11 |
Lilly Co Eli |
ANTIBODY DKK -1 (DICKKOPF-1) HUMAN DESIGNED BY ENGINEERING
|
WO2010117057A1
(en)
|
2009-04-10 |
2010-10-14 |
協和発酵キリン株式会社 |
Method for treatment of blood tumor using anti-tim-3 antibody
|
US20120121706A1
(en)
|
2009-04-10 |
2012-05-17 |
Tufts Medical Center, Inc. |
PAR-1 Activation by Metalloproteinase-1 (MMP-1)
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
WO2010121140A1
(en)
|
2009-04-16 |
2010-10-21 |
Facet Biotech Corporation |
ANTI-TNF-α ANTIBODIES AND THEIR USES
|
WO2010121093A2
(en)
*
|
2009-04-17 |
2010-10-21 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
JP5822822B2
(en)
|
2009-04-17 |
2015-11-24 |
ニューヨーク ユニバーシティ |
Peptides that target TNF family receptors and antagonize TNF action, compositions, methods and uses thereof
|
WO2010121141A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Biogen Idec Ma Inc. |
Compositions and methods to treat acute myelogenous leukemia
|
WO2010125566A2
(en)
|
2009-04-27 |
2010-11-04 |
Technion Research And Development Foundation Ltd. |
Markers for cancer detection
|
AU2010242598C1
(en)
|
2009-04-27 |
2015-02-05 |
Kyowa Kirin Co., Ltd. |
Anti-IL-3Ralpha antibody for use in treatment of blood tumor
|
BRPI1012162A2
(en)
|
2009-04-29 |
2016-01-12 |
Abbott Biotech Ltd |
automatic injection device
|
WO2010126972A1
(en)
|
2009-04-29 |
2010-11-04 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Erg monoclonal antibodies
|
US9125861B2
(en)
|
2009-05-04 |
2015-09-08 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
PAR2 agonists for use in the treatment or prevention of influenza virus type A infections
|
SG176060A1
(en)
|
2009-05-13 |
2011-12-29 |
Genzyme Corp |
Anti-human cd52 immunoglobulins
|
GB0908425D0
(en)
|
2009-05-15 |
2009-06-24 |
Medical Res Council |
Medical use
|
PL2432467T3
(en)
|
2009-05-20 |
2018-07-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
|
CA2682429A1
(en)
*
|
2009-05-20 |
2010-11-20 |
Gary Levy |
An assay for measuring plasma fgl-2 and methods and uses thereof
|
EP2253316B1
(en)
|
2009-05-20 |
2013-08-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
|
CA2763275A1
(en)
|
2009-05-25 |
2010-12-02 |
Merck Patent Gmbh |
Continuous administration of integrin ligands for treating cancer
|
US20100317539A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Guo-Liang Yu |
Library of Engineered-Antibody Producing Cells
|
KR20120034739A
(en)
|
2009-06-17 |
2012-04-12 |
애보트 바이오테라퓨틱스 코포레이션 |
Anti-vegf antibodies and their uses
|
US20120156221A1
(en)
|
2009-06-19 |
2012-06-21 |
Ludivine Perrocheau |
Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders
|
BRPI1015234A2
(en)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
fc regions designed for site specific conjugation.
|
JP2012531423A
(en)
|
2009-06-24 |
2012-12-10 |
エルパス, インコーポレーテッド |
Method for increasing neuronal differentiation using antibodies against lysophosphatidic acid
|
US8435961B2
(en)
*
|
2009-06-26 |
2013-05-07 |
Massachusetts Institute Of Technology |
Methods and compositions for increasing the activity of inhibitory RNA
|
US20110097329A1
(en)
|
2009-06-26 |
2011-04-28 |
Massachusetts Institute Of Technology |
Compositions and methods for treating cancer and modulating stress granule formation
|
US8268550B2
(en)
*
|
2009-06-26 |
2012-09-18 |
Massachusetts Institute Of Technology |
Compositions and methods for identification of PARP function, inhibitors, and activators
|
EP2448599A1
(en)
|
2009-06-30 |
2012-05-09 |
Philogen S.p.A. |
Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
|
EP2448966B1
(en)
|
2009-07-03 |
2018-11-14 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
CN102481380A
(en)
|
2009-07-09 |
2012-05-30 |
霍夫曼-拉罗奇有限公司 |
In vivo tumor vasculature imaging
|
WO2011008959A1
(en)
|
2009-07-15 |
2011-01-20 |
Abbott Laboratories |
Enhancement of cellular production through mechanotransduction
|
WO2011011592A1
(en)
|
2009-07-22 |
2011-01-27 |
Actinium Pharmaceuticals Inc. |
Methods for generating radioimmunoconjugates
|
EP2456428A1
(en)
|
2009-07-23 |
2012-05-30 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease
|
WO2011015333A2
(en)
|
2009-08-05 |
2011-02-10 |
Philogen S.P.A. |
Targeting of bone marrow neovasculature
|
WO2011020024A2
(en)
|
2009-08-13 |
2011-02-17 |
The Johns Hopkins University |
Methods of modulating immune function
|
ES2553440T3
(en)
*
|
2009-08-13 |
2015-12-09 |
Crucell Holland B.V. |
Antibodies against human respiratory syncytial virus (RSV) and method of use
|
GB0914446D0
(en)
|
2009-08-18 |
2009-09-30 |
King S College London |
Bioconjugates and their uses in imaging
|
US20120258093A1
(en)
|
2009-08-20 |
2012-10-11 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
|
GB0914691D0
(en)
|
2009-08-21 |
2009-09-30 |
Lonza Biologics Plc |
Immunoglobulin variants
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
CN102002104A
(en)
|
2009-08-28 |
2011-04-06 |
江苏先声药物研究有限公司 |
Anti-VEGF monoclonal antibody and medicinal composition containing same
|
PE20121647A1
(en)
|
2009-08-29 |
2012-12-31 |
Abbvie Inc |
THERAPEUTIC BINDING PROTEINS TO DLL4
|
WO2011023824A2
(en)
|
2009-08-31 |
2011-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Estrogen receptor modulators for the treatment of diseases involving plasmacytoid dendritic cells
|
EP2293072A1
(en)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Use of cathepsin H
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
RU2595409C2
(en)
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Anti-gitr antibodies
|
US8293483B2
(en)
|
2009-09-11 |
2012-10-23 |
Epitomics, Inc. |
Method for identifying lineage-related antibodies
|
MX2012003138A
(en)
*
|
2009-09-14 |
2012-07-04 |
Abbott Lab Y Abbott Gmbh & Co Kg |
Methods for treating psoriasis.
|
US20110070227A1
(en)
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
US20120244170A1
(en)
|
2009-09-22 |
2012-09-27 |
Rafal Ciosk |
Treating cancer by modulating mex-3
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
WO2011040973A2
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
|
AR078470A1
(en)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER
|
EP2483316A1
(en)
|
2009-10-02 |
2012-08-08 |
Ludwig Institute for Cancer Research Ltd. |
Anti-fibroblast activation protein antibodies and methods and uses thereof
|
LT2486141T
(en)
|
2009-10-07 |
2018-05-25 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
AU2010308030B2
(en)
|
2009-10-12 |
2014-05-29 |
Pfizer Inc. |
Cancer treatment
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
WO2011047340A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
GEP201706604B
(en)
|
2009-10-16 |
2017-01-25 |
Inst Nat De La Santé Et De La Recherché Médicale (Inserm) |
Monoclonal antibodies to progastrin and their uses
|
BR112012009289B8
(en)
|
2009-10-20 |
2021-05-25 |
Abbott Laboratoires |
method for purifying an anti-il-13 antibody from a sample mixture comprising an anti-il-13 antibody and at least one host cell protein (hcp)
|
WO2011048070A1
(en)
|
2009-10-20 |
2011-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
|
CA3031851C
(en)
|
2009-10-23 |
2020-07-07 |
Amgen British Columbia |
Anti-gcc antibody molecules and related compositions and methods
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
WO2011051350A1
(en)
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
ES2639056T3
(en)
|
2009-10-28 |
2017-10-25 |
Abbvie Biotherapeutics Inc. |
Anti-EGFR antibodies and their uses
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
MX2012005180A
(en)
|
2009-11-04 |
2012-06-08 |
Merck Sharp & Dohme |
Engineered anti-tslp antibody.
|
WO2011057188A1
(en)
|
2009-11-06 |
2011-05-12 |
Idexx Laboratories, Inc. |
Canine anti-cd20 antibodies
|
US9588121B2
(en)
|
2009-11-06 |
2017-03-07 |
Go Therapeutics, Inc. |
Method for early detection of cancer
|
EP3351558B1
(en)
|
2009-11-13 |
2020-03-11 |
Daiichi Sankyo Europe GmbH |
Material and methods for treating or preventing her-3 associated diseases
|
EP2502076B1
(en)
|
2009-11-20 |
2018-04-18 |
Oregon Health and Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
ES2638370T3
(en)
|
2009-11-23 |
2017-10-20 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Inhibitors of the PP1 / GADD34 complex for the treatment of a condition that requires immunosuppressive activity
|
NZ599405A
(en)
|
2009-11-24 |
2014-09-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
WO2011064395A2
(en)
|
2009-11-30 |
2011-06-03 |
Inserm |
Inhibitors and antagonists of calcium channels in the treatment of asthma
|
WO2011068870A2
(en)
|
2009-12-01 |
2011-06-09 |
President And Fellows Of Harvard College |
Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
|
CA2780069C
(en)
*
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
EP2509594A1
(en)
|
2009-12-09 |
2012-10-17 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
|
EP3144323A3
(en)
|
2009-12-09 |
2017-05-31 |
Bayer Pharma Aktiengesellschaft |
Anti-c4.4a antibodies and uses thereof
|
TWI619521B
(en)
*
|
2009-12-15 |
2018-04-01 |
艾伯維生物技術有限責任公司 |
Automatic injection device, automatic injection method and method for preventing misfiring
|
ES2594893T3
(en)
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anti HER2 antibodies and their uses
|
EA201270662A1
(en)
|
2009-12-23 |
2013-01-30 |
4-Антибоди Аг |
BINDING ELEMENTS FOR HUMAN CYTAMEGALOVIRUS
|
CA2784610C
(en)
|
2009-12-23 |
2020-07-14 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
HUE045270T2
(en)
|
2010-01-05 |
2019-12-30 |
Inst Nat Sante Rech Med |
Flt3 receptor antagonists for the treatment or the prevention of pain disorders
|
WO2011084882A2
(en)
|
2010-01-05 |
2011-07-14 |
Contrafect Corporation |
Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
|
CN102893154A
(en)
|
2010-01-15 |
2013-01-23 |
加利福尼亚大学董事会 |
Compositions and methods for detecting cancer
|
US9415028B2
(en)
|
2010-01-15 |
2016-08-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Compounds for the treatment of autism
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
AU2011207253B2
(en)
|
2010-01-20 |
2015-02-12 |
Merck Sharp & Dohme Corp. |
Anti-ILT5 antibodies and ILT5-binding antibody fragments
|
CA2787755A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
CA2789168A1
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
|
EP2536432B1
(en)
|
2010-02-19 |
2018-08-08 |
Cornell University |
Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
|
WO2011106723A2
(en)
*
|
2010-02-26 |
2011-09-01 |
Lpath, Inc. |
Anti-paf antibodies
|
AU2011219029B2
(en)
|
2010-02-26 |
2017-02-02 |
Columbia University |
Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
|
SG10201501562VA
(en)
|
2010-03-02 |
2015-04-29 |
Abbvie Inc |
Therapeutic dll4 binding proteins
|
JP6190113B2
(en)
|
2010-03-03 |
2017-08-30 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
Oligomer-specific amyloid beta epitopes and antibodies
|
US20130004519A1
(en)
|
2010-03-05 |
2013-01-03 |
Ruth Chiquet-Ehrismann |
Smoci, tenascin-c and brain cancers
|
EP2545073B1
(en)
|
2010-03-12 |
2015-09-30 |
AbbVie Biotherapeutics Inc. |
Ctla4 proteins and their uses
|
WO2011113904A1
(en)
|
2010-03-17 |
2011-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
|
WO2011113118A1
(en)
|
2010-03-19 |
2011-09-22 |
Katholieke Universiteit Leuven |
Drug tolerance/persistence of fungal biofilms
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US10472426B2
(en)
|
2010-03-25 |
2019-11-12 |
Ucb Biopharma Sprl |
Disulfide stabilized DVD-Ig molecules
|
JP5837567B2
(en)
|
2010-03-26 |
2015-12-24 |
メモリアル スローン−ケタリング キャンサー センター |
Antibodies against MUC16 and methods of use thereof
|
US9441032B2
(en)
|
2010-04-07 |
2016-09-13 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
EP2374816B1
(en)
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
BR112012025728B1
(en)
|
2010-04-09 |
2022-01-11 |
Critical Care Diagnostics, Inc |
ISOLATED ANTIBODIES OR FRAGMENTS THAT BIND TO SOLUBLE HUMAN ST2, HYBRIDOMA, KIT, AS WELL AS METHODS FOR QUANTIFICATION OF A LEVEL OF HUMAN SOLUBLE ST2 IN A SAMPLE FROM AN INDIVIDUAL, AND FOR PREDICTING THE RISK OF DEATH WITHIN ONE YEAR IN AN INDIVIDUAL
|
MX336196B
(en)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Amyloid-beta binding proteins.
|
SG10201502967RA
(en)
|
2010-04-16 |
2015-05-28 |
Biogen Ma Inc |
Anti-vla-4 antibodies
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
GB201006768D0
(en)
|
2010-04-22 |
2010-06-09 |
Cancer Rec Tech Ltd |
Method for obtaining dendritic cells
|
US20130078238A1
(en)
|
2010-04-29 |
2013-03-28 |
Hadasit Medical Research Services & Decvelopment Co. Ltd. |
Methods and Compositions for Treating Hepatitis with Anti-CD3 Immune Molecule Therapy
|
EP2563394B1
(en)
|
2010-04-30 |
2018-03-21 |
Beth Israel Deaconess Medical Center |
Methods and compositions for treating celiac disease
|
ES2641144T3
(en)
|
2010-05-10 |
2017-11-07 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Methods and compositions for the treatment of fluid accumulation in and / or under the retina
|
HUE033063T2
(en)
|
2010-05-14 |
2017-11-28 |
Abbvie Inc |
Il-1 binding proteins
|
WO2011145085A2
(en)
|
2010-05-21 |
2011-11-24 |
Procognia (Israel) Ltd |
Novel antibodies and methods of use for the treatment and diagnosis of cancer
|
GB201008541D0
(en)
|
2010-05-21 |
2010-07-07 |
Univ Geneve |
Diagnostic methods
|
US8853158B2
(en)
|
2010-05-25 |
2014-10-07 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor
|
EP2808344A1
(en)
|
2010-06-01 |
2014-12-03 |
Monash University |
Antibodies directed to the receptor tyrosine kinase c-Met
|
US20130236480A1
(en)
|
2010-06-02 |
2013-09-12 |
Pierre-Louis Tharaux |
Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
|
EP2575884B1
(en)
|
2010-06-03 |
2018-07-18 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of hidradenitis suppurativa (hs)
|
GB201009455D0
(en)
|
2010-06-04 |
2010-07-21 |
King S College London |
Nanoparticles and their uses in molecular imaging
|
US9127051B2
(en)
|
2010-06-09 |
2015-09-08 |
Queen Mary & Westfield College, University Of London |
Annexin 1 antibody
|
JO3330B1
(en)
|
2010-06-10 |
2019-03-13 |
Lilly Co Eli |
Cgrp antibodies
|
WO2011154485A1
(en)
|
2010-06-10 |
2011-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
SG186302A1
(en)
|
2010-06-16 |
2013-02-28 |
Abbott Lab |
Comparison of protein samples
|
WO2011157798A1
(en)
|
2010-06-16 |
2011-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for stimulating reepithelialisation during wound healing
|
EP3459558B1
(en)
|
2010-06-25 |
2020-07-29 |
Aston University |
Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
|
ES2690760T3
(en)
|
2010-06-25 |
2018-11-22 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Flagelin polypeptide as a TLR5 agonist for use in the treatment of respiratory tract infections
|
US9095591B2
(en)
|
2010-06-28 |
2015-08-04 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Pharmaceutical composition for use in the treatment of glaucoma
|
WO2012004565A1
(en)
|
2010-07-06 |
2012-01-12 |
Robert White |
Cancer biomarker brf1
|
WO2012005076A1
(en)
|
2010-07-08 |
2012-01-12 |
本田技研工業株式会社 |
High frequency heating coil
|
EP3560962A1
(en)
|
2010-07-09 |
2019-10-30 |
Bioverativ Therapeutics Inc. |
Processable single chain molecules and polypeptides made using same
|
AR082149A1
(en)
|
2010-07-09 |
2012-11-14 |
Calmune Corp |
ANTIBODIES AGAINST HUMAN RESPIRATORY SYNTHETIC VIRUS (RSV) AND METHODS FOR USE
|
CN103153331B
(en)
|
2010-07-15 |
2017-03-22 |
亚德赫伦医疗公司 |
Humanized antibodies targeting the EC1 domain of cadherin-11 and related compositions and methods
|
WO2012007880A2
(en)
|
2010-07-16 |
2012-01-19 |
Ablynx Nv |
Modified single domain antigen binding molecules and uses thereof
|
CA2805338A1
(en)
|
2010-07-16 |
2012-01-19 |
Merck Patent Gmbh |
Peptide for use in the treatment of breast cancer and/or bone metastases
|
JP5972871B2
(en)
|
2010-07-20 |
2016-08-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
Anti-IL-23 heterodimer specific antibody
|
WO2012010696A1
(en)
|
2010-07-23 |
2012-01-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for cancer management targeting co-029
|
SG187682A1
(en)
|
2010-08-02 |
2013-03-28 |
Macrogenics Inc |
Covalent diabodies and uses thereof
|
CA2815154A1
(en)
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
WO2012019991A1
(en)
|
2010-08-09 |
2012-02-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of hiv-1 infections
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
RS59652B1
(en)
|
2010-08-12 |
2020-01-31 |
Lilly Co Eli |
Anti-n3pglu amyloid beta peptide antibodies and uses thereof
|
WO2012024187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
US9505829B2
(en)
|
2010-08-19 |
2016-11-29 |
Zoetis Belgium S.A. |
Anti-NGF antibodies and their use
|
CA2807607A1
(en)
|
2010-08-20 |
2012-02-23 |
Wyeth Llc |
Cell culture of growth factor-free adapted cells
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
PT2609118T
(en)
|
2010-08-23 |
2017-03-22 |
Univ Texas |
Anti-ox40 antibodies and methods of using the same
|
WO2012030394A1
(en)
|
2010-09-01 |
2012-03-08 |
Genzyme Corporation |
Treatment of myocardial infarction using tgf - beta antagonists
|
WO2013119964A2
(en)
|
2012-02-08 |
2013-08-15 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
WO2012031280A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
CA2810909A1
(en)
|
2010-09-20 |
2012-03-29 |
Abbvie Inc. |
Purification of antibodies using simulated moving bed chromatography
|
US20130195863A1
(en)
|
2010-09-28 |
2013-08-01 |
Philippe Clezardin |
Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases
|
JP5843170B2
(en)
|
2010-09-30 |
2016-01-13 |
国立研究開発法人理化学研究所 |
Method for treating glioma, method for examining glioma, method for delivering desired substance to glioma, and drug used in these methods
|
US20140079769A1
(en)
|
2010-10-01 |
2014-03-20 |
Fabiola Terzi |
Methods for predicting the progression and treating a chronic kidney disease in a patient
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
UA112062C2
(en)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
CD33-Binding Agent
|
WO2012054077A2
(en)
|
2010-10-19 |
2012-04-26 |
Mayo Foundation For Medical Education And Research |
Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
|
EP3581206A1
(en)
|
2010-10-22 |
2019-12-18 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway
|
EP2632489B1
(en)
|
2010-10-27 |
2020-01-15 |
The Research Foundation for The State University of New York |
Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
|
US20120108651A1
(en)
|
2010-11-02 |
2012-05-03 |
Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) |
Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
|
AU2011325871B2
(en)
|
2010-11-05 |
2016-02-04 |
Medvet Science Pty Ltd |
Markers of endothelial progenitor cells and uses thereof
|
GB201019118D0
(en)
|
2010-11-11 |
2010-12-29 |
King S College |
Conjugates and their uses in molecular imaging
|
US9297813B2
(en)
|
2010-11-11 |
2016-03-29 |
Agency For Science, Technology And Research |
Targeting metabolic enzymes in human cancer
|
JP2014502262A
(en)
|
2010-11-12 |
2014-01-30 |
ザ ロックフェラー ユニバーシティ |
Fusion protein for HIV treatment
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
US9072766B2
(en)
|
2010-11-18 |
2015-07-07 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
|
SG10201509499RA
(en)
|
2010-11-19 |
2015-12-30 |
Eisai R&D Man Co Ltd |
Neutralizing anti-ccl20 antibodies
|
CN103534392A
(en)
|
2010-12-01 |
2014-01-22 |
默沙东公司 |
Surface, anchored FC-bait antibody display system
|
US20120148559A1
(en)
|
2010-12-01 |
2012-06-14 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
EP2646572B1
(en)
|
2010-12-01 |
2017-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Diagnostic and treatment of chronic heart failure
|
EP2646555B1
(en)
|
2010-12-03 |
2015-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of heart failure
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201238973A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
KR20140003467A
(en)
|
2010-12-20 |
2014-01-09 |
메디뮨 리미티드 |
Anti-il-18 antibodies and their uses
|
US9631002B2
(en)
|
2010-12-21 |
2017-04-25 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin K-dependent proteins
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
KR101941514B1
(en)
|
2010-12-22 |
2019-01-23 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
Modified antibody with improved half-life
|
WO2012090939A1
(en)
|
2010-12-27 |
2012-07-05 |
国立大学法人名古屋大学 |
Method for suppressing receptor tyrosine kinase-mediated prosurvival signaling in cancer cells
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
US20140050743A1
(en)
|
2011-01-19 |
2014-02-20 |
Bayer Intellectual Property Gmbh |
Binding proteins to inhibitors of coagulation factors
|
EP3187216B1
(en)
|
2011-01-24 |
2019-08-21 |
AbbVie Biotechnology Ltd. |
Automatic injection devices having overmolded gripping surfaces
|
US20120189633A1
(en)
|
2011-01-26 |
2012-07-26 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
CA3042620A1
(en)
|
2011-02-02 |
2012-11-29 |
Emory University |
Antagonism of the vip signaling pathway
|
US20120201752A1
(en)
|
2011-02-04 |
2012-08-09 |
Xiaojiang Cui |
Foxc1 antibodies and methods of their use
|
WO2012110824A1
(en)
|
2011-02-18 |
2012-08-23 |
Astrazeneca Ab |
Binding agents with specificity for a nucleic acid modification
|
MY181093A
(en)
|
2011-03-02 |
2020-12-17 |
Berg Llc |
Interrogatory cell-based assays and uses thereof
|
KR20190006083A
(en)
|
2011-03-09 |
2019-01-16 |
셀 시그널링 테크놀러지, 인크. |
Methods and reagents for creating monoclonal antibodies
|
WO2012125735A1
(en)
|
2011-03-15 |
2012-09-20 |
Abott Laboratories |
An integrated approach to the isolation and purification of antibodies
|
EP2686014A1
(en)
|
2011-03-16 |
2014-01-22 |
Sanofi |
Uses of a dual v region antibody-like protein
|
WO2012128810A1
(en)
|
2011-03-23 |
2012-09-27 |
Abbott Laboratories |
Methods and systems for the analysis of protein samples
|
KR20140018299A
(en)
|
2011-03-30 |
2014-02-12 |
아블린쓰 엔.브이. |
Methods of treating immune disorders with single domain antibodies against tnf-alpha
|
CA3019531A1
(en)
|
2011-04-19 |
2012-10-26 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
EP2699264B1
(en)
|
2011-04-20 |
2018-03-14 |
Medlmmune, LLC |
Antibodies and other molecules that bind b7-h1 and pd-1
|
CN103619877B
(en)
|
2011-04-21 |
2018-01-02 |
加文医学研究所 |
The variable domains molecule and its generation and application method B of modification
|
US9034322B2
(en)
|
2011-04-21 |
2015-05-19 |
The Rockefeller University |
Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
|
US20130122024A1
(en)
|
2011-04-21 |
2013-05-16 |
Bayer Intellectual Property Gmbh |
New binder-drug conjugates (adcs) and use thereof
|
EP2518157A1
(en)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Test Systems and methods for identifying a compound altering cellular DDR activity
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
PE20141672A1
(en)
|
2011-05-02 |
2014-11-26 |
Millennium Pharm Inc |
FORMULATION FOR ANTI-alpha4�7 ANTIBODY
|
UA116189C2
(en)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
FORMULATION FOR ANTI-α4β7 ANTIBODY
|
GB201107467D0
(en)
|
2011-05-05 |
2011-06-15 |
Univ Leuven Kath |
Novel treatment of pain
|
EP2708560A4
(en)
|
2011-05-09 |
2015-01-14 |
Perseus Proteomics Inc |
Antibody specifically recognising transferrin receptor
|
US20140086827A1
(en)
|
2011-05-09 |
2014-03-27 |
The Cleveland Clinic Foundation |
Serum S100B And Uses Thereof
|
EP2524699A1
(en)
|
2011-05-17 |
2012-11-21 |
Trion Research GmbH |
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
ES2703780T3
(en)
|
2011-05-17 |
2019-03-12 |
Trion Res Gmbh |
Preparation of a vaccine containing trifunctional antibodies with potentiating properties of antigen immunogenicity
|
US9376495B2
(en)
|
2011-05-21 |
2016-06-28 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use in extending serum half-life
|
AR086543A1
(en)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
GALECTIN-3 INHIBITORS AND METHODS OF USE OF THE SAME, PHARMACEUTICAL COMPOSITION
|
EP2715364A1
(en)
|
2011-06-01 |
2014-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for predicting the risk of developing a colonic neoplasia
|
EP2717911A1
(en)
|
2011-06-06 |
2014-04-16 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
AU2012267530A1
(en)
|
2011-06-08 |
2014-01-16 |
Indiana University Research And Technology Corporation |
Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
|
GB201109965D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
HUE038509T2
(en)
|
2011-06-10 |
2018-10-29 |
Medimmune Ltd |
Anti-pseudomonas psl binding molecules and uses thereof
|
LT2717898T
(en)
|
2011-06-10 |
2019-03-25 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
GB201109966D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating pten mutated or deficient cancer
|
AU2012271450A1
(en)
|
2011-06-17 |
2014-01-16 |
Adrian L. Harris |
Methods of enhancing the response to radiation in tumor therapy using anti-DLL4 antibodies
|
EP2537532A1
(en)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
|
WO2012175711A1
(en)
|
2011-06-24 |
2012-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy
|
JP6113721B2
(en)
|
2011-06-28 |
2017-04-12 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
Therapeutic and diagnostic targets
|
PT2726101T
(en)
|
2011-06-30 |
2018-11-21 |
Genzyme Corp |
Inhibitors of t-cell activation
|
AU2012280474A1
(en)
|
2011-07-01 |
2014-01-16 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
WO2013007563A1
(en)
|
2011-07-08 |
2013-01-17 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
MX2014000531A
(en)
|
2011-07-13 |
2014-12-05 |
Abbvie Inc |
Methods and compositions for treating asthma using anti-il-13 antibodies.
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
EP2548891A1
(en)
|
2011-07-18 |
2013-01-23 |
Universiteit Maastricht |
Human monoclonal antibody against the gamma subunit of the acetylcholine receptor for use in the treatment of rhabdomyosarcoma.
|
WO2013014538A2
(en)
|
2011-07-25 |
2013-01-31 |
American University In Cairo |
Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
|
WO2013014149A1
(en)
|
2011-07-27 |
2013-01-31 |
Philogen S.P.A. |
Il-12 immunoconjugate
|
EP2739975B1
(en)
|
2011-08-03 |
2015-06-17 |
Quidel Corporation |
N-acetyl-d-glucosamine for enhanced specificity of strep a immunoassay
|
US20140242085A1
(en)
|
2011-08-12 |
2014-08-28 |
Medical & Biological Laboratories Co., Ltd. |
Methods and composition for testing, preventing, and treating aspergillus fumigatus infection
|
AU2012296613B2
(en)
|
2011-08-15 |
2016-05-12 |
Amplimmune, Inc. |
Anti-B7-H4 antibodies and their uses
|
UY34317A
(en)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
T cell antireceptor antibody (alpha) / ß
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
RU2014115676A
(en)
|
2011-09-21 |
2015-10-27 |
Фуджиребайо Инк. |
ANTIBODIES AGAINST AFFINE COMPLEX
|
AU2012310328A1
(en)
|
2011-09-23 |
2014-04-10 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. |
Anti-Tumor Necrosis Factor-alpha agents and uses thereof
|
JP2014533929A
(en)
|
2011-09-23 |
2014-12-18 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
Bispecific binding molecules for 5T4 and CD3
|
RU2628089C2
(en)
|
2011-09-26 |
2017-08-14 |
Филоген С.П.А. |
Immunocytocins combined therapy
|
EP2748198A2
(en)
|
2011-09-27 |
2014-07-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
|
KR101982899B1
(en)
|
2011-09-30 |
2019-05-27 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
Antibodies against tl1a and uses thereof
|
EP2764093B1
(en)
|
2011-10-05 |
2018-04-18 |
The Rockefeller University |
Dimeric bacteriophage lysins
|
CA2851322C
(en)
|
2011-10-10 |
2020-03-31 |
Medimmune Limited |
Treatment for rheumatoid arthritis with gm csfr alpha antibodies
|
EP2766041B1
(en)
|
2011-10-12 |
2018-12-05 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
WO2013055911A1
(en)
|
2011-10-14 |
2013-04-18 |
Dana-Farber Cancer Institute, Inc. |
Znf365/zfp365 biomarker predictive of anti-cancer response
|
EP2768861A1
(en)
|
2011-10-21 |
2014-08-27 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
|
KR20170021919A
(en)
|
2011-10-21 |
2017-02-28 |
화이자 인코포레이티드 |
Addition of iron to improve cell culture
|
AR088513A1
(en)
|
2011-10-24 |
2014-06-18 |
Abbvie Inc |
IMMUNO LINKERS AGAINST SCLEROSTINE
|
WO2013059886A1
(en)
|
2011-10-28 |
2013-05-02 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
US10202643B2
(en)
|
2011-10-31 |
2019-02-12 |
University Of Utah Research Foundation |
Genetic alterations in glioma
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
US9221906B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of inhibiting solid tumor growth by administering GPR49 antibodies
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
US20140286965A1
(en)
|
2011-11-07 |
2014-09-25 |
Inserm |
Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
|
ES2859323T3
(en)
|
2011-11-07 |
2021-10-01 |
Medimmune Ltd |
Combination therapies using Pseudomonas anti-Psl and PcrV binding molecules
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
EP2776838A1
(en)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
SG11201401649VA
(en)
|
2011-11-11 |
2014-07-30 |
Ucb Pharma Sa |
Albumin binding antibodies and binding fragments thereof
|
TWI679212B
(en)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
Binding molecules for e3 of bcma and cd3
|
US20140314667A1
(en)
|
2011-11-16 |
2014-10-23 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
BR112014012609A2
(en)
|
2011-11-17 |
2020-10-20 |
Pfizer Inc |
cytotoxic and conjugated antibody drug peptides thereof
|
AR088941A1
(en)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
ANTI-FGFR2 ANTIBODIES AND THEIR USES
|
EP2599496A1
(en)
|
2011-11-30 |
2013-06-05 |
Kenta Biotech AG |
Novel targets of Acinetobacter baumannii
|
WO2013080050A2
(en)
|
2011-11-30 |
2013-06-06 |
Universitaetsklinikum Erlangen |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
EP2788379B1
(en)
|
2011-12-05 |
2020-02-05 |
X-Body, Inc. |
Pdgf receptor beta binding polypeptides
|
WO2013088136A1
(en)
|
2011-12-12 |
2013-06-20 |
Ahrens Susan |
Ligand for dngr-1 receptor
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
GB201121564D0
(en)
|
2011-12-14 |
2012-01-25 |
Queen Mary & Westfield College |
Use of antibody
|
MX2014007121A
(en)
|
2011-12-14 |
2014-09-04 |
Seattle Genetics Inc |
Fgfr antibody drug conjugates (adcs) and the use thereof.
|
ES2721882T3
(en)
|
2011-12-23 |
2019-08-06 |
Pfizer |
Constant regions of genetically engineered antibody for site-specific conjugation and procedures and uses thereof
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
EP2802606B1
(en)
|
2012-01-10 |
2018-04-25 |
Biogen MA Inc. |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
ES2676725T3
(en)
|
2012-01-27 |
2018-07-24 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of diseases associated with the degeneration of neurites
|
ES2725569T3
(en)
|
2012-02-10 |
2019-09-24 |
Seattle Genetics Inc |
Diagnosis and treatment of cancers that express CD30
|
CN108103069B
(en)
|
2012-02-15 |
2021-08-10 |
诺和诺德股份有限公司 |
Antibodies that bind to and block trigger receptor-1 (TREM-1) expressed by myeloid cells
|
PL2814842T3
(en)
|
2012-02-15 |
2018-12-31 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
US20150037334A1
(en)
|
2012-03-01 |
2015-02-05 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
EP2828291A1
(en)
|
2012-03-21 |
2015-01-28 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Peptides derived from the d1-domain of nkp46
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
CN104350156B
(en)
|
2012-03-27 |
2019-04-02 |
弗·哈夫曼-拉罗切有限公司 |
Improved harvest for recombinant protein operates
|
SI2831113T1
(en)
|
2012-03-28 |
2018-08-31 |
Sanofi |
Antibodies to bradykinin b1 receptor ligands
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
BR112014024537A2
(en)
|
2012-04-02 |
2017-08-08 |
Berg Llc |
methods to identify modulators of a biological system, a disease process, and angiogenesis
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US9566329B2
(en)
|
2012-04-06 |
2017-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Live, attenuated rubella vector to express vaccine antigens
|
US9534059B2
(en)
|
2012-04-13 |
2017-01-03 |
Children's Medical Center Corporation |
TIKI inhibitors
|
BR112014025898A2
(en)
|
2012-04-17 |
2017-11-07 |
Mayo Found Medical Education & Res |
human antibodies and specific binding sequences for use in stroke and ischemia or ischemic conditions
|
WO2013156867A2
(en)
|
2012-04-19 |
2013-10-24 |
Inserm |
Methods and pharmaceutical compositions for the treatment of hypertension
|
HUE045944T2
(en)
|
2012-04-20 |
2020-02-28 |
Merus Nv |
Methods and means for the production of heterodimeric ig-like molecules
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
WO2013164444A1
(en)
|
2012-05-03 |
2013-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
US9273140B2
(en)
|
2012-05-10 |
2016-03-01 |
Fujita Health University |
Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D
|
CN104271816A
(en)
|
2012-05-11 |
2015-01-07 |
默沙东公司 |
Surface anchored light chain bait antibody display system
|
EP2848633B1
(en)
|
2012-05-11 |
2019-02-06 |
Microbial Chemistry Research Foundation |
Anti-cxadr antibody
|
JP2015518829A
(en)
|
2012-05-14 |
2015-07-06 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
LINGO-2 antagonist for treatment of conditions involving motor neurons
|
KR102475777B1
(en)
|
2012-05-15 |
2022-12-09 |
씨젠 인크. |
Self-stabilizing linker conjugates
|
BR112014028306A2
(en)
|
2012-05-15 |
2018-04-17 |
Morphotek, Inc. |
methods for treating gastric cancer.
|
WO2013171296A1
(en)
|
2012-05-16 |
2013-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Diagnostic and treatment of sarcoidosis
|
WO2013177115A2
(en)
|
2012-05-21 |
2013-11-28 |
Abbvie Inc. |
Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
SG11201408330XA
(en)
|
2012-05-24 |
2015-01-29 |
Mountgate Group Ltd |
Compositions and methods related to prevention and treatment of rabies infection
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
EP2863940A4
(en)
|
2012-06-08 |
2016-08-10 |
Biogen Ma Inc |
Chimeric clotting factors
|
DK2858647T3
(en)
|
2012-06-08 |
2018-08-20 |
Sensorion |
H4 RECEPTOR INHIBITORS FOR TINNITUS TREATMENT
|
JP2015521589A
(en)
|
2012-06-08 |
2015-07-30 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Procoagulant compounds
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
EP2870242A1
(en)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
WO2014011908A1
(en)
|
2012-07-11 |
2014-01-16 |
Esperion Therapeutics, Inc. |
Apolipoprotein mixtures
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
WO2014021339A1
(en)
|
2012-07-30 |
2014-02-06 |
国立大学法人名古屋大学 |
Monoclonal antibody against human midkine
|
WO2014020293A1
(en)
|
2012-07-31 |
2014-02-06 |
Imperial Innovations Limited |
Assay
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2692357A1
(en)
|
2012-08-03 |
2014-02-05 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Novel anti-plasmodium parasite antibodies
|
BR112015003326A2
(en)
|
2012-08-16 |
2017-07-04 |
Ipierian Inc |
methods of treatment of a tauopathy
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
SG11201501924UA
(en)
|
2012-09-13 |
2015-05-28 |
Chugai Pharmaceutical Co Ltd |
Gene knock-in non-human animal
|
ES2752190T3
(en)
|
2012-09-14 |
2020-04-03 |
Us Health |
Brachyury protein, adenoviral vectors encoding Brachyury protein and their use
|
DK2897978T3
(en)
|
2012-09-19 |
2017-05-15 |
Abbvie Biotherapeutics Inc |
PROCEDURES FOR IDENTIFYING ANTIBODIES WITH REDUCED IMMUNOGENICITY
|
JP6259828B2
(en)
|
2012-09-24 |
2018-01-10 |
ヴェンタナ メディカル システムズ, インク. |
Method for identifying treatment-responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker
|
WO2014051433A1
(en)
|
2012-09-27 |
2014-04-03 |
Merus B.V. |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
US9594083B2
(en)
|
2012-09-28 |
2017-03-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method for the treatment of cardiovascular fibrosis
|
NO2760138T3
(en)
|
2012-10-01 |
2018-08-04 |
|
|
PL2903629T3
(en)
|
2012-10-03 |
2019-12-31 |
Philogen S.P.A. |
Antibody conjugate for use in treating inflammatory bowel disease
|
EP3677310A1
(en)
|
2012-10-08 |
2020-07-08 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
KR102450670B1
(en)
|
2012-10-15 |
2022-10-04 |
메디뮨 리미티드 |
Antibodies to amyloid beta
|
CN110818798A
(en)
|
2012-10-25 |
2020-02-21 |
美国比奥维拉迪维股份有限公司 |
Anti-complement C1s antibodies and uses thereof
|
WO2014064192A1
(en)
|
2012-10-26 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction
|
EP2914291B1
(en)
|
2012-11-02 |
2022-02-23 |
Bioverativ USA Inc. |
Anti-complement c1s antibodies and uses thereof
|
EP2917195B9
(en)
|
2012-11-05 |
2018-05-30 |
Pfizer Inc |
Spliceostatin analogs
|
TW201726746A
(en)
|
2012-11-07 |
2017-08-01 |
輝瑞股份有限公司 |
Anti-Notch3 antibodies and antibody-drug conjugates
|
JP6212497B2
(en)
|
2012-11-08 |
2017-10-11 |
国立大学法人 宮崎大学 |
Antibodies that can specifically recognize transferrin receptor
|
GB201220924D0
(en)
|
2012-11-21 |
2013-01-02 |
Cancer Res Inst Royal |
Materials and methods for determining susceptibility or predisposition to cancer
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
UA118255C2
(en)
|
2012-12-07 |
2018-12-26 |
Санофі |
Compositions comprising anti-cd38 antibodies and lenalidomide
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
ES2862950T3
(en)
|
2012-12-18 |
2021-10-08 |
Univ Rockefeller |
Glycan-modified anti-CD4 antibodies for HIV prevention and therapy
|
CA2894879A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
WO2014100602A1
(en)
|
2012-12-20 |
2014-06-26 |
Hospital For Special Surgery |
Treatment of egf-receptor dependent pathologies
|
CA2896091C
(en)
|
2012-12-21 |
2018-06-19 |
Amplimmune, Inc. |
Anti-h7cr antibodies
|
GB201223172D0
(en)
|
2012-12-21 |
2013-02-06 |
Immunocore Ltd |
Method
|
US11211167B2
(en)
|
2012-12-28 |
2021-12-28 |
Ventana Medical Systems, Inc. |
Image analysis for breast cancer prognosis
|
KR102449868B1
(en)
|
2013-02-01 |
2022-10-04 |
키라 바이오테크 피티와이 리미티드 |
Anti-cd83 antibodies and use thereof
|
ES2942636T3
(en)
|
2013-02-07 |
2023-06-05 |
Csl Ltd |
IL-11R binding proteins and uses thereof
|
EP2955226B1
(en)
|
2013-02-08 |
2019-06-26 |
Medical & Biological Laboratories Co., Ltd. |
Antibodies to human nrg1 protein
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
CN105263319A
(en)
|
2013-02-13 |
2016-01-20 |
法国化学与生物科技实验室 |
Proteins with modified glycosylation and methods of production thereof
|
TW201506041A
(en)
|
2013-02-13 |
2015-02-16 |
Lab Francais Du Fractionnement |
highly galactosylated anti-TNF-alpha antibodies and uses thereof
|
EP2963059B1
(en)
|
2013-02-28 |
2018-04-04 |
National Cancer Center |
Antibody against insoluble fibrin
|
WO2014164472A1
(en)
|
2013-03-10 |
2014-10-09 |
The Board Of Regents Of The University Of Texas System |
Biomarkers for chagas disease related cardiomyopathy
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
JOP20140087B1
(en)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
SG10201913777XA
(en)
|
2013-03-13 |
2020-03-30 |
Sanofi Sa |
Compositions comprising anti-cd38 antibodies and carfilzomib
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
BR112015023239A8
(en)
|
2013-03-14 |
2018-04-17 |
Abbott Lab |
hcv antibody-antigen combination assay and methods and compositions for use thereof
|
EP2970375A1
(en)
|
2013-03-14 |
2016-01-20 |
AbbVie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
EP2968550B1
(en)
|
2013-03-14 |
2018-11-14 |
Ffe Therapeutics LLC |
Compositions and methods for treating angiogenesis-related disorders
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
MX2015012824A
(en)
|
2013-03-14 |
2016-06-24 |
Abbott Lab |
Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection.
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
CA2926301A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing and using the same
|
JP6739329B2
(en)
|
2013-03-14 |
2020-08-12 |
アボット・ラボラトリーズAbbott Laboratories |
HCV core lipid binding domain monoclonal antibody
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
AR095374A1
(en)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
UNION MOLECULES FOR BCMA AND CD3
|
AU2014233503A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Biotechnology Ltd. |
Anti-CD25 antibodies and their uses
|
SG11201507619PA
(en)
|
2013-03-15 |
2015-10-29 |
Ct For Drug Res And Dev |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
EP2971077B1
(en)
|
2013-03-15 |
2019-05-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction
|
AU2014233528B2
(en)
|
2013-03-15 |
2019-02-28 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
WO2014145000A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Biotherapeutics Inc. |
Anti-cd25 antibodies and their uses
|
AR095199A1
(en)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
ANTI-CD52 ANTIBODIES
|
EP2976362B1
(en)
|
2013-03-19 |
2019-10-23 |
Beijing Shenogen Pharma Group Ltd. |
Antibodies and methods for treating estrogen receptor-associated diseases
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
WO2014167083A1
(en)
|
2013-04-12 |
2014-10-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for predicting the risk of developing a colonic neoplasia
|
WO2014174596A1
(en)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor
|
JP2016521283A
(en)
|
2013-05-06 |
2016-07-21 |
スカラー ロック インコーポレイテッドScholar Rock,Inc. |
Compositions and methods for growth factor modulation
|
GB201308259D0
(en)
|
2013-05-08 |
2013-06-12 |
Iles Raymond K |
Cancer diagnosis and monitoring
|
SG11201509284VA
(en)
|
2013-05-17 |
2015-12-30 |
Centre Nat Rech Scient |
Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
|
CA2913312A1
(en)
|
2013-05-24 |
2014-11-27 |
Medimmune, Llc |
Anti-b7-h5 antibodies and their uses
|
SG11201509982UA
(en)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
CA2914768A1
(en)
|
2013-06-10 |
2014-12-18 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
JP2016521715A
(en)
|
2013-06-14 |
2016-07-25 |
バイエル ファーマ アクチエンゲゼルシャフト |
Anti-TWEAKR antibody and use thereof
|
CA2952390A1
(en)
|
2013-06-20 |
2014-12-24 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosing pancreatic cancer
|
US10221239B2
(en)
|
2013-06-28 |
2019-03-05 |
Singapore Health Services Pte Ltd |
TRPM4 channel inhibitors for stroke treatment
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
EP3632458A1
(en)
|
2013-07-26 |
2020-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
EP3030902B1
(en)
|
2013-08-07 |
2019-09-25 |
Friedrich Miescher Institute for Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
MX2016001851A
(en)
|
2013-08-13 |
2016-05-16 |
Sanofi Sa |
Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof.
|
TW201722994A
(en)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and uses thereof
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
WO2015036618A1
(en)
|
2013-09-16 |
2015-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of epilepsy
|
EP3049438B1
(en)
|
2013-09-24 |
2018-07-25 |
The Feinstein Institute for Medical Research |
Peptides inhibiting cold-inducible rna binding protein activity
|
US9974788B2
(en)
|
2013-09-26 |
2018-05-22 |
Beth Israel Deaconess Medical Center, Inc. |
Inhibition of SGK1 in the treatment of heart conditions
|
GB201317207D0
(en)
|
2013-09-27 |
2013-11-13 |
Univ Glasgow |
Materials and methods for modulating disc1 turnover
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
EA036927B1
(en)
|
2013-10-11 |
2021-01-15 |
Оксфорд Биотерепьютикс Лтд |
Conjugated antibodies against ly75 for the treatment of cancer
|
IL293071A
(en)
|
2013-10-15 |
2022-07-01 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
AU2014342528A1
(en)
|
2013-10-28 |
2016-04-28 |
Dots Technology Corp. |
Allergen detection
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
JPWO2015068781A1
(en)
|
2013-11-06 |
2017-03-09 |
国立大学法人大阪大学 |
Antibodies with broad neutralizing activity against group 1 of influenza virus type A
|
US20160272674A1
(en)
|
2013-11-07 |
2016-09-22 |
Abbvie Inc. |
Isolation and purification of antibodies
|
EP2871189A1
(en)
|
2013-11-07 |
2015-05-13 |
Institut Pasteur |
High-affinity monoclonal anti-strep-tag antibody
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
GB201320061D0
(en)
|
2013-11-13 |
2013-12-25 |
Electrophoretics Ltd |
Materials nad methods for diagnosis and prognosis of liver cancer
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
CN105899230B
(en)
|
2013-11-27 |
2020-06-09 |
伊皮埃里安股份有限公司 |
Methods of treating tauopathy
|
PL3074038T3
(en)
|
2013-11-28 |
2019-08-30 |
Csl Limited |
Method of treating diabetic nephropathy
|
JP2017502002A
(en)
|
2013-12-09 |
2017-01-19 |
ニューヨーク・ユニバーシティ |
Composition and method for phagocytic cell delivery of anti-staphylococcal agents
|
WO2015086727A2
(en)
|
2013-12-11 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New prognostic method for patients suffering of a cancer
|
EP3080611B1
(en)
|
2013-12-13 |
2018-11-14 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
WO2015088346A1
(en)
|
2013-12-13 |
2015-06-18 |
Rijksuniversiteit Groningen |
Antibodies against staphylococcus aureus and uses thereof.
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
DK3082860T3
(en)
|
2013-12-18 |
2021-01-25 |
Csl Ltd |
PROCEDURE FOR WOUND TREATMENT
|
EP4212181A3
(en)
|
2013-12-19 |
2023-11-15 |
Seagen Inc. |
Methylene carbamate linkers for use with targeted-drug conjugates
|
EP3086814B1
(en)
|
2013-12-23 |
2020-06-24 |
Bayer Pharma Aktiengesellschaft |
Drug conjugates (adcs) with kinesin spindel protein (ksp)
|
TW201609805A
(en)
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
Multifunctional antibodies binding to EGFR and MET
|
CN106255513B
(en)
|
2013-12-27 |
2022-01-14 |
酵活有限公司 |
Sulfonamide-containing linking systems for drug conjugates
|
CN106459055B
(en)
|
2014-01-27 |
2019-11-01 |
辉瑞大药厂 |
Difunctional cytotoxic drug agent
|
JP6712428B2
(en)
|
2014-02-04 |
2020-06-24 |
コントラフェクト コーポレイション |
Antibodies useful for influenza passive immunization and compositions, combinations and methods for their use
|
EP4190809A1
(en)
|
2014-02-11 |
2023-06-07 |
Seagen Inc. |
Selective reduction of proteins
|
CA2937753A1
(en)
|
2014-02-17 |
2015-08-20 |
Seattle Genetics, Inc. |
Hydrophilic antibody-drug conjugates
|
SG10201913289TA
(en)
|
2014-02-28 |
2020-02-27 |
Merus Nv |
Antibody that binds erbb-2 and erbb-3
|
JP6771385B2
(en)
|
2014-02-28 |
2020-10-21 |
メルス ナムローゼ フェンノートシャップ |
Bispecific antibody and pharmaceutical composition
|
GB201403815D0
(en)
|
2014-03-04 |
2014-04-16 |
Mologic Ltd |
Assay
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
US10544395B2
(en)
|
2014-03-19 |
2020-01-28 |
Pfizer Inc. |
Method of cell culture
|
KR102399028B1
(en)
|
2014-03-21 |
2022-05-17 |
엑스-바디 인코포레이티드 |
Bi-specific antigen-binding polypeptides
|
CN106536556B
(en)
|
2014-04-04 |
2020-02-07 |
生态学有限公司 |
Humanized antibodies that bind LGR5
|
SG10201907807XA
(en)
|
2014-04-10 |
2019-09-27 |
Daiichi Sankyo Co Ltd |
Anti-her3 antibody-drug conjugate
|
CA2945880A1
(en)
|
2014-04-16 |
2015-10-22 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Apoo for use in a method for treating cancer and various pathophysiological situations
|
GB201407132D0
(en)
|
2014-04-23 |
2014-06-04 |
Velgene Biotechnology |
Marker for neurodegenerative disorders
|
US11624093B2
(en)
|
2014-04-24 |
2023-04-11 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
EP3148567A4
(en)
|
2014-04-25 |
2018-01-10 |
The Brigham and Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
US20170267780A1
(en)
|
2014-05-16 |
2017-09-21 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
NZ726513A
(en)
|
2014-05-28 |
2023-07-28 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
EP3154579A1
(en)
|
2014-06-13 |
2017-04-19 |
Friedrich Miescher Institute for Biomedical Research |
New treatment against influenza virus
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
WO2015199976A1
(en)
|
2014-06-24 |
2015-12-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Target activated microdissection
|
EP3145951A1
(en)
|
2014-06-24 |
2017-03-29 |
InSight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
TWI745962B
(en)
|
2014-06-27 |
2021-11-11 |
法商賽諾菲公司 |
Methods of determining whether a dose comprising a dual-v-region antibody-like protein or a fragment thereof administered to a human subject specifically binds to il-4 or il-13 within the human subject
|
RU2017100658A
(en)
|
2014-06-30 |
2018-07-30 |
Мёрдок Чилдренс Рисерч Инститьют |
THERAPEUTIC AGAINST Helicobacter
|
WO2016001830A1
(en)
|
2014-07-01 |
2016-01-07 |
Friedrich Miescher Institute For Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
SG11201609707WA
(en)
|
2014-07-01 |
2017-01-27 |
Pfizer |
Bispecific heterodimeric diabodies and uses thereof
|
US20170226552A1
(en)
|
2014-07-03 |
2017-08-10 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
US20160185848A1
(en)
|
2014-07-09 |
2016-06-30 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using sugars
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
ES2825708T3
(en)
|
2014-07-17 |
2021-05-17 |
Univ Pennsylvania |
Methods for using exosomes to monitor transplanted organ status
|
TN2017000008A1
(en)
|
2014-07-17 |
2018-07-04 |
Novo Nordisk As |
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
|
AR101936A1
(en)
|
2014-07-31 |
2017-01-25 |
Amgen Res (Munich) Gmbh |
SPECIFIC BIESPECIFIC CHAIN ANTIBODY CONSTRUCTS SPECIFIED FOR OPTIMIZED CROSSED SPECIES
|
AU2015295242B2
(en)
|
2014-07-31 |
2020-10-22 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
AR101669A1
(en)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
|
WO2016016442A1
(en)
|
2014-08-01 |
2016-02-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An anti-cd45rc antibody for use as drug
|
AU2015300915B2
(en)
|
2014-08-08 |
2020-09-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Photo-controlled removal of targets in vitro and in vivo
|
WO2016027859A1
(en)
*
|
2014-08-20 |
2016-02-25 |
中外製薬株式会社 |
Method for measuring viscosity of protein solution
|
EP3189132B1
(en)
|
2014-09-04 |
2020-06-24 |
Stemcell Technologies Inc. |
Soluble antibody complexes for t cell or nk cell activation and expansion
|
CA2960899C
(en)
|
2014-09-17 |
2021-08-17 |
Zymeworks Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
US10080790B2
(en)
|
2014-09-19 |
2018-09-25 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
EP3197557A1
(en)
|
2014-09-24 |
2017-08-02 |
Friedrich Miescher Institute for Biomedical Research |
Lats and breast cancer
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
AU2015328163B2
(en)
|
2014-10-09 |
2020-10-15 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable IL-2 dose regimen for treating immune disorders
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
EP3009147A1
(en)
|
2014-10-16 |
2016-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating resistant glioblastoma
|
EP3209695A4
(en)
|
2014-10-23 |
2018-05-30 |
DendroCyte BioTech Pty Ltd |
Cd83 binding proteins and uses thereof
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
WO2016066671A1
(en)
|
2014-10-29 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating resistant cancers using progastrin inhibitors
|
JP2017537893A
(en)
|
2014-10-31 |
2017-12-21 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Anti-CS1 antibody and antibody drug conjugate
|
MX2017006167A
(en)
|
2014-11-12 |
2018-03-23 |
Siamab Therapeutics Inc |
Glycan-interacting compounds and methods of use.
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
GB201420852D0
(en)
|
2014-11-24 |
2015-01-07 |
Genevillage Kft |
Method
|
CN113209306A
(en)
|
2014-12-09 |
2021-08-06 |
艾伯维公司 |
Antibody drug conjugates with cell permeable BCL-XL inhibitors
|
SG11201704710PA
(en)
|
2014-12-09 |
2017-07-28 |
Abbvie Inc |
Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
|
PT3333191T
(en)
|
2014-12-11 |
2020-12-15 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
CN107001480B
(en)
|
2014-12-11 |
2021-12-03 |
生物运动有限公司 |
Binding members for human C-MAF
|
WO2016096610A1
(en)
|
2014-12-15 |
2016-06-23 |
Bayer Pharma Aktiengesellschaft |
Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
|
AU2015367224B2
(en)
|
2014-12-19 |
2020-12-10 |
Monash University |
IL-21 antibodies
|
US10221248B2
(en)
|
2014-12-22 |
2019-03-05 |
The Rockefeller University |
Anti-MERTK agonistic antibodies and uses thereof
|
WO2016109310A1
(en)
|
2014-12-31 |
2016-07-07 |
Checkmate Pharmaceuticals, Llc |
Combination tumor immunotherapy
|
EP3242893A1
(en)
|
2015-01-08 |
2017-11-15 |
Biogen MA Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
CA2916283A1
(en)
|
2015-01-09 |
2016-07-09 |
Pfizer Inc. |
Dosage regimen for madcam antagonists
|
CA2975059C
(en)
|
2015-01-29 |
2023-02-21 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
|
GB201501613D0
(en)
|
2015-01-30 |
2015-03-18 |
Ucb Biopharma Sprl |
Treatment of autoimmune disorders with CD154 antibodies
|
PL3265123T3
(en)
|
2015-03-03 |
2023-03-13 |
Kymab Limited |
Antibodies, uses & methods
|
JP2018510212A
(en)
|
2015-03-06 |
2018-04-12 |
ツェー・エス・エル・ベーリング・レコンビナント・ファシリティ・アクチエンゲゼルシャフト |
Modified von Willebrand factor with improved half-life
|
CA2977532A1
(en)
|
2015-03-06 |
2016-09-15 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
GB201503967D0
(en)
|
2015-03-09 |
2015-04-22 |
Univ Glasgow |
Biocompatible implants for use in tendon therapy
|
EP3268027B1
(en)
|
2015-03-13 |
2022-11-02 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Hepcidin antagonists for use in the treatment of inflammation
|
KR102618312B1
(en)
|
2015-03-17 |
2023-12-28 |
메모리얼 슬로안 케터링 캔서 센터 |
Anti-MUC16 antibody and use thereof
|
US10870706B2
(en)
|
2015-03-20 |
2020-12-22 |
Pfizer Inc. |
Bifunctional cytotoxic agents containing the CTI pharmacophore
|
CN107743495B
(en)
|
2015-03-23 |
2021-05-14 |
拜耳制药股份公司 |
anti-CEACAM 6 antibodies and uses thereof
|
CN108348598B
(en)
|
2015-04-06 |
2023-09-01 |
比奥贝拉蒂美国公司 |
Humanized anti-C1 s antibodies and methods of use thereof
|
EP3078378B1
(en)
|
2015-04-08 |
2020-06-24 |
Vaiomer |
Use of factor xa inhibitors for regulating glycemia
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
EP3081575A1
(en)
|
2015-04-12 |
2016-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-plasmodium parasite antibodies
|
EP3283524B1
(en)
|
2015-04-17 |
2023-04-05 |
Amgen Research (Munich) GmbH |
Bispecific antibody constructs for cdh3 and cd3
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
EP3291836A4
(en)
|
2015-05-06 |
2018-11-14 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
FI3447075T3
(en)
|
2015-05-15 |
2023-11-07 |
Massachusetts Gen Hospital |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
WO2016185026A1
(en)
|
2015-05-20 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for modulation polarization and activation of macrophages
|
WO2016189104A1
(en)
|
2015-05-27 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to produce t cells
|
PE20180193A1
(en)
|
2015-05-29 |
2018-01-26 |
Abbvie Inc |
ANTI-CD40 ANTIBODIES AND THEIR USES
|
HUE050750T2
(en)
|
2015-05-29 |
2021-01-28 |
Agenus Inc |
Anti-ctla-4 antibodies and methods of use thereof
|
US10723793B2
(en)
|
2015-06-12 |
2020-07-28 |
Ludwig Institute For Cancer Research, Ltd. |
TGF-β3 specific antibodies and methods and uses thereof
|
CN107922457B
(en)
|
2015-06-19 |
2022-05-13 |
森托瑞恩生物制药公司 |
Delivery system for controlled drug release
|
MX2017017172A
(en)
|
2015-06-22 |
2018-02-23 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups.
|
CA2990394A1
(en)
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
|
JP6905941B2
(en)
|
2015-06-23 |
2021-07-21 |
バイエル ファーマ アクチエンゲゼルシャフト |
Antibody drug conjugate with anti-B7H3 antibody of kinesin spindle protein (KSP) inhibitor
|
KR20180020225A
(en)
|
2015-06-23 |
2018-02-27 |
바이엘 파마 악티엔게젤샤프트 |
Targeted conjugates of KSP inhibitors
|
GB201511196D0
(en)
|
2015-06-25 |
2015-08-12 |
Cytosystems Ltd |
Monoclonal antibodies
|
JP2018524588A
(en)
|
2015-06-26 |
2018-08-30 |
ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド |
Cancer therapy targeting tetraspanin 33 (Tspan33) in bone marrow-derived suppressor cells
|
JOP20200312A1
(en)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
Factor xi antibodies and methods of use
|
CA2991264C
(en)
|
2015-07-06 |
2023-10-10 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
MA42377A
(en)
|
2015-07-06 |
2018-05-16 |
Ucb Biopharma Sprl |
ANTIBODIES BONDING TO TAU
|
WO2017010874A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
TWI796283B
(en)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for msln and cd3
|
TWI793062B
(en)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for dll3 and cd3
|
TWI829617B
(en)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for flt3 and cd3
|
TWI717375B
(en)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for cd70 and cd3
|
TWI744242B
(en)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for egfrviii and cd3
|
WO2017023861A1
(en)
|
2015-08-03 |
2017-02-09 |
The Regents Of The University Of California |
Compositions and methods for modulating abhd2 activity
|
WO2017040790A1
(en)
|
2015-09-01 |
2017-03-09 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
RU2760582C2
(en)
|
2015-09-02 |
2021-11-29 |
Иммутеп С.А.С. |
Anti-lag-3 antibodies
|
EP3350220B1
(en)
|
2015-09-15 |
2021-05-19 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
CA3214798A1
(en)
|
2015-09-23 |
2017-03-30 |
Pfizer Inc. |
Cells and method of cell culture
|
PT3356412T
(en)
|
2015-09-29 |
2021-08-24 |
Inst Catalana Recerca Estudis Avancats |
Targeting metastasis stem cells through a fatty acid receptor (cd36)
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
US11939394B2
(en)
|
2015-10-23 |
2024-03-26 |
Merus N.V. |
Binding molecules that inhibit cancer growth
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
JP6486316B2
(en)
|
2015-11-03 |
2019-03-20 |
財團法人工業技術研究院Industrial Technology Research Institute |
Antibody-drug conjugate (ADC) and method for forming the same
|
KR20180088381A
(en)
|
2015-11-12 |
2018-08-03 |
시아맙 쎄라퓨틱스, 인코포레이티드 |
Glycan-interacting compounds and methods of use
|
WO2017085566A1
(en)
|
2015-11-20 |
2017-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for increase/induction of immune responses
|
GB201607535D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520589D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520595D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520566D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520570D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520558D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
WO2018083505A1
(en)
|
2016-11-07 |
2018-05-11 |
Immunocore Limited |
Peptides
|
GB201520557D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520592D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520544D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201604468D0
(en)
|
2016-03-16 |
2016-04-27 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520579D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520543D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520603D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
WO2017089786A1
(en)
|
2015-11-23 |
2017-06-01 |
Immunocore Limited |
Peptides
|
GB201520567D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520559D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520565D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520539D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520545D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520541D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520562D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520564D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520575D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520550D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520563D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520597D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520546D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520548D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520542D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201607534D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520568D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd |
Peptides
|
GB201520536D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520583D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
EP3383429B1
(en)
|
2015-11-30 |
2020-10-14 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Nmdar antagonists for the treatment of tumor angiogenesis
|
JP2019501124A
(en)
|
2015-11-30 |
2019-01-17 |
アッヴィ・インコーポレイテッド |
Anti-huLRRC15 antibody drug conjugate and method of use thereof
|
US10188660B2
(en)
|
2015-11-30 |
2019-01-29 |
Abbvie Inc. |
Anti-huLRRC15 antibody drug conjugates and methods for their use
|
CN109415437B
(en)
|
2015-12-02 |
2022-02-01 |
斯特库伯株式会社 |
Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof
|
CN108925136B
(en)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
Antibodies specific for glycosylated BTLA (B and T lymphocyte attenuating factor)
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
AU2016363013B2
(en)
|
2015-12-04 |
2022-03-10 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
WO2017096361A1
(en)
|
2015-12-04 |
2017-06-08 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
JP6797203B2
(en)
|
2015-12-17 |
2020-12-09 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
Improvement of systemic sclerosis by death receptor agonist
|
EP3184544A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein v inhibitors for use as coagulants
|
CN109071645A
(en)
|
2016-01-08 |
2018-12-21 |
供石公司 |
Anti- Promyostatin/latent flesh amicine antibody and its application method
|
WO2017121880A1
(en)
|
2016-01-15 |
2017-07-20 |
Philogen S.P.A |
Intestinal antigens for pharmacodelivery applications
|
CA3012960A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
SG11201806150RA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
EA039859B1
(en)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Bispecific antibody constructs binding egfrviii and cd3
|
MD3411402T2
(en)
|
2016-02-03 |
2022-05-31 |
Amgen Res Munich Gmbh |
BCMA and CD3 bispecific T cell engaging antibody constructs
|
EP3207937A1
(en)
|
2016-02-17 |
2017-08-23 |
Royal College of Surgeons in Ireland |
A method of treating or preventing sepsis
|
KR102424496B1
(en)
|
2016-03-02 |
2022-07-25 |
아이덱스 래보러토리즈, 인코포레이티드 |
Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
US11014088B2
(en)
|
2016-03-09 |
2021-05-25 |
The Board Of Regents Of The University Of Texas System |
Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates
|
WO2017156500A1
(en)
|
2016-03-11 |
2017-09-14 |
Scholar Rock, Inc. |
Tgfb1-binding immunoglobulins and use thereof
|
MA43716A
(en)
|
2016-03-17 |
2018-11-28 |
Numab Innovation Ag |
ANTI-TNF ANTIBODIES AND FUNCTIONAL FRAGMENTS OF THEM
|
DK3219727T3
(en)
|
2016-03-17 |
2021-01-04 |
Tillotts Pharma Ag |
Anti-THF alpha antibodies and functional fragments thereof
|
CN109153718B
(en)
|
2016-03-17 |
2022-02-08 |
努玛治疗有限公司 |
anti-TNF alpha antibodies and functional fragments thereof
|
ES2836349T3
(en)
|
2016-03-17 |
2021-06-24 |
Tillotts Pharma Ag |
Anti-TNF-alpha antibodies and functional fragments thereof
|
JP7049311B2
(en)
|
2016-03-17 |
2022-04-06 |
ヌマブ イノヴェイション アーゲー |
Anti-TNFα antibodies and their functional fragments
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
RU2744959C2
(en)
|
2016-03-23 |
2021-03-17 |
Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд |
New anti-pd-l1 antibodies
|
KR20180123047A
(en)
|
2016-03-24 |
2018-11-14 |
바이엘 파마 악티엔게젤샤프트 |
Prodrugs of cytotoxic activators with enzymatically cleavable groups
|
SG11201806548UA
(en)
|
2016-03-24 |
2018-08-30 |
Bayer Pharma AG |
Radio-pharmaceutical complexes
|
WO2017165851A1
(en)
|
2016-03-25 |
2017-09-28 |
Seattle Genetics, Inc. |
Process for the preparation of pegylated drug-linkers and intermediates thereof
|
AU2017242031B2
(en)
|
2016-03-29 |
2023-07-27 |
Geltor, Inc. |
Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
|
EP3452510A4
(en)
|
2016-04-04 |
2020-01-15 |
Bioverativ USA Inc. |
Anti-complement factor bb antibodies and uses thereof
|
AU2017247701B2
(en)
|
2016-04-05 |
2022-11-10 |
Pfizer Inc. |
Cell culture process
|
CN109195620B
(en)
|
2016-04-07 |
2022-06-28 |
约翰霍普金斯大学 |
Compositions and methods for treating pancreatitis and pain with death receptor agonists
|
CN109414489B
(en)
|
2016-04-08 |
2022-08-16 |
埃缇健康公司D/B/A泽尔拜尔 |
Netin-1 binding antibodies and uses thereof
|
WO2017182834A1
(en)
|
2016-04-19 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating resistant glioblastoma
|
JOP20170091B1
(en)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
|
CA3021334C
(en)
|
2016-04-27 |
2022-11-29 |
Abbvie Inc. |
Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
|
CN115873904A
(en)
|
2016-05-11 |
2023-03-31 |
美国安进公司 |
Direct selection of cells expressing high levels of heteromeric proteins using complementary vectors in the glutamine synthetase gene
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
EP4233909A3
(en)
|
2016-05-17 |
2023-09-20 |
AbbVie Biotherapeutics Inc. |
Anti-cmet antibody drug conjugates and methods for their use
|
KR20230128144A
(en)
|
2016-05-25 |
2023-09-01 |
인바이오모션 에스.엘. |
Therapeutic treatment of breast cancer based on c-maf status
|
TW201802121A
(en)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
|
WO2017203051A1
(en)
|
2016-05-26 |
2017-11-30 |
University College Cork - National University Of Ireland, Cork |
An engineered gram positive bacterium
|
KR102366813B1
(en)
|
2016-05-27 |
2022-02-24 |
아게누스 인코포레이티드 |
Anti-TIM-3 Antibodies and Methods of Using Same
|
AU2017271601A1
(en)
|
2016-05-27 |
2018-12-13 |
Abbvie Biotherapeutics Inc. |
Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
|
PL3464361T3
(en)
|
2016-05-27 |
2022-01-31 |
Abbvie Biotherapeutics Inc. |
Anti-cd40 antibodies and their uses
|
EP3464362B1
(en)
|
2016-05-27 |
2020-12-09 |
AbbVie Biotherapeutics Inc. |
Anti-4-1bb antibodies and their uses
|
CA3025894A1
(en)
|
2016-06-02 |
2017-12-07 |
Immunocore Limited |
Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
|
JP2019526529A
(en)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
Anti-B7-H3 antibody and antibody drug conjugate
|
WO2017214458A2
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
JP2019521973A
(en)
|
2016-06-08 |
2019-08-08 |
アッヴィ・インコーポレイテッド |
Anti-BH7-H3 antibody and antibody drug conjugate
|
CN109963870B
(en)
|
2016-06-08 |
2023-07-28 |
艾伯维公司 |
anti-B7-H3 antibodies and antibody drug conjugates
|
JP2019524649A
(en)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
Anti-CD98 antibodies and antibody drug conjugates
|
WO2017211809A1
(en)
|
2016-06-10 |
2017-12-14 |
Bayer Pharma Aktiengesellschaft |
Radio-pharmaceutical complexes
|
PH12018502623A1
(en)
|
2016-06-13 |
2019-10-07 |
I Mab |
Anti-pd-l1 antibodies and uses thereof
|
US11001636B2
(en)
|
2016-06-15 |
2021-05-11 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
|
US10829563B2
(en)
|
2016-06-16 |
2020-11-10 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Method of screening a candidate compound for activity as an elastase 2A (ELA2A) inhibitor
|
SG11201811064TA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Delta Ltd |
Binding molecules binding pd-l1 and lag-3
|
AU2017292184A1
(en)
|
2016-07-08 |
2019-02-07 |
Staten Biotechnology B.V. |
Anti-Apoc3 antibodies and methods of use thereof
|
WO2018017708A1
(en)
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Cd229 car t cells and methods of use thereof
|
GB201613167D0
(en)
|
2016-07-29 |
2016-09-14 |
Univ Southampton |
Cancer and b-cell related disease therapy
|
CA3032559C
(en)
|
2016-08-03 |
2022-04-19 |
Pfizer Inc. |
Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
|
SG11201900699QA
(en)
|
2016-08-09 |
2019-02-27 |
Seattle Genetics Inc |
Drug conjugates with self-stabilizing linkers having improved physiochemical properties
|
EP3502141A4
(en)
|
2016-08-22 |
2020-04-08 |
Fudan University |
Antibody targeted to tissue factor, preparation method therefor, and use thereof
|
CN106938051B
(en)
|
2016-08-22 |
2019-10-11 |
复旦大学 |
Target the antibody-drug conjugates of tissue factor
|
EP3506920A4
(en)
|
2016-09-02 |
2020-05-27 |
180 Therapeutics LP |
Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
|
EP3570865A4
(en)
|
2016-09-02 |
2020-05-20 |
180 Therapeutics LP |
Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
|
EP3293271A1
(en)
|
2016-09-12 |
2018-03-14 |
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin |
Marker and target as a diagnostic variable and target for therapy of metastatic cancer
|
EP3778643A1
(en)
|
2016-09-14 |
2021-02-17 |
AbbVie Biotherapeutics Inc. |
Pharmaceutical uses of anti-pd-1(cd279) antibodies
|
IL265331B2
(en)
|
2016-09-19 |
2024-01-01 |
I Mab |
Anti-gm-csf antibodies and uses thereof
|
US11136409B2
(en)
|
2016-09-20 |
2021-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
|
EP3515478B1
(en)
|
2016-09-21 |
2024-02-28 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
CA3034105A1
(en)
|
2016-09-23 |
2018-03-29 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
US11059908B2
(en)
|
2016-09-29 |
2021-07-13 |
Amgen Inc. |
Low-viscosity antigen binding proteins and methods of making them
|
IL265800B2
(en)
|
2016-10-11 |
2023-10-01 |
Agenus Inc |
Anti-lag-3 antibodies and methods of use thereof
|
SG11201903012RA
(en)
|
2016-10-12 |
2019-05-30 |
Bioverativ Usa Inc |
Anti-c1s antibodies and methods of use thereof
|
KR20190074292A
(en)
|
2016-10-18 |
2019-06-27 |
시애틀 지네틱스, 인크. |
Targeted delivery of remedial pathway inhibitors of nicotinamide adenine dinucleotides
|
EP3532099A1
(en)
|
2016-10-26 |
2019-09-04 |
Leap Therapeutics, Inc. |
Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
|
WO2018078083A1
(en)
|
2016-10-28 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating multiple myeloma
|
WO2018085359A1
(en)
|
2016-11-02 |
2018-05-11 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
EP3318277A1
(en)
|
2016-11-04 |
2018-05-09 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
|
AU2017353939A1
(en)
|
2016-11-07 |
2019-06-06 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
JP6925431B2
(en)
|
2016-11-09 |
2021-08-25 |
フィロジェン エッセ.ピー.アー. |
Immunoconjugates of IL2 and TNF mutants
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
EP3544628A4
(en)
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
4-1bb binding proteins and uses thereof
|
KR102603681B1
(en)
|
2016-12-07 |
2023-11-17 |
아게누스 인코포레이티드 |
Antibodies and methods of using them
|
MA50949B1
(en)
|
2016-12-07 |
2023-12-29 |
Memorial Sloan Kettering Cancer Center |
ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
|
JP7244987B2
(en)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
Multidrug Antibody Drug Conjugates
|
EP3725809A1
(en)
|
2016-12-15 |
2020-10-21 |
AbbVie Biotherapeutics Inc. |
Anti-ox40 antibodies and their uses
|
WO2018114798A1
(en)
|
2016-12-21 |
2018-06-28 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
EP3558387B1
(en)
|
2016-12-21 |
2021-10-20 |
Bayer Pharma Aktiengesellschaft |
Specific antibody drug conjugates (adcs) having ksp inhibitors
|
EP3558388A1
(en)
|
2016-12-21 |
2019-10-30 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) having enzymatically cleavable groups
|
WO2018115083A1
(en)
|
2016-12-21 |
2018-06-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of gut diseases such as irritable bowel syndrome (ibs)
|
EP3559039A1
(en)
|
2016-12-22 |
2019-10-30 |
Università Degli Studi Magna Graecia Catanzaro |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
IL308980A
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Factor xi antibodies and methods of use
|
WO2018127791A2
(en)
|
2017-01-06 |
2018-07-12 |
Biosion, Inc. |
Erbb2 antibodies and uses therefore
|
EP4218817A3
(en)
|
2017-01-06 |
2023-09-06 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
WO2018129395A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
JP7157744B2
(en)
|
2017-01-06 |
2022-10-20 |
スカラー ロック インコーポレイテッド |
Isoform-specific, context-tolerant TGFβ1 inhibitors and uses thereof
|
GB201700345D0
(en)
|
2017-01-09 |
2017-02-22 |
F-Star Beta Ltd |
Conditional agonists of immune responses
|
US20190382462A1
(en)
|
2017-01-13 |
2019-12-19 |
Pietro P. Sanna |
Methods and compositions for treating hpa hyperactivity
|
CA3049047A1
(en)
|
2017-01-20 |
2018-07-26 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-1 antibodies and uses thereof
|
PE20191208A1
(en)
|
2017-01-24 |
2019-09-10 |
I Mab |
ANTI-CD73 ANTIBODIES AND USES OF THEM
|
KR20190111086A
(en)
|
2017-01-24 |
2019-10-01 |
화이자 인코포레이티드 |
Calikimycin Derivatives and Antibody Drug Conjugates thereof
|
WO2018141753A1
(en)
|
2017-01-31 |
2018-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating squamous cell carcinomas
|
JOP20190189A1
(en)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
Low ph pharmaceutical composition comprising t cell engaging antibody constructs
|
EP3589319A4
(en)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
MX2019010994A
(en)
|
2017-03-14 |
2020-12-01 |
Bioverativ Usa Inc |
Methods for treating complement-mediated diseases and disorders.
|
EP3596126A4
(en)
|
2017-03-15 |
2021-03-03 |
Tsinghua University |
Novel anti-trkb antibodies
|
SG11201908391XA
(en)
|
2017-03-15 |
2019-10-30 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
US20200056190A1
(en)
|
2017-03-16 |
2020-02-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
AU2018237683A1
(en)
|
2017-03-24 |
2019-10-31 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
AU2018244276A1
(en)
|
2017-03-27 |
2019-10-17 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
WO2018181059A1
(en)
|
2017-03-30 |
2018-10-04 |
日油株式会社 |
Heterobifunctional monodispersed polyethylene glycol, and complex using same
|
JP7022328B2
(en)
|
2017-03-30 |
2022-02-18 |
日油株式会社 |
Hydrophilic polymer derivative with self-destructive acetal linker and complex using it
|
BR112019020508A2
(en)
|
2017-03-31 |
2020-08-04 |
Merus N.V. |
bispecific antibodies binding to erbb-2 and erbb3 for use in the treatment of cells that have an nrg1 fusion gene
|
TW201841942A
(en)
|
2017-04-13 |
2018-12-01 |
美商艾吉納斯公司 |
Anti-CD137 antibodies and methods of use thereof
|
EP3612560A1
(en)
|
2017-04-21 |
2020-02-26 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
CN110799217A
(en)
|
2017-04-27 |
2020-02-14 |
西雅图基因公司 |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
WO2018196782A1
(en)
|
2017-04-27 |
2018-11-01 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
EP3615065A1
(en)
|
2017-04-28 |
2020-03-04 |
Amgen Inc. |
Excipients to reduce the viscosity of antibody formulations and formulation compositions
|
MA50957A
(en)
|
2017-05-01 |
2020-10-14 |
Agenus Inc |
ANTI-TIGIT ANTIBODIES AND THEIR METHODS OF USE
|
AR111773A1
(en)
|
2017-05-05 |
2019-08-21 |
Amgen Inc |
PHARMACEUTICAL COMPOSITION THAT INCLUDES CONSTRUCTS OF BISPECTIFIC ANTIBODIES FOR STORAGE AND ADMINISTRATION
|
EP3401328A1
(en)
|
2017-05-10 |
2018-11-14 |
Bayer Pharma Aktiengesellschaft |
One step antibody humanization by golden gate based germline framework region shuffling
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
JOP20190256A1
(en)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
Newcastle disease viruses and uses thereof
|
WO2018215535A1
(en)
|
2017-05-23 |
2018-11-29 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
EP3409297A1
(en)
|
2017-05-30 |
2018-12-05 |
AlfaRim Medial Holding B.V. |
The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
|
CN111051346A
(en)
|
2017-05-31 |
2020-04-21 |
斯特库伯株式会社 |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1a1
|
CA3065301A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
WO2018226685A2
(en)
|
2017-06-06 |
2018-12-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
|
US11542331B2
(en)
|
2017-06-06 |
2023-01-03 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
|
CA3065153C
(en)
|
2017-06-07 |
2023-09-05 |
Philogen S.P.A. |
Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
|
US11325957B2
(en)
|
2017-06-19 |
2022-05-10 |
Cell Design Labs, Inc. |
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
|
WO2018234538A1
(en)
|
2017-06-23 |
2018-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
|
WO2019005503A1
(en)
|
2017-06-29 |
2019-01-03 |
Rutgers, The State University Of New Jersey |
Compositions and methods targeting g12 signaling for bronchodilator therapy
|
EP3421607A1
(en)
|
2017-06-29 |
2019-01-02 |
Fundación Centro Nacional de Investigaciones Oncológicas Carlos III |
Identification and elimination of damaged and/or senescent cells
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Dhodh inhibitor and chk1 inhibitor for treating cancer
|
US20210032364A1
(en)
|
2017-07-27 |
2021-02-04 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
EP3658583A1
(en)
|
2017-07-28 |
2020-06-03 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
|
CN117050176A
(en)
|
2017-07-31 |
2023-11-14 |
豪夫迈·罗氏有限公司 |
Humanization method based on three-dimensional structure
|
US11773170B2
(en)
|
2017-08-09 |
2023-10-03 |
Merus N.V. |
Antibodies that bind EGFR and cMET
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
EP3679070A1
(en)
|
2017-09-07 |
2020-07-15 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
JP2020533983A
(en)
|
2017-09-15 |
2020-11-26 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Online biomass capacitance monitoring during large-scale production of the polypeptide of interest
|
SI3681483T1
(en)
|
2017-09-15 |
2022-10-28 |
Amgen Inc. |
Process for lyophilized pharmaceutical formulation of a therapeutic protein
|
US20200230266A1
(en)
|
2017-09-20 |
2020-07-23 |
Alfarim Medical Holding B.V. |
The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
US20200317783A1
(en)
|
2017-10-06 |
2020-10-08 |
Ono Pharmaceutical Co., Ltd. |
Bispecific antibody
|
CN111405911A
(en)
|
2017-10-10 |
2020-07-10 |
梅迪塞纳医疗股份有限公司 |
I L-4 fusion preparation for treating Central Nervous System (CNS) tumors
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
CN111247165B
(en)
|
2017-10-18 |
2023-11-10 |
Csl有限公司 |
Human serum albumin variants and uses thereof
|
BR112020008514A2
(en)
|
2017-10-31 |
2020-10-20 |
Staten Biotechnology B.V. |
anti-apoc3 antibodies and methods of using them
|
US20190160089A1
(en)
|
2017-10-31 |
2019-05-30 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
AU2018361819A1
(en)
|
2017-11-02 |
2020-04-16 |
Oxford Biotherapeutics Ltd |
Antibodies and methods of use
|
JP2021502125A
(en)
|
2017-11-09 |
2021-01-28 |
ピンテオン セラピューティクス インコーポレイテッド |
Methods and Compositions for the Preparation and Use of Humanized Conformation-Specific Phosphorylated Tau Antibodies
|
EP3713581A1
(en)
|
2017-11-22 |
2020-09-30 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-maf
|
EP3713603A1
(en)
|
2017-11-23 |
2020-09-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
New method for treating dengue virus infection
|
CN111727075B
(en)
|
2017-11-27 |
2024-04-05 |
普渡制药公司 |
Humanized antibodies targeting human tissue factor
|
JP7359449B2
(en)
|
2017-11-30 |
2023-10-11 |
センチュリオン バイオファーマ コーポレイション |
Albumin-binding prodrug of auristatin E derivative
|
WO2019108975A1
(en)
|
2017-11-30 |
2019-06-06 |
Centurion Biopharma Corporation |
Maytansinoid-based drug delivery systems
|
JP7344206B2
(en)
|
2017-12-11 |
2023-09-13 |
アムジェン インコーポレイテッド |
Continuous manufacturing process for bispecific antibody products
|
EP3502139A1
(en)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antibodies to tumour antigens
|
TW201940518A
(en)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
Bispecific antibody construct directed to MUC17 and CD3
|
BR112020013405A2
(en)
|
2018-01-25 |
2020-12-01 |
Acm Biolabs Pte Ltd. |
polymerosomes comprising a soluble encapsulated antigen, as well as methods of its manufacture and use
|
JP2021512103A
(en)
|
2018-01-31 |
2021-05-13 |
バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft |
Antibody drug conjugate (ADCS) containing a NAPPT inhibitor
|
TWI804572B
(en)
|
2018-02-09 |
2023-06-11 |
日商小野藥品工業股份有限公司 |
Bispecific antibody
|
WO2019157772A1
(en)
|
2018-02-13 |
2019-08-22 |
和元生物技术(上海)股份有限公司 |
Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy
|
AU2019225845A1
(en)
|
2018-02-20 |
2020-09-24 |
Seagen Inc. |
Hydrophobic Auristatin F compounds and conjugates thereof
|
SG11202007495SA
(en)
|
2018-02-21 |
2020-09-29 |
Celgene Corp |
Bcma-binding antibodies and uses thereof
|
WO2019164979A1
(en)
|
2018-02-21 |
2019-08-29 |
Cell Design Labs, Inc. |
Chimeric transmembrane receptors and uses thereof
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
WO2019170131A1
(en)
|
2018-03-07 |
2019-09-12 |
复旦大学 |
Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
|
WO2019176875A1
(en)
|
2018-03-13 |
2019-09-19 |
日油株式会社 |
Heterobifunctional compound having monodispersed polyethylene glycol in main chain or side chain
|
CN110272490B
(en)
|
2018-03-14 |
2021-05-14 |
上海开拓者生物医药有限公司 |
Targeted CTLA-4 antibody, preparation method and application thereof
|
CN111902160A
(en)
|
2018-03-16 |
2020-11-06 |
百时美施贵宝公司 |
Metabolic enzyme activity and disulfide bond reduction during protein production
|
ES2950740T3
(en)
|
2018-03-26 |
2023-10-13 |
Glycanostics S R O |
Means and methods for glycoprofiling of a protein
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
JOP20200240A1
(en)
|
2018-04-02 |
2020-09-27 |
Bristol Myers Squibb Co |
Anti-trem-1 antibodies and uses thereof reference to sequence listing submitted electronically via efs-web
|
CN110343178B
(en)
|
2018-04-03 |
2022-07-22 |
上海开拓者生物医药有限公司 |
Anti-human LAG-3 monoclonal antibody and application thereof
|
EP3553082A1
(en)
|
2018-04-12 |
2019-10-16 |
Bayer Aktiengesellschaft |
Brain natriuretic peptide engrafted antibodies
|
EP3553081A1
(en)
|
2018-04-12 |
2019-10-16 |
Bayer Aktiengesellschaft |
Atrial natriuretic peptide engrafted antibodies
|
EP3773739A1
(en)
|
2018-04-12 |
2021-02-17 |
MediaPharma S.r.l. |
Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
|
EP3553079A1
(en)
|
2018-04-12 |
2019-10-16 |
Bayer Aktiengesellschaft |
C-type natriuretic peptide engrafted antibodies
|
US11471506B2
(en)
|
2018-04-23 |
2022-10-18 |
Emory University |
VIP antagonists and uses in treating cancer
|
US20210230255A1
(en)
|
2018-04-27 |
2021-07-29 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
CN110483639A
(en)
|
2018-05-15 |
2019-11-22 |
复旦大学 |
Target antibody and the antibody-drug conjugates and its preparation method and application of AXL
|
US20210238238A1
(en)
|
2018-05-16 |
2021-08-05 |
Csl Limited |
Soluble complement receptor type i variants and uses thereof
|
AR126019A1
(en)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
|
GB201808927D0
(en)
|
2018-05-31 |
2018-07-18 |
Institute Of Cancer Res Royal Cancer Hospital |
Materials and methods for monitoring the development of resistance of cancers to treatment
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
JP2021526014A
(en)
|
2018-06-05 |
2021-09-30 |
アムジエン・インコーポレーテツド |
Regulation of antibody-dependent cellular cytotoxicity
|
TW202015740A
(en)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
Camptothecin conjugates
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
WO2019243159A1
(en)
|
2018-06-18 |
2019-12-26 |
Bayer Aktiengesellschaft |
Binder-drug conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
|
TW202016144A
(en)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
Compositions including cd3 antigen binding fragments and uses thereof
|
US11241417B2
(en)
|
2018-06-21 |
2022-02-08 |
Yumanity Therapeutics, Inc. |
Compositions and methods for the treatment and prevention of neurological disorders
|
US11884729B2
(en)
|
2018-06-29 |
2024-01-30 |
ApitBio, Inc |
Anti-L1CAM antibodies and uses thereof
|
WO2020008083A1
(en)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Therapeutic target in chemokine receptors for the screening of compounds useful for the treatment of pathological processes involving chemokine signaling
|
JP2021531254A
(en)
|
2018-07-11 |
2021-11-18 |
スカラー ロック インコーポレイテッドScholar Rock, Inc. |
High affinity isoform-selective TGFβ1 inhibitor, and its use
|
PT3677278T
(en)
|
2018-07-11 |
2022-02-03 |
Scholar Rock Inc |
Isoform selective tgfbeta1 inhibitors and use thereof
|
EP3820896A1
(en)
|
2018-07-11 |
2021-05-19 |
Scholar Rock, Inc. |
TGFbeta1 INHIBITORS AND USE THEREOF
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
JP7397055B2
(en)
|
2018-07-12 |
2023-12-12 |
エフ-スター セラピューティクス リミテッド |
Antibody molecules that bind to CD137 and OX40
|
US20220049007A1
(en)
|
2018-07-12 |
2022-02-17 |
F-Star Beta Limited |
Antibody molecules that bind pd-l1 and cd137
|
CN110713537B
(en)
|
2018-07-13 |
2023-04-21 |
江苏怀瑜药业有限公司 |
SEMA4D antibody and preparation method and application thereof
|
WO2020016160A1
(en)
|
2018-07-16 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat neurological diseases
|
US20210290633A1
(en)
|
2018-07-19 |
2021-09-23 |
INSERM (Insstitut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
WO2020016459A1
(en)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Receptor for vista
|
US20210308170A1
(en)
|
2018-07-27 |
2021-10-07 |
Osaka University |
Composition for suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan
|
JP2021532140A
(en)
|
2018-07-30 |
2021-11-25 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Long-term administration of bispecific antibody constructs that bind to CD33 and CD3
|
KR20210042117A
(en)
|
2018-08-03 |
2021-04-16 |
암젠 리서치 (뮌헨) 게엠베하 |
Antibody constructs against CLDN18.2 and CD3
|
CA3109999A1
(en)
|
2018-08-21 |
2020-02-27 |
Abl Bio Inc. |
Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
|
AU2019327155A1
(en)
|
2018-08-27 |
2021-03-18 |
Affimed Gmbh |
Cryopreserved NK cells preloaded with an antibody construct
|
EP3850006A1
(en)
|
2018-09-11 |
2021-07-21 |
Amgen Inc. |
Methods of modulating antibody-dependent cell-mediated cytotoxicity
|
CN112996539A
(en)
|
2018-09-12 |
2021-06-18 |
Acm生物实验室私人有限公司 |
Polymersomes comprising covalently bound antigens, methods of making and uses thereof
|
US10899826B1
(en)
|
2018-09-13 |
2021-01-26 |
Teva Pharmaceuticals International Gmbh |
Pharmaceutical compositions for an anti-CGRP antagonist antibody
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
JPWO2020059847A1
(en)
|
2018-09-21 |
2021-09-16 |
国立大学法人 東京医科歯科大学 |
A human monoclonal antibody that specifically binds to human HMGB1 and a pharmaceutical composition containing the same for treating or preventing Alzheimer's disease.
|
CN112703204A
(en)
|
2018-09-28 |
2021-04-23 |
安进公司 |
Antibodies to soluble BCMA
|
EP3856773A1
(en)
|
2018-09-28 |
2021-08-04 |
Kyowa Kirin Co., Ltd. |
Il-36 antibodies and uses thereof
|
JP2022504287A
(en)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
Antibodies specific for human and cynomolgus monkey APOC3, and methods of their use
|
SG11202103275YA
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc |
Downstream processing of bispecific antibody constructs
|
US11674961B2
(en)
|
2018-10-12 |
2023-06-13 |
Quidel Corporation |
Extraction reagent for use in an assay for detection of group A Streptococcus
|
UY38407A
(en)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
TREM2 STABILIZING ANTIBODIES
|
BR112021007765A2
(en)
|
2018-10-23 |
2021-08-03 |
Scholar Rock, Inc. |
selective rgmc inhibitors and their use
|
US20210395390A1
(en)
|
2018-10-31 |
2021-12-23 |
Bayer Aktiengesellschaft |
Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
|
US20220000893A1
(en)
|
2018-10-31 |
2022-01-06 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Method for treating t-helper type 2 mediated disease
|
AU2019374496A1
(en)
|
2018-11-05 |
2021-05-27 |
Centre Hospitalier Universitaire Vaudois |
Humanized and variant TGF-β3 specific antibodies and methods and uses thereof
|
EP3877055A1
(en)
|
2018-11-05 |
2021-09-15 |
Ludwig Institute for Cancer Research Ltd |
Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
|
WO2020094071A1
(en)
|
2018-11-07 |
2020-05-14 |
上海怀越生物科技有限公司 |
Nkg2a antibody, preparation method therefor and application thereof
|
WO2020103836A1
(en)
|
2018-11-20 |
2020-05-28 |
上海开拓者生物医药有限公司 |
Ox40 antibody, preparation method thereof and use thereof
|
CN111234018A
(en)
|
2018-11-29 |
2020-06-05 |
上海开拓者生物医药有限公司 |
Fully human anti-GITR antibody and preparation method thereof
|
WO2020107715A1
(en)
|
2018-11-30 |
2020-06-04 |
Abl Bio Inc. |
Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
|
CN111253485A
(en)
|
2018-11-30 |
2020-06-09 |
上海开拓者生物医药有限公司 |
Anti-human TIM-3 monoclonal antibody and application thereof
|
CN113166257B
(en)
|
2018-12-03 |
2023-05-30 |
上海开拓者生物医药有限公司 |
CD47 antibody and preparation method and application thereof
|
JP2022513702A
(en)
|
2018-12-06 |
2022-02-09 |
ファイザー・インク |
Cells with reduced inhibitor production and how to use them
|
WO2020118293A2
(en)
|
2018-12-07 |
2020-06-11 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
CN111303284A
(en)
|
2018-12-12 |
2020-06-19 |
尚华科创投资管理(江苏)有限公司 |
Monoclonal antibody for resisting human interleukin 5(IL-5) and application thereof
|
JP2022514903A
(en)
|
2018-12-20 |
2022-02-16 |
協和キリン株式会社 |
FN14 antibody and its use
|
CN111349162A
(en)
|
2018-12-21 |
2020-06-30 |
神州细胞工程有限公司 |
Humanized anti-PD-1 antibodies and uses thereof
|
CN111434688A
(en)
|
2019-01-11 |
2020-07-21 |
上海开拓者生物医药有限公司 |
CD73 antibody and preparation method and application thereof
|
JP2022522265A
(en)
|
2019-01-16 |
2022-04-15 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Erythroferrone mutants and their use
|
EP3911675A1
(en)
|
2019-01-17 |
2021-11-24 |
Bayer Aktiengesellschaft |
Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
|
AU2020216295A1
(en)
|
2019-01-28 |
2021-09-09 |
Maple Biotech Llc |
PSMP antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
SG11202108099WA
(en)
|
2019-01-30 |
2021-08-30 |
Scholar Rock Inc |
LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
|
CA3127776A1
(en)
|
2019-01-30 |
2020-08-06 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
TWI756633B
(en)
|
2019-02-15 |
2022-03-01 |
大陸商上海藥明生物技術有限公司 |
Antibody-drug conjugates with improved homogeneity, pharmaceutical compositions thereof, uses and methods of preparation
|
JP2022530301A
(en)
|
2019-02-22 |
2022-06-29 |
武▲漢▼友芝友生物制▲薬▼有限公司 |
CD3 antigen-binding fragment and its use
|
JP2022530934A
(en)
|
2019-02-22 |
2022-07-05 |
武▲漢▼友芝友生物制▲薬▼有限公司 |
Modified Fc fragments, antibodies containing them, and their use
|
US11242407B2
(en)
|
2019-02-26 |
2022-02-08 |
Inspirna, Inc. |
High-affinity anti-MERTK antibodies and uses thereof
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
GB201904717D0
(en)
|
2019-04-03 |
2019-05-15 |
Univ London Queen Mary |
Treatment and diagnosis of mental disorders
|
WO2020206063A1
(en)
|
2019-04-03 |
2020-10-08 |
Genzyme Corporation |
Anti-alpha beta tcr binding polypeptides with reduced fragmentation
|
TW202102544A
(en)
|
2019-04-04 |
2021-01-16 |
日商小野藥品工業股份有限公司 |
Bispecific antibody
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
EP3953380A4
(en)
|
2019-04-12 |
2023-01-25 |
Geltor, Inc. |
Recombinant elastin and production thereof
|
MX2021013657A
(en)
|
2019-05-10 |
2022-02-21 |
Takeda Pharmaceuticals Co |
Antibody drug conjugates.
|
US20220227859A1
(en)
|
2019-05-16 |
2022-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat type 2 inflammation or mast-cell dependent disease
|
CR20210576A
(en)
|
2019-05-21 |
2021-12-15 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
JP2022532928A
(en)
|
2019-05-24 |
2022-07-20 |
サノフイ |
Methods for treating systemic scleroderma
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
TW202045711A
(en)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
Automated biomass-based perfusion control in the manufacturing of biologics
|
US20230340086A1
(en)
|
2019-06-19 |
2023-10-26 |
Christopher Roland Oelkrug |
Antibody-mediated neutralization of beta-lactamases
|
GB201909393D0
(en)
|
2019-06-28 |
2019-08-14 |
Gen2 Neuroscience Ltd |
Tau epitope and binding molecules
|
CA3143087A1
(en)
|
2019-07-03 |
2021-01-07 |
Arnima BISHT |
Antibodies and methods of use
|
WO2021001539A1
(en)
|
2019-07-04 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy to detect and treat eosinophilic fasciitis
|
GB2585252A
(en)
|
2019-07-05 |
2021-01-06 |
Gen2 Neuroscience Ltd |
Tau epitope and binding molecules
|
JP6881658B2
(en)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Blood cancer treatment with PD-1 / CD3 bispecific protein
|
EP3998286A4
(en)
|
2019-07-11 |
2023-04-26 |
Wuhan Yzy Biopharma Co., Ltd. |
Tetravalent symmetric bispecific antibody
|
WO2021013065A1
(en)
|
2019-07-19 |
2021-01-28 |
神州细胞工程有限公司 |
Humanized anti-vegf fab antibody fragment and use thereof
|
CN114008075A
(en)
|
2019-07-19 |
2022-02-01 |
神州细胞工程有限公司 |
Humanized anti-VEGF monoclonal antibody
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
US20220281966A1
(en)
|
2019-07-26 |
2022-09-08 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
WO2021018035A1
(en)
|
2019-07-26 |
2021-02-04 |
神州细胞工程有限公司 |
Humanized anti-il17a antibody and use thereof
|
KR20220039720A
(en)
|
2019-07-30 |
2022-03-29 |
오노 야꾸힝 고교 가부시키가이샤 |
bispecific antibody
|
WO2021022304A2
(en)
|
2019-07-30 |
2021-02-04 |
Qlsf Biotherapeutics, Inc. |
MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
EP4031658A1
(en)
|
2019-08-07 |
2022-07-27 |
DB Biotech, AS |
Improved horseradish peroxidase polypeptides
|
WO2021025140A1
(en)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
Dual-specific protein
|
WO2021042019A1
(en)
|
2019-08-30 |
2021-03-04 |
Agenus Inc. |
Anti-cd96 antibodies and methods of use thereof
|
US20220348650A1
(en)
|
2019-09-03 |
2022-11-03 |
Bio-Thera Solutions, Ltd. |
Anti-tigit immunosuppressant and application thereof
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
US20220332799A1
(en)
|
2019-09-04 |
2022-10-20 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
Herv inhibitors for use in treating tauopathies
|
EP4025712A1
(en)
|
2019-09-05 |
2022-07-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Method of treatment and pronostic of acute myeloid leukemia
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
WO2021050640A1
(en)
|
2019-09-10 |
2021-03-18 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
EP3792632A1
(en)
|
2019-09-16 |
2021-03-17 |
Vito NV |
Immunotherapy markers
|
TW202124446A
(en)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
Combination therapies with entpd2 antibodies
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
CN114423459A
(en)
|
2019-09-19 |
2022-04-29 |
飞跃治疗公司 |
DKK-1 inhibitors for the treatment of cancer
|
WO2021055865A1
(en)
|
2019-09-19 |
2021-03-25 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
US20220362397A1
(en)
|
2019-09-26 |
2022-11-17 |
Nof Corporation |
Heterobifunctional monodispersed polyethylene glycol having peptide linker
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
CA3152316A1
(en)
|
2019-10-04 |
2021-04-08 |
Scott C. Jeffrey |
Camptothecin peptide conjugates
|
JP2022552282A
(en)
|
2019-10-09 |
2022-12-15 |
エスティーキューブ アンド カンパニー |
Antibodies specific for glycosylated LAG3 and methods of use thereof
|
GB201915163D0
(en)
|
2019-10-18 |
2019-12-04 |
Univ Southampton |
Cancer vaccine
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
AU2020381534A1
(en)
|
2019-11-15 |
2022-06-23 |
Pliant Therapeutics, Inc. |
Compositions and methods for activation of integrins
|
IL293090A
(en)
|
2019-11-22 |
2022-07-01 |
Leap Therapeutics Inc |
Methods of treating cancer using dkk-1-inhibitors
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
EP4077376A2
(en)
|
2019-12-19 |
2022-10-26 |
Quidel Corporation |
Monoclonal antibody fusions
|
US11926672B2
(en)
|
2019-12-20 |
2024-03-12 |
Amgen Inc. |
Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
CN113045655A
(en)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
anti-OX 40 antibodies and uses thereof
|
WO2021130383A1
(en)
|
2019-12-27 |
2021-07-01 |
Affimed Gmbh |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
TW202138388A
(en)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
Methods of treating cancer with nonfucosylated anti-cd70 antibodies
|
CN115052663A
(en)
|
2020-01-08 |
2022-09-13 |
辛瑟斯治疗股份有限公司 |
ALK5 inhibitor conjugates and uses thereof
|
BR112022013733A2
(en)
|
2020-01-11 |
2022-11-01 |
Scholar Rock Inc |
TGFBETA INHIBITORS AND THEIR USE
|
WO2021142448A2
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock,Inc. |
Tgf-beta inhibitors and use thereof
|
TWI793503B
(en)
|
2020-01-20 |
2023-02-21 |
美商美國禮來大藥廠 |
ANTI-IL-1β ANTIBODIES
|
EP4093771A1
(en)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
IL295093A
(en)
|
2020-01-30 |
2022-09-01 |
Ona Therapeutics S L |
Combination therapy for treatment of cancer and cancer metastasis
|
EP4169939A4
(en)
|
2020-01-31 |
2024-02-21 |
Fundacao Oswaldo Cruz |
Antibody, related use, pharmaceutical composition including method for diagnosing fungal infections, fungal infection diagnosis kit and method for treating fungal infections
|
CN115551552A
(en)
|
2020-02-25 |
2022-12-30 |
祐方有限公司 |
Camptothecin derivatives and conjugates thereof
|
CN115315446A
(en)
|
2020-03-06 |
2022-11-08 |
Go医疗股份有限公司 |
anti-sugar-CD 44 antibodies and uses thereof
|
JP2023516724A
(en)
|
2020-03-06 |
2023-04-20 |
オーエヌエー セラピューティクス エセ.エレ. |
Anti-CD36 antibodies and their use to treat cancer
|
AU2021232853A1
(en)
|
2020-03-10 |
2022-09-22 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
EP4117727A2
(en)
|
2020-03-10 |
2023-01-18 |
Tiziana Life Sciences PLC |
Compositions of il-6/il-6r antibodies and methods of use thereof
|
TW202200615A
(en)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
Method for treatment and prophylaxis of crs in patients
|
MX2022011632A
(en)
|
2020-03-19 |
2022-10-13 |
Amgen Inc |
Antibodies against mucin 17 and uses thereof.
|
EP4121106A1
(en)
|
2020-03-20 |
2023-01-25 |
Centre National de la Recherche Scientifique (CNRS) |
New anti-vegfc antibodies and uses thereof
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
JPWO2021200131A1
(en)
|
2020-03-30 |
2021-10-07 |
|
|
CN115362171A
(en)
|
2020-03-31 |
2022-11-18 |
百奥泰生物制药股份有限公司 |
Antibody for treating coronavirus, fusion protein and application thereof
|
US20230173093A1
(en)
|
2020-04-10 |
2023-06-08 |
Seagen Inc. |
Charge variant linkers
|
EP4135841A1
(en)
|
2020-04-15 |
2023-02-22 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
AU2021256056A1
(en)
|
2020-04-17 |
2022-10-20 |
Zoetis Services Llc |
Canine antibody variants
|
IL297290A
(en)
|
2020-04-17 |
2022-12-01 |
Zoetis Services Llc |
Feline antibody variants
|
GB202005779D0
(en)
|
2020-04-21 |
2020-06-03 |
Scancell Ltd |
Anti-tumour immune responses
|
MX2022013455A
(en)
|
2020-04-28 |
2022-11-16 |
Sinocelltech Ltd |
Tgfî²r2 extracellular domain truncated molecule, fusion protein of tgfî²r2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein.
|
US20210340586A1
(en)
*
|
2020-04-30 |
2021-11-04 |
Sutro Biopharma, Inc. |
Methods of Producing Full-Length Antibodies Using E. coli
|
EP3909601A1
(en)
|
2020-05-11 |
2021-11-17 |
LeukoCom GmbH |
A novel antibody binding specifically to human ceacam1/3/5 and use thereof
|
AU2021275049A1
(en)
|
2020-05-19 |
2022-12-22 |
Amgen Inc. |
MAGEB2 binding constructs
|
WO2021234178A1
(en)
|
2020-05-22 |
2021-11-25 |
Philogen S.P.A |
TNFα IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORS
|
JP2023527972A
(en)
|
2020-05-29 |
2023-07-03 |
アムジエン・インコーポレーテツド |
Reduced Adverse Effect Administration of Bispecific Constructs that Bind CD33 and CD3
|
WO2021245107A2
(en)
|
2020-06-02 |
2021-12-09 |
Institut Gustave Roussy |
Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
|
CN113754766A
(en)
|
2020-06-02 |
2021-12-07 |
明慧医药(上海)有限公司 |
anti-B7-H3 antibody and preparation and application thereof
|
EP3919062A1
(en)
|
2020-06-02 |
2021-12-08 |
Institut Gustave-Roussy |
Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
|
JP2023529853A
(en)
|
2020-06-17 |
2023-07-12 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
Compositions and methods for enhancing chimeric antigen receptor (CAR) T cell therapy
|
US20230218608A1
(en)
|
2020-06-18 |
2023-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
WO2022005883A1
(en)
|
2020-06-29 |
2022-01-06 |
Zoetis Services Llc |
Feline antibody variants for improving stability
|
EP3933035A1
(en)
|
2020-07-03 |
2022-01-05 |
Aarhus Universitet |
Compositions comprising extracellular vesicles and sting stimulatory agents
|
US20230227555A1
(en)
|
2020-07-30 |
2023-07-20 |
Tiziana Life Sciences Plc |
Cd-3 antibodies for the treatment of coronavirus
|
CN116724236A
(en)
|
2020-08-06 |
2023-09-08 |
美国比奥维拉迪维股份有限公司 |
Inflammatory cytokines and fatigue in subjects with complement-mediated diseases
|
CN114057877A
(en)
|
2020-08-07 |
2022-02-18 |
百奥泰生物制药股份有限公司 |
anti-PD-L1 antibody and application thereof
|
US20240010750A1
(en)
|
2020-09-15 |
2024-01-11 |
Bayer Aktiengesellschaft |
Novel anti-a2ap antibodies and uses thereof
|
BR112023005393A2
(en)
|
2020-09-28 |
2023-04-25 |
Zoetis Services Llc |
CANINE ANTIBODY VARIANTS
|
EP4221744A1
(en)
|
2020-09-29 |
2023-08-09 |
Zoetis Services LLC |
Feline antibody variants
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
JP2023545447A
(en)
|
2020-10-16 |
2023-10-30 |
キューエルエスエフ バイオセラピューティクス, インコーポレイテッド |
Multispecific binding compounds that bind to PD-L1
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
KR20230104256A
(en)
|
2020-11-06 |
2023-07-07 |
암젠 인크 |
Multitargeting bispecific antigen binding molecules of increased selectivity
|
WO2022096704A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
WO2022095970A1
(en)
|
2020-11-06 |
2022-05-12 |
百奥泰生物制药股份有限公司 |
Bispecific antibody and use thereof
|
WO2022097061A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
WO2022096698A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
AU2021374958A1
(en)
|
2020-11-09 |
2023-06-22 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
JP2023551194A
(en)
|
2020-11-20 |
2023-12-07 |
ゾエティス・サービシーズ・エルエルシー |
bovine antibody variants
|
GB202018395D0
(en)
|
2020-11-23 |
2021-01-06 |
Scancell Ltd |
Immunotherapy
|
US20240025985A1
(en)
|
2020-12-09 |
2024-01-25 |
National University Corporation Tokyo Medical And Dental University |
Agent for Preventing or Treating Frontotemporal Lobar Degeneration
|
EP4263599A1
(en)
|
2020-12-16 |
2023-10-25 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
AU2021401316A1
(en)
|
2020-12-18 |
2023-07-06 |
Kiniksa Pharmaceuticals, Ltd. |
Protein compositions and methods for producing and using the same
|
CN116547298A
(en)
|
2020-12-18 |
2023-08-04 |
硕腾服务有限责任公司 |
Mutations in cat antibody constant regions
|
EP4273167A1
(en)
|
2020-12-30 |
2023-11-08 |
Bio-Thera Solutions, Ltd. |
Anti-cldn18.2 antibody, and preparation method therefor and use thereof
|
CN114763381A
(en)
|
2021-01-13 |
2022-07-19 |
博生吉医药科技(苏州)有限公司 |
B7-H3 chimeric antigen receptor modified T cell and application thereof
|
JP2024503657A
(en)
|
2021-01-13 |
2024-01-26 |
メモリアル スローン-ケタリング キャンサー センター |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
KR20230146522A
(en)
|
2021-01-13 |
2023-10-19 |
메모리얼 슬로안 케터링 캔서 센터 |
Anti-DLL3 antibody-drug conjugate
|
WO2022155518A1
(en)
|
2021-01-15 |
2022-07-21 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
AR124681A1
(en)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
ANTI-EGFR ANTIBODY-DRUG CONJUGATES
|
WO2022157336A1
(en)
|
2021-01-22 |
2022-07-28 |
Royal College Of Surgeons In Ireland |
Treatment of coronavirus
|
CN116802205A
(en)
|
2021-01-28 |
2023-09-22 |
硕腾服务有限责任公司 |
Mutations in canine antibody constant regions
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
CN116847886A
(en)
|
2021-02-03 |
2023-10-03 |
思进公司 |
Immunostimulatory compounds and conjugates
|
WO2022180145A2
(en)
|
2021-02-26 |
2022-09-01 |
Bayer Aktiengesellschaft |
Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
|
IL305575A
(en)
|
2021-03-02 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
Methods of treating red blood cell disorders
|
JP2024512324A
(en)
|
2021-03-05 |
2024-03-19 |
ジーオー セラピューティクス,インコーポレイテッド |
Anti-glycoCD44 antibodies and their uses
|
CN117203232A
(en)
|
2021-03-17 |
2023-12-08 |
瑞塞普托斯有限责任公司 |
Methods of treating atopic dermatitis with anti-IL-13 antibodies
|
IL305886A
(en)
|
2021-03-18 |
2023-11-01 |
Seagen Inc |
Selective drug release from internalized conjugates of biologically active compounds
|
AU2022238571A1
(en)
|
2021-03-18 |
2023-09-14 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
JP2024512633A
(en)
|
2021-03-30 |
2024-03-19 |
バイエル・アクチエンゲゼルシヤフト |
Anti-SEMA3A antibody and its uses
|
CN117241828A
(en)
|
2021-03-31 |
2023-12-15 |
美国比奥维拉迪维股份有限公司 |
Reducing surgery-related hemolysis in patients with cold lectin disease
|
EP4314078A1
(en)
|
2021-04-02 |
2024-02-07 |
Amgen Inc. |
Mageb2 binding constructs
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
CN117440798A
(en)
|
2021-04-12 |
2024-01-23 |
Acm 生物实验室私人有限公司 |
Polymer vesicles comprising soluble encapsulated polynucleotides and ionizable lipids, methods of making and uses thereof
|
WO2022219076A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
IL307267A
(en)
|
2021-04-14 |
2023-11-01 |
Villaris Therapeutics Inc |
Anti-cd122 antibodies and uses thereof
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
EP4323404A1
(en)
|
2021-04-16 |
2024-02-21 |
Tiziana Life Sciences PLC |
Subcutaneous administration of antibodies for the treatment of disease
|
CA3212610A1
(en)
|
2021-04-20 |
2022-10-27 |
Philip MOQUIST |
Modulation of antibody-dependent cellular cytotoxicity
|
IL308183A
(en)
|
2021-05-04 |
2024-01-01 |
Regeneron Pharma |
Multispecific fgf21 receptor agonists and their uses
|
EP4334358A1
(en)
|
2021-05-06 |
2024-03-13 |
Amgen Research (Munich) GmbH |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
KR20240015670A
(en)
|
2021-05-28 |
2024-02-05 |
씨젠 인크. |
Anthracycline antibody conjugate
|
WO2022253910A1
(en)
|
2021-06-02 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new method to treat an inflammatory skin disease
|
EP4348260A2
(en)
|
2021-06-03 |
2024-04-10 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
WO2022271867A1
(en)
|
2021-06-23 |
2022-12-29 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
CA3221281A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
WO2023285620A2
(en)
|
2021-07-14 |
2023-01-19 |
Alchemab Therapeutics Ltd. |
Compositions and methods for targeting viral proteins
|
CA3225252A1
(en)
|
2021-07-14 |
2023-01-19 |
Jordan JARJOUR |
Engineered t cell receptors fused to binding domains from antibodies
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
IL308154A
(en)
|
2021-07-30 |
2023-12-01 |
Affimed Gmbh |
Duplexbodies
|
AU2022320051A1
(en)
|
2021-07-30 |
2024-01-25 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
AU2022324456A1
(en)
|
2021-08-05 |
2024-02-15 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
CN115702931A
(en)
|
2021-08-06 |
2023-02-17 |
百奥泰生物制药股份有限公司 |
Application of anti-PD-L1/CD 47 bi-specific antibody in treating diseases
|
WO2023025927A1
(en)
|
2021-08-26 |
2023-03-02 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
CA3230117A1
(en)
|
2021-09-02 |
2023-03-09 |
Mark Trautwein |
Anti-cecam6 antibodies with reduced side-effects
|
CA3230934A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
WO2023034571A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
WO2023039249A1
(en)
|
2021-09-10 |
2023-03-16 |
Leap Therapeutics, Inc. |
Combination therapy
|
IL310815A
(en)
|
2021-09-14 |
2024-04-01 |
Glycanostics S R O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
WO2023044094A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023044280A1
(en)
|
2021-09-20 |
2023-03-23 |
Eli Lilly And Company |
Anti-il-1-beta antibodies
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
WO2023057484A1
(en)
|
2021-10-06 |
2023-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
|
WO2023064942A1
(en)
|
2021-10-14 |
2023-04-20 |
Tiziana Life Sciences Plc |
Methods of suppressing microglial activation
|
WO2023078906A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating acute myeloid leukemia
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
TW202334221A
(en)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
Bispecific cd16a binders
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
WO2023086835A1
(en)
|
2021-11-09 |
2023-05-19 |
Sensei Biotherapeutics, Inc. |
Anti-vista antibodies and uses thereof
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023089159A1
(en)
|
2021-11-22 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy targeting stroma/tumor cell crosstalk to treat a cancer
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
GB202117928D0
(en)
|
2021-12-11 |
2022-01-26 |
Cancer Research Tech Ltd |
Immunotherapy for cancer
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
WO2023170434A1
(en)
|
2022-03-11 |
2023-09-14 |
Macomics Limited |
Compositions and methods for modulation of macrophage activity
|
TW202400137A
(en)
|
2022-03-17 |
2024-01-01 |
美商思進公司 |
Camptothecin conjugates
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
TW202346368A
(en)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
US20240117021A1
(en)
|
2022-06-15 |
2024-04-11 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
WO2023250388A1
(en)
|
2022-06-22 |
2023-12-28 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2023250507A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
WO2024003114A1
(en)
|
2022-06-29 |
2024-01-04 |
Actome Gmbh |
Detection of biomolecules in single cells
|
WO2024003380A1
(en)
|
2022-06-30 |
2024-01-04 |
Icm (Institut Du Cerveau Et De La Moelle Épinière) |
Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
|
WO2024015463A1
(en)
|
2022-07-12 |
2024-01-18 |
Leap Therapeutics, Inc. |
Combination therapy
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
US20240108744A1
(en)
|
2022-07-27 |
2024-04-04 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|
WO2024030982A2
(en)
|
2022-08-02 |
2024-02-08 |
Diadem Spa |
Device for detection and prognostic assessment of neurodegenerative disorders
|
WO2024030577A1
(en)
|
2022-08-03 |
2024-02-08 |
Seagen Inc. |
Immunostimulatory anti-pd-l1-drug conjugates
|
WO2024028476A1
(en)
|
2022-08-05 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of th2-mediated diseases
|
EP4321522A1
(en)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Cytotoxic compounds and conjugates thereof
|
WO2024037910A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Syk inhibitors for use in the treatment of cancer
|
WO2024044687A1
(en)
|
2022-08-26 |
2024-02-29 |
Valo Health, Inc. |
Biomarker combinations for prognosis and management of diabetic retinopathy
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024062074A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|